irinotecan has been researched along with Cancer of Colon in 544 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 48 (8.82) | 18.2507 |
2000's | 255 (46.88) | 29.6817 |
2010's | 177 (32.54) | 24.3611 |
2020's | 64 (11.76) | 2.80 |
Authors | Studies |
---|---|
Boehm, JC; Caranfa, MJ; Faucette, LF; Gallagher, G; Hecht, SM; Holden, KG; Jakas, DR; Johnson, RK; Kingsbury, WD; McCabe, FL | 1 |
Aherne, GW; Box, G; Boxall, KJ; Collins, I; de Haven Brandon, AK; Eccles, SA; Eve, PD; Garrett, MD; Hayes, A; Lainchbury, M; Matthews, TP; McHardy, T; Raynaud, FI; Reader, JC; Valenti, MR; Walton, MI | 1 |
Bae, SY; Hong, JY; Jung, C; Kang, SS; Lee, SK; Park, HJ | 1 |
Fischer, C; Hetterling, G; Kliem, M; Micikas, RJ; Plauth, A; Rousseau, M; Sauer, S; Schroeder, FC; Siems, K; Weidner, C; Wowro, SJ | 1 |
Fujimoto, M; Fukuda, T; Ishibashi, F; Iwao, M; Nanjo, Y; Natsui, Y; Okazaki, F; To, H; Yoshida, K | 1 |
Callan, B; Callan, JF; Gao, J; Griffith, DM; Logan, KA; Love, M; McHale, AP; McKaig, T; Nesbitt, H; Taylor, M | 1 |
Aloia, TA; Cao, HST; Chun, YS; Hwang, H; Kawaguchi, Y; Kopetz, S; Panettieri, E; Tzeng, CD; Vauthey, JN; Wang, X | 1 |
Gao, T; Guo, B; Hasani, S; Li, AT; Martinez, R; Skaggs, AT; Wen, YA; Xiong, X | 1 |
Fujii, M; Ichikawa, W; Kataoka, M; Manaka, D; Matsuoka, H; Nakamura, M; Takeuchi, M; Tsuji, A; Watanabe, T | 1 |
Chang, TK; Chen, PJ; Chen, YC; Huang, CW; Li, CC; Su, WC; Tsai, HL; Wang, JY; Yin, TC | 1 |
Hong, JY; Jo, H; Kang, WK; Kim, H; Kim, ST; Lee, J; Lee, MS; Lee, YP; Lim, HY; Park, JO; Park, SH; Park, YS | 1 |
Ando, M; Bando, H; Honda, K; Kadowaki, S; Kato, K; Masuishi, T; Matsubara, Y; Muro, K; Nakazawa, T; Narita, Y; Nozawa, K; Ogata, T; Tajika, M; Taniguchi, H | 1 |
Chen, X; Sun, M; Yang, Z | 1 |
Bhaskaran, NA; Cheruku, S; Jitta, SR; Kumar, L; Kumar, N | 1 |
Arbabi, E; Hassanzadeh, P | 1 |
Li, Y; Shi, W; Wu, D; Yu, H; Zhang, G; Zhao, D; Zhong, B | 1 |
Chakraborty, S; Senapati, S; Suresh, V | 1 |
Gao, L; Liu, X; Ma, X; Ou, K; Wang, Q; Yang, L; Zhang, H | 1 |
Chen, Y; Gou, J; Guo, Q; Huang, M; Li, W; Li, X; Liu, H; Liu, Y; Pen, R; Sun, X; Wen, M; Yu, S; Zuo, W | 1 |
Decker, T; Denzlinger, C; Fischer von Weikersthal, L; Gießen-Jung, C; Graeven, U; Heinemann, V; Heinrich, K; Held, S; Jung, A; Kaiser, F; Kirchner, T; Kurreck, A; Modest, DP; Neumann, J; Schenk, M; Schwaner, I; Stahler, A; Stintzing, S | 1 |
Antonuzzo, L; Avallone, A; Berardi, R; Bordonaro, R; Castellano, G; Chiarazzo, C; Ciardiello, D; Ciardiello, F; Damato, A; De Stefano, A; De Vita, F; Di Maio, M; Famiglietti, V; Gervaso, L; Giampieri, R; Latiano, TP; Lavacchi, D; Maiello, E; Maiorano, BA; Martinelli, E; Martini, G; Napolitano, S; Normanno, N; Oneda, E; Parisi, A; Parrella, P; Pinto, C; Rapisardi, S; Tamburini, E; Troiani, T; Zampino, MG; Zaniboni, A; Zichi, C | 1 |
Afable, M; Gathirua-Mwangi, W; Khan, T; Wu, Y; Yang, T | 1 |
Paduch, R; Piet, M | 1 |
Hanuš, J; Kroupová, J; Štěpánek, F | 1 |
Dasari, A; Deming, D; George, TJ; Kopetz, S; Lieu, CH; Lin, Y; Lucas, PC; Sahin, IH; Yothers, G | 1 |
Hamamoto, Y; Hazama, S; Iida, M; Ioka, T; Kanesada, K; Matsui, H; Nagano, H; Ogihara, H; Shindo, Y; Suzuki, N; Takeda, S; Tokumitsu, Y; Tsunedomi, R; Yoshida, S | 1 |
Arnold, D; Asselain, B; Castagné, C; Chibaudel, B; Cremolini, C; Cuyle, PJ; Ghanem, I; Khan, S; Kim, S; Martinelli, E; Mazard, T; Tougeron, D; Vidal, J; Virchow, I; Zkik, A | 1 |
Fang, Z; Gao, F; Peng, L; Peng, W; Song, F; Zhu, C | 1 |
Buckland, A; Clay, E; Howard, D; Laramée, P; Macabeo, B; Malka, D; Poll, A; Samalin, E; Sivignon, M; Toumi, M; Trouiller, JB | 1 |
Bai, Y; Gong, J; Huang, D; Ji, C; Li, J; Li, Y; Shen, L; Sun, Y; Wang, X; Wang, Z; Xin, Y; Xu, T; Zhang, X; Zhao, F | 1 |
Denda, T; Ishizuka, N; Kato, K; Kumekawa, Y; Nakano, D; Narikazu, B; Osumi, H; Ouchi, K; Sawada, R; Shinozaki, E; Shiozawa, M; Takashima, A; Wakatsuki, T; Yamaguchi, K | 1 |
Ahmed, KA; Aidy, SE; Azmy, AF; Dishisha, T; El-Gendy, AO; Hassan, A; Mahdy, MS; Mohamed, WR | 1 |
Hara, H; Ishihara, S; Kagawa, Y; Kajiwara, T; Kawakami, H; Kotaka, M; Kuboki, Y; Makiyama, A; Masuishi, T; Morita, S; Nakajima, TE; Nakamura, M; Ojima, H; Oki, E; Ozawa, D; Shirao, K; Sugimoto, N; Sunakawa, Y; Takashima, A; Takenaka, N; Taniguchi, H; Terazawa, T; Watanabe, J; Yoshino, T | 1 |
Antoniotti, C; Aprile, G; Avallone, A; Ciardiello, D; Ciardiello, F; Cremolini, C; Del Re, M; Esposito, L; Famiglietti, V; Latiano, TP; Lonardi, S; Maiello, E; Martinelli, E; Martini, G; Masi, G; Napolitano, S; Normanno, N; Pietrantonio, F; Pinto, C; Rossini, D; Santini, D; Troiani, T | 1 |
André, T; Bodoky, G; Cremolini, C; Heinemann, V; Maughan, T; McDermott, R; Osterlund, P; Pfeiffer, P; Punt, CJA; Teske, AJ; Van Cutsem, E | 1 |
Bohnenberger, H; Ghadimi, M; Kauffels, A; Nowack, H; Sperling, J; Spitzner, M; Sprenger, T | 1 |
Cao, J; Ding, Y; Feng, X; Ji, D; Liu, L; Mao, C; Song, L; Song, W; Wu, Y; Xu, N; Zhang, J; Zhang, Y | 1 |
Azarkan, M; Chang, YJ; Chen, HA; Huang, CY; M'Rabet, N; Makondi, PT; Tsai, KY; Wei, PL | 1 |
Ando, M; Hamauchi, S; Honda, K; Kadowaki, S; Kawakami, T; Masuishi, T; Mori, K; Muro, K; Narita, Y; Onozawa, Y; Shirasu, H; Taniguchi, H; Todaka, A; Tsushima, T; Yamazaki, K; Yasui, H; Yokota, T | 1 |
Barg, E; Bęben, D; Emhemmed, F; Frąszczak, J; Gębczak, K; Moreira, H; Muller, CD; Nowak, P; Radajewska, A; Siwiela, O; Szyjka, A | 1 |
Alevisopoulos, N; Charokopakis, A; Delicha, E; Emmanouil, E; Filippiadis, DK; Glantzounis, G; Kartsouni, V; Kelekis, N; Kiakidis, T; Malagari, K; Moschouris, H; Panagiotou, I; Pellerin, O; Psarros, G; Tsavaris, N; Vergadis, C | 1 |
Chin, K; Fukuda, K; Fukuoka, S; Nakayama, I; Ogura, M; Ooki, A; Osumi, H; Shinozaki, E; Takahari, D; Wakatsuki, T; Yamaguchi, K; Yoshino, K | 1 |
Chang, W; Fu, J; Lin, Q; Lv, Y; Tang, W; Wang, G; Xu, J; Xu, Y; Zhang, T; Zheng, X; Zhu, Z | 1 |
Ekielski, A; Gupta, N; Hasan, N; Iqbal, Z; Jaggi, M; Kesharwani, P; Madaan, A; Mishra, PK; Saad, S; Siddiqui, L; Singh, AT; Talegaonkar, S | 1 |
Dechaphunkul, A; Sathitruangsak, C; Sunpaweravong, P; Wonglhow, J | 1 |
Connors, DE; Curry, M; Dercle, L; Flynn, JR; Fojo, AT; Gönen, M; Moskowitz, CS; Schwartz, LH; Yang, H; Zhao, B | 1 |
Abd El-Sadek, I; Lichtenegger, A; Makita, S; Matsusaka, S; Mori, T; Mukherjee, P; Shen, LT; Yasuno, Y | 1 |
Aparicio, T; Ben Abdelghani, M; Blons, H; Boige, V; Bouché, O; Brument, E; Castan, F; De La Fouchardière, C; François, E; Galais, MP; Genet, D; Gourgou, S; Hautefeuille, V; Jacquot, S; Le Brun-Ly, V; Levaché, CB; Levasseur, N; Miglianico, L; Mineur, L; Mitry, E; Penel, N; Phelip, JM; Villing, AL | 1 |
Čatalinac, M; Jurič, A; Karačonji, IB; Katić, A; Kozina, G; Micek, V; Neuberg, M; Vrdoljak, AL; Žunec, S | 1 |
Kim, KP; Lee, BK; Yoon, S | 1 |
Ozawa, S | 1 |
Arambula, JF; Chi, SG; Kim, JS; Koo, S; Lee, MG; Sessler, JL; Sharma, A; Won, M | 1 |
Fan, C; Gu, L; Ren, N; Shi, B; Tian, H; Wang, R; Xu, G; Zhao, C; Zhu, T; Zhu, Y | 1 |
Acikgoz, Y; Akdeniz, N; Bal, O; Caliskan Yildirim, E; Dirikoc, M; Ergun, Y; Ucar, G; Uncu, D | 1 |
Huang, H; Jiang, W; Jinbo, M; Wang, H; Wang, X; Yu, P; Zhang, G; Zhang, X | 1 |
Gajek, G; Kontek, R; Lewkowski, J; Marciniak, B | 1 |
Agrawal, S; Makuch, S; Winograd, K; Wiśniewski, J; Woźniak, M; Ziółkowski, P | 1 |
Anantharaman, A; Azarm, A; Cao, C; Lai, J; Moezardalan, K; Parikh, P | 1 |
Ando, K; Bharti, AK; Hu, Q; Mathew, J; Matsuoka, H; Mori, M; Nakashima, Y; Oki, E; Saeki, H; Swayze, EJ; Tsuda, Y; Unan, EC | 1 |
Hu, K; Li, Q; Sun, T; Wang, F; Wang, Y; Xing, S | 1 |
Du, GH; Wang, L; Wang, R; Wang, SM; Wang, Z; Wei, GY; Zhang, RP; Zhu, Y | 1 |
Endo, S; Hisamatsu, A; Ikari, A; Matsunaga, T; Morikawa, Y; Okumura, N; Saito, H; Suenami, K | 1 |
Al-Rajabi, R; Carroll, E; Diab, O; Kasi, A; Melancon, T; Rawlley, B | 1 |
Abdel-Bar, HM; Akhtar, M; Al-Jamal, KT; Faruqu, FN; Garnaik, B; Giram, PS; Han, S; Rade, PP; Walters, AA; Wang, JT | 1 |
Chawla, SP; Higuchi, T; Hoffman, RM; Hu, K; Kawaguchi, K; Kiyuna, T; Miyake, K; Miyake, M; Oshiro, H; Razmjooei, S; Singh, SR; Wangsiricharoen, S; Zhang, Z | 1 |
Aittomäki, K; Andersson, E; Anttonen, AK; Holm, M; Kytölä, S; Osterlund, E; Osterlund, P; Ovissi, A; Ristimäki, A; Soveri, LM | 1 |
Cepero, A; Martin-Guerrero, SM; Martin-Oliva, D; Melguizo, C; Munoz-Gamez, JA; Ortiz, R; Prados, J; Quinonero, F; Urbano, D | 1 |
Cai, X; Gu, Y; Guo, W; Hu, J; Li, X; Liu, W; Wang, M; Wang, Y; Wei, B; Wu, J; Xu, L; Xu, Q | 1 |
Chan, KY; Chen, KH; Cheng, YM; Hsu, WL; Lee, CC; Liang, YH; Tsai, JH; Yeh, KH | 1 |
Chen, MC; Ho, TJ; Hsu, CH; Huang, CY; Li, CC; Mahalakshmi, B; Nhan, DC; Wang, TF; Yang, LY | 1 |
Bharali, MK; Borah, G | 1 |
Bezdenezhnykh, N; Kocherga, R; Kovalova, O; Kudryavets, Y; Lykhova, O; Maksimyak, GI; Vorontsova, A; Zhylchuk, V | 1 |
Chen, QK; Chen, XW; Huang, YF; Liao, NZ; Liu, CC; Luo, ZT; Wang, GX; Zhang, WJ; Zhu, DJ | 1 |
Adam, R; Barroso, E; Capussotti, L; Elias, D; Giuliante, F; Gruenberger, T; Guglielmi, A; Hubert, C; Innominato, PF; Isoniemi, H; Lapointe, R; Laurent, C; Lin, JK; Lopez-Ben, S; Regimbeau, JM; Skipenko, OG; Yi, B | 1 |
Abdel-Rahman, WM; Al-Khayyal, NA; Aravind, SR; Nair, VA; Saber-Ayad, M | 1 |
Chen, X; Huang, Y; Luo, Y; Su, P; Wang, G; Wang, Q; Yang, Y; Zhu, D | 1 |
He, Y; Jia, B; Lac, D; Lam, KS; Li, Y; Lin, TY; Luo, Y; Xiao, K; Xue, X; Yang, X; Zhang, H | 1 |
Azrumelashvili, T; Chikovani, T; Janikashvili, N; Kikodze, N; Mizandari, M; Paksashvili, N; Pantsulaia, I; Shanava, K | 1 |
Barszcz, K; Bernas, T; Czarnecka, J; Kaminska, B; Kominek, A; Piwocka, K; Was, H | 1 |
Blocker, SJ; Chen, W; Douglas, KA; Hendriks, BS; Lalo, E; Lee, H; Polin, LA; Shields, AF | 1 |
Fukuda, M; Hosokawa, M; Iwakawa, S; Masuda, A; Tanaka, S; Ueda, K | 1 |
Chen, HM; Cheng, AL; Lai, MS; Liang, YH; Shao, YY; Yeh, KH | 1 |
Chang, W; Li, R; Liu, W; Shen, Q; Tao, K; Tao, R; Xie, G; Yin, Y; Zhang, P | 1 |
Ebadi, M; Field, CJ; Lehner, R; Mazurak, VC | 1 |
Fei, Z; Li, G; Li, W; Wang, H; Xu, Y; Yan, H; Zhang, C | 1 |
Liu, B; Liu, S | 1 |
Anan, C; Katada, E; Mitsui, A; Sasaki, S; Uematsu, N | 1 |
Chen, MC; Day, CH; Ho, TJ; Hsu, HH; Huang, CY; Jeng, LB; Kumar Velmurugan, B; Lin, YM; Padma, VV; Tu, CC | 1 |
Abrantes, AM; Amaral, RA; Botelho, MF; Casalta-Lopes, JE; Encarnação, JC; Gonçalves, AC; Gonçalves, TJ; Laranjo, M; Pires, AS; Sarmento-Ribeiro, AB | 1 |
Chen, H; Chen, Y; Gu, Y; Hoffman, RM; Li, Y; Wang, H; Wang, W; Wu, M; Xu, M; Yang, Z; Zhu, P | 1 |
Albrecht, MH; Gruber-Rouh, T; Hammerstingl, R; Lahrsow, M; Thompson, ZM; Vogl, TJ | 1 |
Cervantes, A; Moreno Vera, S; Peeters, M; Taieb, J | 1 |
Chen, X; Ju, Y; Su, P; Wang, G; Yang, Y | 1 |
Cao, B; Guo, S; Li, Q; Lin, H; Wang, J; Yang, G; Yu, J | 1 |
Esna-Ashari, O; Fathi-Azarbayjani, A; Kheradmand, F; Malekinejad, H; Mohammadian, M; Rasmi, Y; Zeynali-Moghaddam, S | 1 |
Chang, JM; Chen, IJ; Chen, YL; Cheng, CM; Cheng, KW; Cheng, TC; Cheng, TL; Cheng, YA; Leu, YL; Lu, YC; Tseng, CH; Tzeng, CC; Wang, JY | 1 |
Druzhkova, I; Ignatova, N; Kiselev, N; Prodanets, N; Shirmanova, M; Zagainov, V; Zagaynova, E; Zhukov, I | 1 |
Bo, R; Dong, L; He, Y; Li, Y; Lin, TY; Ma, Z; Wang, Z; Xue, X; Yuan, Y | 1 |
Fu, J; Guo, M; Liu, D; Liu, H; Sun, B; Wei, W; Yang, W; Yang, Z | 1 |
Chan, R; Chang, CH; Ji, Y; Jiang, J; Liao, YP; Lin, J; Lin, P; Liu, X; Lu, J; Meng, H; Nel, AE; Okene, M; Qiu, W; Tang, I; Wainberg, ZA; Wang, X; Zheng, E | 1 |
Ichikawa, W; Imataka, H; Sekikawa, T | 1 |
Baskaran, R; Chen, MC; Ho, TJ; Hsu, HH; Huang, CY; Kuo, WW; Lee, NH; Lin, YM; Tu, CC; Viswanadha, VP | 1 |
Du, P; Long, F; Ma, J; Pang, B; Pang, X; Qiu, W; Sun, Z; Wang, Q; Wang, S; Yu, X; Yu, Y; Zeng, D; Zhang, C; Zheng, Y | 1 |
Hui, SC; Kang, C; Lang, HD; Mi, MT; Wang, XL; Yi, L; Zhang, Y; Zhou, M; Zhu, XH | 1 |
Boige, V; Boilève, A; Ducreux, M; Jozwiak, M; Le Roy, F; Malka, D; Paques, M | 1 |
Boulet, S; Burgun, A; Jannot, AS; Landi, B; Lepère, C; Pernot, S; Taieb, J; Thall, P; Ursino, M; Zaanan, A; Zohar, S | 1 |
Bang, OS; Hong, S; Kim, HY; Kim, J; Kim, NS; Kim, YA; Shin, S | 1 |
Chen, Y; Cheng, G; Lee, RJ; Wang, J; Wang, K; Yao, J; Yu, B; Zhang, C; Zhang, X; Zhang, Y | 1 |
Chen, KW; Cheng, SX; Dong, X; Fan, JX; Pan, P; Zhang, XZ; Zheng, DW | 1 |
Chen, P; Gu, N; Ji, M; Sun, C; Wang, Z; Xing, J; Zhang, H; Zhang, X; Zhou, G | 1 |
Bradshaw-Pierce, EL; Eckhardt, SG; Gustafson, DL; Kulikowski, G; Merz, AL; Pitts, TM; Selby, H; Serkova, NJ; Weekes, CD | 1 |
Diasio, RB | 1 |
Fujii, H; Horie, H; Inoue, T; Kotake, K; Miyakura, Y; Sugano, K; Tahara, M; Yasuda, Y | 1 |
Campolo, F; Dolci, S; Dorio, AS; Graziani, G; Lacal, PM; Leonetti, C; Muzi, A; Porru, M; Praz, F; Tentori, L; Vernole, P | 1 |
Huang, S; Park, JM; Sinicrope, FA; Tougeron, D | 1 |
Alberts, SR; Blanke, CD; Cassidy, J; Cheung, WY; Kerr, DJ; Meyers, J; O'Connell, M; Sargent, DJ; Shi, Q; Van Cutsem, E; Yothers, G | 1 |
Ge, FJ; Lin, L; Liu, ZY; Sharma, MR; Wang, Y; Xu, JM | 1 |
Fujiyama, Y; Kaneko, H; Kikuchi, M; Kinoshita, S; Nishizawa, T; Sakuno, T; Suzuki, H; Takahashi, M | 1 |
Goi, T; Katayama, K; Koneri, K; Sawai, K; Yamaguchi, A | 1 |
Bellemare, J; Guillemette, C; Roberge, J; Rouleau, M | 1 |
Delaunay, F; Dulong, S; Dumitru, M; Filipski, E; Guettier, C; Lévi, F; Li, XM; Mohammad-Djafari, A; Mteyrek, A; Scaglione, F; Siffroi-Fernandez, S | 1 |
Ikehata, M; Iwakawa, S; Ogawa, M; Tanaka, S; Ueda, K; Yamada, Y | 1 |
Dong, S; Qi, B; Qu, H; Tang, N; Tong, X; Wang, L; Yu, B; Yu, M; Zhang, C; Zhang, N | 1 |
Benson, AB; Bertagnolli, MM; Fuchs, CS; Goldberg, RM; Hantel, A; Imamura, Y; Liao, X; Mayer, RJ; McCleary, NJ; Meyerhardt, JA; Mowat, RB; Ng, K; Niedzwiecki, D; Ogino, S; Saltz, LB; Spiegelman, D; Whittom, R; Yamauchi, M | 1 |
Brown, KM; Gajjar, A; Han, Y; Parmar, AD; Riall, TS; Sheffield, KM; Vargas, GM | 1 |
Doki, Y; Fukunaga, M; Hasegawa, J; Hata, T; Ide, Y; Ikeda, M; Mizushima, T; Mori, M; Murata, K; Nezu, R; Ohashi, I; Sekimoto, M; Takemasa, I; Takemoto, H; Tamagawa, H; Yamamoto, H; Yasumasa, K | 1 |
Amaral, SS; Besnard, AG; Beyaert, R; Braun, H; Cunha, FQ; Graham, GJ; Guabiraba, R; Jabir, MS; Liew, FY; Lima-Junior, RC; Menezes, GB; Ribeiro, RA; Secher, T; Teixeira, MM | 1 |
Aster, RH; Curtis, BR; George, JN; Mirtsching, BC | 1 |
Endo, S; Hirai, S; Hirose, M; Hyodo, I; Saito, R; Suzuki, H; Ueno, T; Yamato, K | 1 |
Van Loon, K; Venook, AP | 1 |
Fujii, H; Horie, H; Inoue, T; Kotake, K; Miyakura, Y; Sato, F; Sugano, K; Tahara, M; Yasuda, Y | 1 |
Cao, W; Cheng, C; Huo, BL; Wang, YH; Zhang, E | 1 |
Chen, MC; Ho, TJ; Hsu, HH; Huang, CY; Kuo, CH; Kuo, WW; Lee, NH; Lin, YM; Tsai, CH; Tsai, FJ | 1 |
Bertagnolli, MM; Dzieciatkowski, S; Emond, MJ; Foster, NR; Goldberg, RM; Grady, WM; Lao, VV; Luo, Y; Maizels, N; Monnat, RJ; Nam, E; Niedzwiecki, D; Renfro, LA; Saltz, LB; Shiovitz, S; Venook, A; Warren, RS | 1 |
Bi, F; Chen, X; Liu, Z; Wei, W | 1 |
Ghazaly, E; Joel, S; Kitromilidou, C; Perry, J; Powles, T | 1 |
Cruz, JE; Hermes-DeSantis, E; Jabbour, SK; Moss, RA; Nosher, JL; Saksena, R | 1 |
Jaggi, M; Joshi, V; Negi, LM; Ronodip, K; Talegaonkar, S | 1 |
Cain, J; Drummond, DC; Fitzgerald, JB; Kalra, AV; Kim, J; Klinz, SG; Nielsen, UB; Paz, N | 1 |
Bertagnolli, MM; Caracol, A; Emond, M; Foster, NR; Goldberg, RM; Grady, WB; Lao, VV; Maizels, N; Monnat, RJ; Niedzwiecki, D; Pavelitz, T; Rabinovitch, PS; Renfro, L; Saltz, LB; Welsch, P | 1 |
Cardillo, TM; Goldenberg, DM; Govindan, SV; McBride, WJ; Rossi, EA; Sharkey, RM; Trisal, P | 1 |
Benson, AB; Chan, AT; Chan, JA; Fuchs, CS; Giovannucci, EL; Goldberg, RM; Hantel, A; Mayer, RJ; Meyerhardt, JA; Ng, K; Niedzwiecki, D; Ogino, S; Saltz, LB; Sato, K; Schaefer, PL; Venook, AP; Whittom, R | 1 |
Fan, S; He, X; Liu, M; Shi, W; Wu, D; Yao, Y; Yu, H; Zhang, P; Zhong, B; Zhou, M | 1 |
Anantha, M; Bally, MB; Gill, N; Karim, T; Neijzen, R; Ng, SS; Strutt, D; Tai, IT; Wang, H; Waterhouse, D; Wong, MQ; Yapp, DT | 1 |
Cheng, YC; Chu, E; Guan, F; Hu, R; Jiang, Z; Lam, W; Liu, SH | 1 |
Hassan, AS; Naicker, M; Wan Ishak, WZ; Yusof, KH | 1 |
Atyabi, F; Dinarvand, M; Dinarvand, R; Esmaeili, A; Kiani, M; Mirzaie, Z; Mirzazadeh, F; Soleimani, M | 1 |
Guo, D; Han, X; Ling, Y; Luo, J; Shi, C; Wang, L; Xu, G | 1 |
Matsui, H; Nagasaki, Y; Vong, LB; Yoshitomi, T | 1 |
Goldstein, SR; Hierro, LC; O'Dwyer, PJ; Selvakumaran, M; Vasilevskaya, IA; Winkler, JD | 1 |
Kapesa, L; Liu, W; Ma, J; Shen, H; Zeng, M; Zeng, S; Zhang, Y | 1 |
Holcombe, RF; Planoutene, MV; Planoutis, KS; Planutis, AK | 1 |
Fu, LW; Lin, G; Poon, DC; To, KK; Wang, F; Wei, Y | 1 |
Gjerset, RA; Zhao, M | 1 |
Cheng, PC; Kuo, MY; Lai, JK; Liang, KH; Liao, MY; Lin, CW; Lu, RM; Wu, HC | 1 |
de Bruijn, P; de Bruin, RW; Ghobadi Moghaddam-Helmantel, IM; Huisman, SA; IJzermans, JN; Mathijssen, RH; Wiemer, EA | 1 |
Arzt, J; Busman, TA; Holen, KD; Lian, G; LoRusso, P; Rosen, LS; Rudersdorf, NS; Tolcher, AW; Vanderwal, CA; Waring, JF; Yang, J | 1 |
Baker, L; Bedford, S; Browne, H; Christie, M; Drysdale, MJ; Fallowfield, M; Fiumana, A; Foloppe, N; Massey, AJ; Scrace, S; Stokes, S; Webb, P; Wood, M | 1 |
Ban, LY; Fang, FQ; Guo, HS; Liu, JW; Yu, PY; Zhang, J | 1 |
Delestre, L; Dewitte, A; Lansiaux, A; Lepretre, F; Pham, MH; Wattez, N | 1 |
Dangi, JS; Prasad, S | 1 |
Bosman, F; Brünner, N; Budinska, E; Delorenzi, M; Nielsen, SL; Nygård, SB; Roth, A; Tejpar, S; Vainer, B | 1 |
Blay, J; Cutler, MJ; Hajducek, DM; Lowthers, EL; Richard, CL; Spagnuolo, PA | 1 |
Bisgin, A; Helmfors, L; Meng, WJ; Nandy, SK; Pathak, S; Ping, J; Sun, XF; Waldmann, P | 1 |
Chen, S; Pan, M; Tong, Y; Zhang, L; Zhang, X | 1 |
Huang, CW; Lin, YW; Lu, CY; Sung, YC; Tang, HC; Tsai, HL; Wang, JH; Wang, JY; Wu, CC; Yeh, YS | 1 |
Adachi, N; Aoyama, H; Fujibayashi, Y; Furukawa, T; Saga, T; Wakizaka, H; Yoshii, Y; Zhang, MR | 1 |
Burnouf, PA; Chen, KC; Cheng, TL; Chou, HC; Huang, PT; Leu, YL; Prijovich, ZM; Roffler, SR | 1 |
Chen, J; Jia, H; Lee, RJ; Lu, L; Qin, L; Weng, S; Yu, B; Zhang, X; Zheng, Y; Zhu, W | 1 |
Agama, K; Brünner, N; Doroshow, JH; Jensen, NF; Knudsen, BR; Pfister, TD; Pommier, Y; Roy, A; Rømer, MU; Smith, DH; Stenvang, J; Zhang, HL | 1 |
Chen, MC; Chen, RJ; Ho, TJ; Hsu, HH; Huang, CY; Kuo, WW; Lee, NH; Lin, YM; Tu, CC; Viswanadha, VP | 1 |
Bosman, F; Brunner, N; Buhl, IK; Delorenzi, M; Gerster, S; Hansen, A; Jensen, PB; Jensen, T; Knudsen, S; Roth, A; Tejpar, S | 1 |
Baik, SH; Bauer, J; Bishehsari, F; Jana, A; Jung, B; Krett, N; Ozden, O; Park, SH; Sporn, JC; Staudacher, JJ; Yazici, C | 1 |
Heller, AA; Hummon, AB; LaBonia, GJ; Lockwood, SY; Spence, DM | 1 |
Havre, RF; Kalaitzakis, E; Meisner, S; Willemoe, GL | 1 |
Bajenova, O; Danilova, A; Koshkin, S; O'Brien, SJ; Petrov, N; Raskin, G; Tolkunova, E; Tomilin, A | 1 |
Amano, R; Fukuoka, T; Hirakawa, K; Ikeya, T; Iseki, Y; Kimura, K; Maeda, K; Matsutani, S; Muguruma, K; Nagahara, H; Ohira, M; Shibutani, M; Tanaka, H; Toyokawa, T | 1 |
Ding, Y; Li, DD; Li, JJ; Liu, W; Peng, RQ; Wen, XZ; Wu, XJ; Xie, B; Zhang, X; Zhang, XS; Zhu, SG | 1 |
Aragão, KS; da Silveira Bitencourt, F; de Alencar, NM; de Castro Brito, GA; de Figueiredo, IS; de Freitas, AP; Lima-Júnior, RC; Luz, PB; Magalhães, PJ; Ramos, MV; Ribeiro, RA | 1 |
Cabal-Hierro, L; O'Dwyer, PJ | 1 |
Duhoux, F; Mano, MS | 1 |
Aoki, Y; Furuta, R; Hibi, S; Ina, K; Kabeya, M; Kataoka, T; Kawai, M; Kayukawa, S; Kojima, S; Masaki, A; Mori, F; Nagao, S; Yamada, K | 1 |
Akagi, Y; Ishibashi, N; Mizobe, T; Mori, S; Murakami, H; Ogata, Y; Sasatomi, T; Shirouzu, K | 1 |
Andrews, C; Belicha-Villanueva, A; Gibbs, JF; Hylander, BL; Repasky, EA; Sugamura, K | 1 |
Bai, Y; Chu, YP; Jin, ML; Li, J; Liu, DQ; Shen, L; Wang, YH; Xu, JM; Zhang, XD | 1 |
Cox, A; Hansen, LT; Helleday, T; Meuth, M; Phear, G; Rodriguez, R; Scorah, J; Spang-Thomsen, M | 1 |
Boisdron-Celle, M; Charasson, V; Chatelut, E; Delord, JP; Fonck, M; Gamelin, E; Laurand, A; Morel, A; Pétain, A; Poirier, AL; Robert, J; Rouits, E | 1 |
Ishii, Y; Mado, K; Manmoto, J; Masuda, H; Mazaki, T; Okame, H; Suzuki, K; Takayama, T | 1 |
Akaike, M; Morinaga, S; Shiozawa, M; Sugano, N; Sugimasa, Y; Tsuchida, K | 1 |
Blumgart, LH; D'Angelica, M; DeMatteo, RP; Fahy, BN; Gonen, M; Jarnagin, WR; Ostrovnaya, I; Weiser, MR | 1 |
Gennatas, C; Gennatas, S; Michalaki, V | 1 |
Angeliki, D; Bonakis, A; Christodoulou, C; Drougou, A; Galani, E; Klouvas, G; Skarlos, D | 1 |
Becouarn, Y; Bedenne, L; Bouché, O; Bugat, R; Conroy, T; Douillard, JY; Ducreux, M; Gamelin, E; Gourgou-Bourgade, S; Kramar, A; Mineur, L; Raoul, JL; Seitz, JF; Viret, F; Ychou, M | 1 |
Gaub, MP; Guenot, D; Guérin, E; Larsen, AK; Lelong-Rebel, I; Nicolet, C; Oudet, P; Pencreach, E; Voegeli, AC | 1 |
Baracos, VE; Dieleman, LA; Field, CJ; Le Roy, S; Sawyer, MB; Xue, H | 1 |
Bertagnolli, MM; Compton, CC; Damas, B; Goldberg, RM; Hahn, HP; Hall, M; Jewell, SD; Mayer, RJ; Niedzwiecki, D; Redston, M; Saltz, LB; Warren, RS | 1 |
Lai, PS; Lin, FH; Peng, CL; Shieh, MJ; Yueh-Hsiu Wu, S | 1 |
Demetter, P; Geurs, F; Knape, S; Ponette, J; Ponette, S; Vandewaeter, S | 1 |
O'Connell, MJ | 2 |
André, T; Aranda, E; Barone, C; Bodoky, G; Bokemeyer, C; Cisar, L; Collette, L; Cunningham, D; Di Costanzo, F; Greil, R; Khayat, D; Labianca, R; Mini, E; Nordlinger, B; Roth, AD; Sobrero, AF; Tabernero, J; Topham, C; Van Cutsem, E; Zhang, X | 1 |
Coward, L; Gary, BD; Gorman, G; Hobrath, JV; Keeton, AB; Li, Y; Mathew, B; Maxuitenko, YY; Piazza, GA; Reynolds, RC; Sani, B; Thaiparambil, J; Tinsley, HN; Whitt, JD | 1 |
Bozkurt, MT; Cirak, Y; Degirmenci, M; Demir Piskin, G; Durusoy, R; Gorumlu, G; Karabulut, B; Karaca, B; Sanli, UA; Tunali, D; Uslu, R | 1 |
Matono, K; Ogata, Y; Shirouzu, K; Torigoe, S | 1 |
Fazzone, W; LaBonte, MJ; Ladner, RD; Lenz, HJ; Louie, SG; Manegold, PC; Wilson, PM | 1 |
Chang, HJ; Hong, YS; Jeong, SY; Jung, KH; Park, JG; Shin, YK; Yoo, BC | 1 |
Gunderson, HD; Leung, N; Shaikh, A; Wiisanen, ME | 1 |
Gon, H; Hamabe, Y; Inui, K; Ishida, T; Kanemitsu, K; Nakajima, T; Tanaka, K; Toyokawa, A; Tsukamoto, T; Yamashita, H | 1 |
Ambrosini, G; Schwartz, GK; Seelman, SL | 1 |
Amanze, A; Di Federico, E; Taylor, J; Verschraegen, C | 1 |
Saltz, LB; Segal, NH | 1 |
Bosman, FT; Dietrich, D; Fiocca, R; Kennedy, RD; Roth, A; Tejpar, S; Van Cutsem, E; Yan, P | 1 |
Iwaya, A; Ohta, T; Sato, R; Takii, Y | 1 |
Gotou, N; Hatori, S; Imada, T; Iwasaki, H; Kawamoto, M; Rino, Y; Samejima, J; Wada, H; Yukawa, N | 1 |
Feng, F; He, YJ; Jiang, WQ; Li, YH; Wang, FH; Wang, ZQ; Xu, RH; Zhang, DS; Zhang, L | 1 |
An, X; Feng, F; He, YJ; Jiang, WQ; Li, YH; Wang, FH; Wang, ZQ; Xiang, XJ; Xu, RH | 1 |
Cardillo, TM; Goldenberg, DM; Govindan, SV; Hansen, HJ; Moon, SJ | 1 |
Chiu, GN; Lin, H; Ling, LU; Tan, KB | 1 |
Bohlin, L; Felth, J; Fryknäs, M; Gullbo, J; Lindskog, M; Rickardson, L; Rosén, J; Wickström, M | 1 |
Ikeda, N; Saito, H; Sakano, T; Tabira, Y; Urakawa, M; Watanuki, A | 1 |
Benson, AB; Bertagnolli, MM; Fuchs, CS; Goldberg, RM; Hantel, A; Hollis, D; Irahara, N; Mayer, RJ; Meyerhardt, JA; Niedzwiecki, D; Ogino, S; Saltz, LB; Schaefer, P; Whittom, R | 1 |
Chen, XX; Guo, GF; Hu, PL; Jiang, WQ; Liu, MZ; Qiu, HJ; Xia, LP; Zhang, B; Zhou, FF | 1 |
Song, ST; Wang, Y; Xu, JM; Xu, QZ; Zhou, PK | 1 |
Inoue, S; Nasu, K; Noda, K; Umekita, N | 1 |
Choi, SH; Chun, HK; Lee, WS; Lee, WY | 1 |
Jakubowicz-Gil, J; Kandefer-Szerszen, M; Paduch, R | 1 |
Francis, P; Nilbert, M; Sun, XF; Svanvik, J; Wallin, A | 1 |
Cao, W; Chen, X; Deng, Z; Gao, Y; Liu, H; Liu, Y; Xu, L | 1 |
D'Andrea, MR; Gasparini, G; Toffoli, G | 1 |
Lenz, HJ; Winder, T | 1 |
Abbruzzese, A; Arcuri, FP; Caraglia, M; Carducci, A; Correale, P; Del Vecchio, MT; Loiacono, L; Marra, M; Migali, C; Misso, G; Remondo, C; Tagliaferri, P; Tassone, P | 1 |
Hirata, K; Nakamura, Y; Takashima, T; Tayama, Y | 1 |
Gallagher, DJ; Kemeny, N | 1 |
Alonso-Varona, A; Caramés, M; García-Alonso, I; Palomares, T | 1 |
Kenmotsu, H; Kinoshita, T; Koga, Y; Kuroda, J; Matsumura, Y; Ohkohchi, N; Takahashi, A; Yasunaga, M | 1 |
Fukushima, M; Nakagawa, F; Ohshimo, H; Sakamoto, K; Taguchi, T | 1 |
Amatu, A; Bernardo, G; Montagna, B; Pagella, C; Poggi, G; Pozzi, E; Quaretti, P; Sottotetti, F; Tagliaferri, B | 1 |
Bouvet, M; Hoffman, RM; Kawaguchi, T; Li, X; Ma, H; Okuno, S; Yagi, S; Yang, Z | 1 |
Bosse, D; Fischer von Weikersthal, L; Giessen, C; Goebeler, M; Grundeis, M; Heinemann, V; Lambertz, H; Maubach, PA; Mittermüller, J; Oruzio, D; Quietzsch, D; Schalhorn, A; Schlag, R; Schulze, M; Stauch, M; Szukics, B; Truckenbrodt, J; Vehling-Kaiser, U; Weigang-Köhler, K; Zwingers, T | 1 |
Cho, DH; Hong, YS; Jin, DH; Jung, KA; Kim, JC; Kim, SM; Kim, TW; Lee, JS; Na, YS; Ro, S; Ryu, MH; Yang, SJ | 1 |
Cho, DH; Hong, YS; Jang, SJ; Jung, KA; Kim, JC; Kim, SM; Kim, TW; Lee, JS; Moon, DH; Na, YS; Ryu, MH | 1 |
Harada, N; Hayashi, T; Sunaga, T; Suzuki, M; Suzuki, S | 1 |
Colucci, G; De Vita, F; Giuliani, F; Pisconti, S | 1 |
Ait-Arsa, I; Askari, N; Bibeau, F; Boissière, F; Causse, A; Cortijo, C; Del Rio, M; Denis, V; Denouel, A; Gongora, C; Martineau, P; Marzi, L; Mollevi, C; Paillas, S; Pourquier, P; Vezzio-Vié, N | 1 |
Guo, GF; Jiang, WQ; Qiu, HJ; Wang, F; Xia, LP; Xu, RH; Zhang, B; Zhou, FF | 1 |
Ge, FJ; Li, SS; Li, ZQ; Lin, L; Liu, JZ; Liu, LJ; Wang, Y; Xu, JM; Zhao, CH | 1 |
Aloyz, R; Amrein, L; Coulombe, Y; Davidson, D; Grenier, J; Hodkinson, K; Martinez-Marignac, VL; Masson, JY; Panasci, L | 1 |
Toema, BM | 1 |
Bot, B; Buyse, M; Cassidy, J; de Gramont, A; Grothey, A; Saltz, L; Sargent, D; Shi, Q; Van Cutsem, E; Wolmark, N; Yothers, G | 1 |
Aravantinos, G; Bafaloukos, D; Bamias, A; Basdanis, G; Dimopoulos, MA; Economopoulos, T; Efstratiou, I; Fountzilas, G; Kafiri, G; Kalofonos, HP; Karanikiotis, C; Karina, M; Klouvas, G; Korantzis, I; Makatsoris, T; Malettou, L; Matsiakou, F; Miliaras, D; Papadimitriou, CA; Papakostas, P; Papaspirou, I; Pectasides, D; Pentheroudakis, G; Pisanidis, N; Samantas, E; Xiros, N | 1 |
Beretta, G; Biroccio, A; D'Angelo, C; Franceschin, M; Gilson, E; Leonetti, C; Orlandi, A; Passeri, D; Pisano, C; Porru, M; Rizzo, A; Salvati, E; Stevens, MF; Zunino, F; Zupi, G | 1 |
Bi, F; Chen, J; Chen, X; Chen, XZ; Lang, N; Liu, M; Tang, QL; Zhao, XF | 1 |
Arita, M; Fujino, H; Kuga, Y; Miwata, T; Moriya, T; Ohya, T; Okanobu, H; Tanaka, T; Yoshimi, S | 1 |
Asanuma, H; Hasegawa, T; Hirata, K; Hirohashi, Y; Inoda, S; Ishitani, K; Kondo, T; Morita, R; Nakatsugawa, M; Nishizawa, S; Sato, N; Takahashi, A; Tamura, Y; Terui, T; Torigoe, T; Tsuruma, T | 1 |
Borel Rinkes, IH; Clevers, H; Emmink, BL; Govaert, KM; Hoogwater, FJ; Jimenez, CR; Kranenburg, O; Nijkamp, MW; Steller, EJ; Van Houdt, WJ; Verheem, A; Vries, RG | 1 |
Bedognetti, D; Bussom, S; Chen, J; Cheng, YC; Guan, F; Jiang, Z; Lam, W; Marincola, FM; Mark, Y; Quinn, C; Stroncek, DF; Wang, E; White, J; Zhao, Y | 1 |
Jerger, K; Kieler-Ferguson, HM; Riviere, K; Szoka, FC | 1 |
Allen, JE; Brown, JM; Daniel, CJ; Dicker, DT; Dolloff, NG; Dorsey, JF; El-Deiry, WS; Furth, EE; Hart, LS; Jee, DI; Klein, PS; Kuribayashi, K; Liu, JJ; Liu, YY; Mayes, PA; Sears, RC | 1 |
Chang, HM; Hong, YS; Jang, SJ; Kang, YK; Kim, JC; Kim, JE; Kim, JH; Kim, MJ; Kim, TW; Lee, JL; Lim, SB; Ryu, MH; Yu, CS | 1 |
Carnaghi, C; Personeni, N; Rimassa, L; Santoro, A; Sclafani, F; Tronconi, MC | 1 |
Basseville, A; Boisdron-Celle, M; Coqueret, O; de Carné Trécesson, S; Gamelin, E; Morel, A; Preisser, L | 1 |
Hanna, N; Hsiao, FY; Mullins, CD; Onukwugha, E; Pandya, N | 1 |
Kamiyama, H; Kato, T; Koizumi, K; Konishi, F; Maeda, T; Miyaki, Y; Saito, M; Shibata, K; Shiya, N; Suzuki, K | 1 |
Azzariti, A; Cantore, M; Cassano, G; Colabufo, NA; Gasparre, G; Iannelli, G; Panaro, MA; Paradiso, A; Porcelli, L; Quatrale, AE; Tommasi, S | 1 |
Alonso, MM; Bandres, E; Bitarte, N; Boni, V; Fortes, P; Garcia-Foncillas, J; Gonzalez-Huarriz, M; Javier Sola, J; Lopez, I; Rodriguez, J; Zarate, R | 1 |
Hanna, N; Hsiao, FY; Mullins, CD; Onukwugha, E; Pandya, NB | 1 |
Benson, AB; Bertagnolli, MM; Fuchs, CS; Goldberg, RM; Hantel, A; Hollis, D; Mayer, RJ; McCleary, NJ; Meyerhardt, JA; Ng, K; Ogino, S; Saltz, LB; Schaefer, P; Shima, K; Spiegelman, D; Whittom, R | 1 |
Antonucci, A; Bruera, G; Cannita, K; Ficorella, C; Giuliante, F; Lanfiuti Baldi, P; Marchetti, P; Nuzzo, G; Ricevuto, E; Vicentini, R | 1 |
Abe, T; Ando, M; Kato, T; Nakashima, H; Shindo, J; Shiraki, A; Yamamoto, K; Yukita, Y | 1 |
Benner, A; Dippold, W; Formentini, A; Kloor, M; Kornmann, M; Link, KH; Michel, S; Tikidzhieva, A; von Knebel Doeberitz, M | 1 |
Cabral, CB; Fram, RJ; Hanna, SK; Lowinger, TB; Rawal, S; Sen, J; Walsh, MD; Yurkovetskiy, AV; Zamboni, WC | 1 |
Abdel-Aziz, H; Abdelwahab, S; Azmy, A; Mahmoud, A; Salim, H | 1 |
Červinka, M; Mls, J; Rudolf, E; Stanislav, J | 1 |
Aigner, E; Block, NL; Buchholz, S; Datz, C; Hohla, F; Krishan, A; Perez, R; Rick, FG; Schally, AV; Seitz, S; Stadlmayr, A; Szalontay, L | 1 |
Alvarez, PJ; Aranega, A; Boulaiz, H; Caba, O; Melguizo, C; Ortiz, R; Prados, J; Rama, AR; Rodríguez-Serrano, F | 1 |
Cai, F; Clerc, A; Dupertuis, YM; Granci, V; Lecumberri, E; Pichard, C | 1 |
Deng, L; He, J; Huang, Y; Yi, C; Yu, S; Zhao, F; Zhu, H | 1 |
Degenhardt, YY; Diskin, SJ; Haglund, E; Maris, JM; Mayes, PA; Moy, C; Toporovskya, Y; Wood, A; Wooster, R | 1 |
Köhne, CH | 1 |
Aloyz, R; Davidson, D; Panasci, L; Wang, Y | 1 |
Block, NL; Buchholz, S; Datz, C; Hohla, F; Krishan, A; Rick, FG; Schally, AV; Seitz, S; Stadlmayr, A; Szalontay, L | 1 |
Bosman, F; Cisar, L; Cunningham, D; d'Ario, G; Delorenzi, M; Fiocca, R; Klingbiel, D; Labianca, R; Nordlinger, B; Roth, AD; Tejpar, S; Van Cutsem, E; Yan, P | 1 |
Benekli, M; Berk, V; Buyukberber, S; Cetin, B; Coskun, U; Isikdogan, A; Kaplan, MA; Ozkan, M; Tufan, G | 1 |
Chang, YL; Cheng, AL; Liau, JY; Lin, LI; Lin, YL; Ou, DL; Tseng, LH; Yeh, KH; Yu, SC | 1 |
Etoh, T; Hayashi, H; Inoue, K; Itoh, K; Kawamura, Y; Kikuyama, M; Kimura, M; Matsumura, T; Minami, S; Sonobe, M; Suzuki, T; Takagi, M; Tsuji, D; Utsuki, H; Yamazaki, T | 1 |
Cha, H; Cho, WJ; Lee, HY; Lee, JC; Lee, SJ; Lee, YH; Min, YJ; Moon, CH; Park, HJ; Park, JW; Seo, J; Song, HT | 1 |
Choi, EW; Cusack, JC; Donahue, JM; Fuchs, BC; Kasuya, H; Kawasaki, H; Kulu, Y; Kuruppu, DK; Tanabe, KK | 1 |
Cassandrini, PA; Cirillo, M; Lunardi, G; Musola, M; Venturini, M | 1 |
Kutner, A; Maciejewska, M; Milczarek, M; Psurski, M; Rosinska, S; Wietrzyk, J | 1 |
Coudray, AM; De Gramont, A; Faivre, S; Gespach, C; Louvet, C; Raymond, E; Tournigand, C | 1 |
Commes, T; Motwani, M; Schwartz, GK; She, Y; Sirotnak, FM | 1 |
Bhonde, MR; Boland, CR; Hanski, C; Hanski, ML; Magrini, R; Notter, M; Scherübl, H; Zeitz, M | 1 |
Arnould, S; Bugat, R; Canal, P; Cassar, G; Guichard, S; Hennebelle, I | 1 |
de Graaf, M; Gerritsen, WR; Haisma, HJ; Kruyt, FA; Oosterhoff, D; Pinedo, HM; Sone, T; van Beusechem, VW; van der Meulen, IH | 1 |
Hylander, BL; Naka, T; Repasky, EA; Rustum, YM; Sugamura, K; Widmer, MB | 1 |
Hojo, K; Maekawa, R; Maki, H; Sawada, TY; Tanaka, H; Yoshioka, T | 1 |
Borel, C; Caroli-Bosc, FX; Couteau, C; Desseigne, F; Hua, A; Jacob, JH; Kramar, A; Lefebvre, P; Merrouche, Y; Raoul, JL; Seitz, JF; Ychou, M | 1 |
Ishikawa, K; Maeda, Y; Makuuchi, H; Murayama, C; Sadahiro, S; Saguchi, T; Suzuki, T; Yamamoto, T; Yasuda, S | 1 |
Azzariti, A; Church, SW; Colucci, G; Johnston, PG; Lacalamita, R; Paradiso, A; Tommasi, S; Xu, JM | 1 |
Akbulut, H; Akbulut, KG; Altuntas, F; Cindoruk, M; Icli, F; Ozturk, G; Unal, E | 1 |
Boku, N; Hyodo, I; Nakamura, A; Ohtsu, A; Saitoh, S; Shimada, Y; Shirao, K; Yamamichi, N; Yamamoto, S; Yoshida, S; Yoshioka, T | 1 |
Braun, MS; Button, CJ; Cheeseman, SL; Chester, JD; Davis, T; Hall, GD; Joel, SP; Perry, J; Seymour, MT | 1 |
Akasu, T; Fujita, S; Hosokawa, A; Matsumura, Y; Moriya, Y; Muro, K; Shimada, Y; Shirao, K; Yamada, Y | 1 |
Chen, PM; Chen, WS; Chiou, TJ; Lin, JK; Liu, JH; Tai, CJ; Wang, WS; Yen, CC | 1 |
Chiba, H; Hirayama, Y; Iyama, S; Niitsu, Y; Oku, T; Sagawa, T; Sakamaki, S; Sato, Y; Takahashi, M; Takayama, T; Takayanagi, N; Tsuji, Y | 1 |
Kikuchi, R; Noguchi, T; Oka, Y; Okada, S; Shibata, T; Toyoda, H; Uchida, Y | 1 |
De Boeck, G; de Bruijn, EA; Guetens, G; Landuyt, B; Landuyt, W; van Oosterom, AT; Verbeken, E; Wildiers, H | 1 |
Sawabu, N | 1 |
Dueland, S; Lund-Johansen, F; Ostenstad, B; Sauer, T; Tveit, KM | 1 |
Fujimoto, T; Hashimoto, M; Ishibashi, K; Iwasaki, K; Kato, H; Ogawa, K; Umehara, A; Yokomizo, H; Yoshida, K; Yoshimatsu, K | 1 |
Levin, M | 1 |
Dimitrakopoulos, A; Giannakakis, T; Gouveris, P; Karadima, D; Kosmas, C; Margaris, H; Papalambros, E; Papastratis, G; Polyzos, A; Rokana, S; Tsavaris, N; Tsipras, H; Vadiaka, M; Ziras, N | 1 |
Atalay, G; Bleiberg, H; Cardoso, F; Goldberg, RM; Paesmans, M | 1 |
Chung, C; Fidler, JM; Gao, M; Li, K; Rosen, GD; Ross, JA; Wei, K | 1 |
Maeda, Y; Sasaki, E; Sasaki, T | 1 |
Bosron, WF; Cummings, OW; Davis, WI; Fredenburg, TB; Murry, DJ; Quinney, SK; Sanghani, SP; Seitz, DE; Sun, Z | 1 |
Bauzon, M; Danks, MK; Dubensky, T; Fattaey, A; Holman, P; Johnson, L; Lemmon, M; Perin, N; Potter, PM; Stubdal, H | 1 |
Evans, SS; Harper, SM; Nagourney, RA; Radecki, S; Sommers, BL | 1 |
Broggini, M; Colombo, T; Geroni, C; Marchini, S; Sabatino, MA | 1 |
Ebuchi, M; Hasegawa, K; Maruyama, M; Nagahama, T; Takashima, I | 1 |
Furukawa, J; Ishigami, H; Katsumoto, Y; Kinuta, M; Maruyama, KT; Maruyama, N; Nagai, K; Nakaguchi, K; Tanaka, J; Yokouchi, H | 1 |
El-Deiry, WS; Wang, S | 1 |
Allegrini, G; Calabresi, P; Darnowski, JW; Goulette, FA | 1 |
Allen, JD; Boyd, G; Cummings, J; Friedberg, TH; Jodrell, DI; Maliepaard, M; Smyth, JF; Yao, D; Zelcer, N | 1 |
Curley, SA; Ellis, LM; Gentner, B; Parikh, AA; Vauthey, JN; Wu, TT | 1 |
Boyd, G; Burchell, B; Cummings, J; Ethell, BT; Jardine, L; Jodrell, DI; Macpherson, JS; Smyth, JF | 1 |
Altundag, K; Barista, I; Celik, I; Engin, H; Guler, N; Gullu, I; Kars, A; Oksuzoglu, B; Ozisik, Y; Tekuzman, G; Turker, A; Yalcin, S | 1 |
Berger, MR; Leible, M; Saenger, J; Seelig, MH | 1 |
Cammia, C; Croci, V; De Nicolao, G; Germani, M; Magni, P; Pesenti, E; Poggesi, I; Rocchetti, M; Simeoni, M | 1 |
Carano, RA; Koeppen, H; Ross, AL; Ross, J; Schwall, RH; Van Bruggen, N; Williams, SP | 1 |
Bibeau, F; Candeil, L; Copois, V; Del Rio, M; Gourdier, I; Khan, QA; Martineau, P; Orsetti, B; Pau, B; Peyron, D; Pommier, Y; Scheffer, GL; Vezzio, N; Ychou, M | 1 |
Fujii, M; Kasakura, Y; Kobayashi, M; Kochi, M; Morishita, Y; Sato, K; Takayama, T | 1 |
Aihara, T; Fukuhara, A; Kouno, T; Murayama, M; Nakagawa, K; Nakamura, E; Niida, M; Nishimoto, Y; Nozaki, H; Syouda, S; Watanabe, Y; Yagyu, T; Yasuoka, H | 1 |
Cao, S; Durrani, FA; Rustum, YM | 2 |
Aozasa, S; Fujino, K; Hase, K; Ito, H; Okada, K; Shikina, A; Suganuma, T; Tanaka, M; Terauchi, R; Tsuda, T; Utsunomiya, K | 1 |
Azzariti, A; Paradiso, A; Porcelli, L; Xu, JM | 1 |
Bajetta, E; Biasco, G; Brandi, G; Calabrese, C; Di Battista, M; Pantaleo, MA; Poggi, R | 1 |
Fox, R; Melisko, ME; Venook, A | 1 |
Bertagnolio, MF; De Marco, S; Squilloni, E; Sternberg, CN; Vigna, L | 1 |
Holcombe, RF; Kong, KM; Wimmer, D | 1 |
Agarwal, R; Ardalan, B; Patel, M | 1 |
Harada, O; Kobayashi, M; Sasamoto, M; Shimaya, S | 1 |
Schwartz, GK; Tse, AN | 1 |
Hayashi, T; Ishiwatari, H; Kato, J; Kogawa, T; Miyanishi, K; Niitsu, Y; Oku, T; Takada, K; Takahashi, M; Takanashi, K; Takayama, T | 1 |
Fukuhara, A; Kikuchi, S; Murayama, M; Nakamura, E; Nishimoto, Y; Nozaki, H; Shouda, S; Watanabe, Y; Yagyu, T | 1 |
Ahmad, I; Ali, S; Chien, PY; Lei, S; Sheikh, S; Zhang, A | 1 |
Earle, CC; Fuchs, CS; Gazelle, GS; Kwok, A | 1 |
Doi, K; Hashimoto, D; Ishimoto, T; Kikuchi, N; Muranaka, T; Ochiai, T; Ogata, K; Ogawa, M; Ohchi, T | 1 |
Reddy, GK | 1 |
Blumenthal, RD; Goldenberg, DM; Hansen, HJ; Hayes, MK; Horak, ID; Osorio, L | 1 |
Allen, H; Ashkenazi, A; Bedi, A; Jain, AJ; Mayer, EG; Pardoll, DM; Pham, V; Prouser, TS; Ravi, R; Schulick, RD; Yu, H | 1 |
André, T; de Gramont, A; Gamelin, E; Garcia, ML; Kalla, S; Lenaers, G; Louvet, C; Méry-Mignard, D; Saavedra, A | 1 |
Bocci, G; Danesi, R; Di Paolo, A | 1 |
Brown, JL; Charlton, PA; Freathy, C; Harris, SM; Mistry, P | 1 |
Arimochi, H; Bunpo, P; Kataoka, K; Kuwahara, T; Nakayama, H; Ohnishi, Y; Vinitketkumnuen, U | 1 |
de Graaf, M; Gerritsen, WR; Giaccone, G; Haisma, HJ; Oosterhoff, D; Overmeer, RM; Pinedo, HM; van Beusechem, VW; van der Meulen, IH | 1 |
Vega-Stromberg, T | 1 |
Im, YH; Ji, SH; Jung, CW; Kang, JH; Kang, WK; Kim, K; Kim, WS; Lee, J; Lee, SH; Lim, DH; Park, BB; Park, JO; Park, K; Park, KW; Park, YS | 1 |
Abbruzzese, JL; Fidler, IJ; Hamilton, SR; He, J; Kim, SJ; Nam, DH; Rebhun, RR; Thaker, PH; Yazici, S; Yokoi, K | 1 |
Alves, PA; da Rocha, AB; Grass, LB; Grivicich, I; Henriques, JA; Kayser, GB; Regner, A; Schunemann, DP; Schwartsmann, G | 1 |
Chen, LB; Dai, M; Owen, DA; Tai, IT | 1 |
Di Costanzo, F; Doni, L | 1 |
Braun-Falco, M; Holtmann, C; Lordick, F; Ring, J | 1 |
Hanyu, F; Harada, N; Hayashi, T; Suzuki, M; Suzuki, S; Takeo, Y; Tanaka, S | 1 |
Harada, S; Hashiguchi, K; Hiraki, M; Yakushiji, H | 1 |
Ahn, JS; Chang, HM; Kang, WK; Kang, YK; Kim, HK; Kim, SR; Kim, TW; Lee, KH; Park, JO; Ryoo, BY; Zang, DY | 1 |
Almerud, A; Gubanski, M; Lideståhl, A; Lind, PA; Naucler, G | 1 |
El-Salhy, M; Hilding, L; Royson, H; Tjomsland, V | 1 |
Handa, O; Higashihara, H; Ishikawa, T; Kokura, S; Naito, Y; Nakabe, N; Sakamoto, N; Takagi, T; Yoshida, N; Yoshikawa, T | 1 |
Barnes, BJ; Hu, G; Mancl, ME | 1 |
Araki, H; Ishizaki, M; Kamiyama, Y; Kawaguchi, Y; Komiyama, Y; Nakagawa, A; Nishimura, N; Takahashi, H | 1 |
Jones, DH; Lynch, H; Silberstein, PT; Ternet, C | 1 |
Allen, WL; Johnston, PG | 1 |
Bhonde, MR; Daniel, PT; Gillissen, BF; Hanski, C; Hanski, ML; Notter, M; Zeitz, M | 1 |
Akasaka, Y; Hata, Y; Honda, S; Ito, T; Matsuoka, S; Nakajima, N; Ohmori, K; Sano, F; Yokoyama, R | 1 |
Braun, AH; Dirsch, O; Hilger, RA; Seeber, S; Stark, K; Vanhoefer, U | 1 |
Fujii, Y; Kobayashi, T; Kuga, T; Matsuoka, T; Morikage, N; Nakayama, T | 1 |
Balasubramanian, BN; Fairchild, CR; Jang, GR; Long, B; Marathe, PH; Monticello, TM; Rose, WC; Wall, ME; Wani, MC | 1 |
Cahn, JY; Merrouche, Y; Mugneret, F | 1 |
Fujishima, M; Fukunaga, M; Furukawa, H; Imamura, H; Kawasaki, T; Kishimoto, T; Kondo, M; Masutani, S; Nakayama, T; Ooshiro, R; Takemoto, H; Tanaka, J; Tatsuta, M; Yamamoto, K | 1 |
Ebisui, C; Fujimoto, T; Fujiwara, S; Fukuchi, S; Hasuike, Y; Hayashi, N; Kida, H; Sakita, I; Tsujie, M; Yoshida, T | 1 |
Chua, YJ; Cunningham, D | 1 |
Dong, QM; He, YJ; Li, YH | 1 |
Chaudhury, PK; Horton, PJ; Martinie, JB; Metrakos, P; Rochon, C; Tzimas, GN; Znajda, TL | 1 |
Beck, S; Bourquin, C; Endres, S; Hartmann, G; Schreiber, S | 1 |
Leichman, CG | 1 |
Bhonde, MR; Budczies, J; Cao, M; Daniel, PT; Gillissen, B; Hagemeier, C; Hanski, C; Hanski, ML; Mewes, HW; Moorthy, D; Scherübl, H; Simonetta, F; Truss, M; Zeitz, M | 1 |
Fujita, J; Hoshimoto, S; Kato, R; Kato, T; Morise, Z; Sugioka, A | 1 |
Alves, PA; da Rocha, AB; Grass, LB; Grivicich, I; Henriques, JA; Kayser, GB; Regner, A; Schwartsmann, G | 1 |
Duncan, J; McLeod, HL; Scheffer, GL; Scheper, RJ; Shannon, WD; Zhang, W | 1 |
Chen, YC; Chern, YT; Chi, CW; Lee, JY; Wang, JJ | 1 |
Drummond, DC; Guo, Z; Hong, K; Kirpotin, DB; Noble, CO; Park, JW | 1 |
Arakawa, Y; Saito, S; Suzuki, H; Yamada, H | 1 |
Chaudhury, P; Hayashi, S; Horton, PJ; Jass, JR; Marcus, VA; Martinie, JB; Metrakos, P; Znajda, TL | 1 |
Borner, MM | 1 |
Agrelo, R; Artiga, MJ; Bohr, VA; Castells, A; Cheng, WH; Espada, J; Esteller, M; Fraga, MF; Guerrero, D; Herranz, M; Paz, MF; Ropero, S; Sanchez-Cespedes, M; Setien, F; von Kobbe, C | 1 |
Akita, H; Ishida, H; Kabuto, T; Nakaguchi, K; Watanabe, Y | 1 |
Bando, K; Ishizuka, T; Tajiri, T; Yanagi, K; Yoshimura, K; Yoshiyasu, M | 1 |
Cuzzocrea, S; Dorio, AS; Forini, O; Graziani, G; Lapidus, R; Leonetti, C; Mazzon, E; Muzi, A; Scarsella, M; Tentori, L; Vergati, M; Xu, W; Zhang, J | 1 |
Afchain, P; André, T; de Gramont, A; Segura, C | 1 |
Hunter, K; Jones-Bolin, S; Klein-Szanto, A; Ruggeri, B; Zhao, H | 1 |
Anazawa, S; Eto, K; Kosuge, M; Mitsuyama, Y; Mouri, T; Ogawa, M; Ushigome, T; Watanabe, M; Yamagata, T; Yanaga, K | 1 |
Caciagli, B; Capaccioli, S; Donnini, M; Landini, I; Lapucci, A; Lulli, M; Mazzei, T; Mini, E; Morganti, M; Nobili, S; Papucci, L; Perna, F; Schiavone, N; Sobrero, A; Tempestini, A; Witort, E | 1 |
Deguchi, Y; Kaneko, I; Kii, E; Murata, T; Sonoda, K; Tsubono, M; Yasuda, K | 1 |
Egami, K; Maruyama, H; Matsutani, T; Miyamoto, M; Sasajima, K; Suzuki, S; Tajiri, T; Yokoyama, T | 1 |
Hiro, J; Inoue, Y; Kusunoki, M; Miki, C; Nakatani, K; Nobori, T; Ojima, E; Toiyama, Y; Watanabe, H | 1 |
Allaire, N; Amatucci, J; Bailly, V; Bottiglio, C; Browning, JL; Carmillo, A; Crowell, T; Ding, J; Fawell, S; Garber, E; Griffith, L; Heaney, G; Hoffman, R; Jarpe, M; Kelly, R; LePage, D; Lukashev, M; Lukashin, A; Mackay, F; Meier, W; Miatkowski, K; Ngam-ek, A; Perrin, S; Prentice, H; Reff, M; Silverio, E; Szeliga, K; Violette, SM; Wilson, C; Wortham, K; Xu, X; Yang, D; Yang, W; Zeng, W | 1 |
Hamaguchi, T; Kitagawa, M; Koizumi, F; Matsumoto, S; Matsumura, Y; Negishi, T; Onda, T | 1 |
Fukushima, M; Hoebe, EK; Peters, GJ; Temmink, OH | 1 |
Higa, GM | 1 |
Ezumi, K; Fujie, Y; Fukunaga, H; Hata, T; Hirota, S; Ikeda, M; Ikenaga, M; Monden, M; Ohue, M; Sekimoto, M; Seshimo, I; Shingai, T; Takayama, O; Takemasa, I; Yamamoto, H; Yasui, M | 1 |
Bucana, CD; Fidler, IJ; Kitadai, Y; Kuwai, T; Nakamura, T; Sasaki, T | 1 |
Enomoto, M; Iida, S; Ishiguro, M; Kato, K; Makino, H; Morita, S; Sugihara, K; Takagi, Y; Uetake, H | 1 |
Azzariti, A; Han, Y; Li, YM; Li, ZQ; Paradiso, A; Wang, Y; Xu, JM; Yang, WW; Yuan, SJ; Zhao, CH | 1 |
Guichard, SM; Hua, ML; Jodrell, DI; Kang, P; Macpherson, JS | 1 |
Kitajima, M; Kubota, T; Wada, N | 1 |
Hiro, J; Inoue, Y; Kusunoki, M; Miki, C; Ojima, E; Toiyama, Y; Watanabe, H; Yanagi, H | 1 |
Honda, K; Kondo, H; Ohura, K; Sumiyoshi, T; Takahari, D; Tanaka, S; Tsuji, Y; Tsushima, T; Yoshizaki, N | 1 |
Kabeya, K; Kamoshita, N; Kobayashi, M; Makita, F; Matsuzaki, Y | 1 |
Hyodo, I | 1 |
Wils, J | 1 |
André, T; de Gramont, A; Larsen, AK; Louvet, C; Tournigand, C | 1 |
Adam, R | 1 |
Benson, AB; Mulcahy, MF; Wisinski, KB | 1 |
Arima, S; Futami, K; Kamitani, T; Koga, M | 1 |
Komatsu, Y | 1 |
Aikou, T; Akiyama, S; Akune, S; Che, XF; Firth, SD; Furukawa, T; Ikeda, R; Ishizawa, T; Kitazono, M; Komatsu, M; Mercer, JF; Owatari, S; Takeuchi, T; Tsujikawa, K; Yamamoto, M | 1 |
Bayer, W; Hoffmann, D; Wildner, O | 1 |
Fakih, MG; Gupta, B; LeVea, C; Litwin, A | 1 |
Berglund, A; Brünner, N; Byström, P; Christensen, IJ; Glimelius, B; Nielsen, HJ; Sørensen, NM | 1 |
Bosron, WF; Davis, WI; Green, SL; Sanghani, PC; Sanghani, SP; Schiel, MA | 1 |
Meropol, NJ | 1 |
Boku, N; Yamazaki, K; Yoshino, T | 1 |
He, YJ; Jiang, WQ; Li, YH; Luo, HY; Shi, YX; Wang, F; Xu, RH; Zhang, L | 1 |
Eguchi, T; Hiro, J; Inoue, Y; Kusunoki, M; Miki, C; Tanaka, K; Toiyama, Y; Yoshiyama, S | 1 |
Ishizu, K; Makuuchi, H; Sadahiro, S; Sunose, N; Tsuruo, T; Yamazaki, K; Yamori, T | 1 |
Choi, CH; Han, HK; Han, SI; Jung, GR; Kim, KJ; Lee, TB; Lim, SC | 1 |
Czaykowski, PM | 1 |
Ciardiello, F; Eckhardt, SG; Gustafson, DL; Henthorn, TK; Lockerbie, O; Long, M; Merz, A; Morrow, M; Serkova, NJ; Troiani, T | 1 |
Arnold, D; Lordick, F | 1 |
Baracos, VE; Dieleman, LA; Field, CJ; Sawyer, MB; Xue, H | 1 |
Alami, N; Belanger, S; Grieshaber, CK; Juste, S; Leyland-Jones, B; Paterson, J | 1 |
Fan, D; Fidler, IJ; Kim, JS; Kim, SJ; Kitadai, Y; Kuwai, T; Langley, RR; Nakamura, T; Sasaki, T; Tsan, RZ | 1 |
Berard, E; Colosetti, P; Czerucka, D; Dreano, M; Fenouille, N; Griessinger, E; Hofman, P; Imbert, V; Lagadec, P; Mari, M; Nawrot, MP; Peyron, JF; Rousseau, D | 1 |
Arita, A; Fujimoto, M; Mochizuki, K; Sakai, Y | 1 |
Breil, C; Candeil, L; Conseiller, E; Copois, V; Del Rio, M; Denis, V; Fraslon, C; Gongora, C; Martineau, P; Molina, F; Pau, B; Vezzio, N | 1 |
Matsuda, T; Shikata, S | 1 |
Baracos, VE; Dieleman, LA; Field, CJ; Murray, D; Sawyer, MB; Xue, H | 1 |
Ambrosini, G; Qin, LX; Schwartz, GK; Seelman, SL | 1 |
Buchsbaum, DJ; Kim, H; LoBuglio, AF; Nan, L; Oliver, PG; Wang, W; Zhou, T; Zinn, KR | 1 |
Inagaki, D; Katayama, K; Oosawa, H; Shiraishi, R; Tanabe, H; Tani, K; Wada, H; Yasuda, S | 1 |
Bar-Eli, M; Fan, D; Fidler, IJ; Kerbel, RS; Kim, SJ; Kuwai, T; Nakamura, T; Sasaki, T; Villares, GJ; Wang, H; Zigler, M | 1 |
Ferreud, L; Holmlund, B; Sun, XF; Svanvik, J; Wallin, A | 1 |
Alami, N; Jerome, L; Leyland-Jones, B; Page, V; Paterson, J; Shiry, L; Yu, Q | 1 |
Cheshire, PJ; Danks, MK; Friedman, HS; Hallman, JD; Houghton, JA; Houghton, PJ; Lutz, L | 1 |
Choh, H; Kusano, M; Nakao, K; Shibusawa, M; Takada, M; Tsunoda, A; Yokoyama, N; Yoshizawa, H | 1 |
Rivory, LP; Robert, J | 1 |
Akiyama, S; Andoh, T; Ito, K; Kodera, Y; Kondou, K; Nagai, S; Nishizawa, M; Satta, T; Takagi, H; Yamauchi, M | 1 |
Fujimura, T; Kanno, M; Kurosaka, Y; Miwa, K; Miyazaki, I; Nishimura, G; Satou, T; Sugiyama, K; Yonemura, Y; Yoshimitsu, Y | 1 |
Kono, A; Shimazoe, T; Takiguchi, S | 1 |
Bissery, MC; Cheshire, PJ; Hallman, JC; Houghton, JA; Houghton, PJ; Mathieu-Boué, A | 1 |
Terada, K | 1 |
Chou, TC; Conti, JA; Gonzalez, C; Huang, Y; Kemeny, NE; Pulliam, S; Saltz, LB; Sun, M; Tong, WP | 1 |
Boisseau, M; Bugat, R; Mahjoubi, M | 1 |
Keith, WN; McLeod, HL | 1 |
Willson, JK | 1 |
Adenis, A; Becouarn, Y; Bonneterre, J; Brunet, P; Bugat, R; Burki, F; Conroy, T; Culine, S; Douillard, JY; Extra, JM; Ganem, G; Herait, P; Mahjoubi, M; Marty, M; Merrouche, Y; Mousseau, M; Namer, M; Negrier, S; Rougier, P; Seitz, JF; Suc, E; Ychou, M | 1 |
Iino, Y; Kobayashi, I; Maemura, M; Morishita, Y; Ogawa, T; Ohwada, S; Satoh, Y | 1 |
Boven, E; Giaccone, G; Hulscher, ST; Jansen, WJ; Pinedo, HM; Zwart, B | 1 |
Cowan, KH; Fukuda, M; Ikeda, K; Kohno, S; Matsuo, I; Nakano, R; Narasaki, F; Oka, M; Soda, H; Takatani, H; Terashi, K; Tomonaga, M | 1 |
Kubota, N; Omura, M; Torigoe, S | 1 |
Egashira, Y; Hirata, I; Katsu, K; Kawabe, S; Nakagawa, K; Nakagawa, Y; Takao, Y; Takiuchi, H | 1 |
Courtney, A; Cox, J; Meyer, W; Mues, G; Nemunaitis, J | 1 |
Aoyagi, K; Aoyagi, Y; Asao, T; Okazaki, S; Sano, M; Utsugi, T; Wierzba, K; Yamada, Y | 1 |
Cheshire, PJ; Hanna, SK; Houghton, JA; Houghton, PJ; Luo, X; McGovren, JP; Poquette, C; Richmond, LB; Stewart, CF; Zamboni, WC | 1 |
Aschele, C; Baldo, C; Bertino, JR; Bornmann, WG; Debernardis, D; Sobrero, AF | 1 |
Bierling, P; Bozec, L; Cvitkovic, E; Debat, P; Fromont, P; Lévi, F; Misset, JL | 1 |
Bugat, R; Canal, P; Chatelut, E; Guichard, S; Lochon, I; Mahjoubi, M | 1 |
McCann, J | 1 |
Jimbo, T; Kumazawa, E; Ochi, Y; Tohgo, A | 1 |
Bours, V; Fillet, G; Jerusalem, G | 1 |
Fidler, IJ; Killion, JJ; Kumar, R; Kuniyasu, H; Shinohara, H | 1 |
Cheshire, PJ; Hallman, JD; Houghton, JA; Houghton, PJ; Li, Y; Luo, X; Lutz, L | 1 |
du Sorbier, BM; Lokiec, F; Sanderink, GJ | 1 |
Etienne, MC; Fischel, JL; Formento, JL; Formento, P; Francoual, M; Milano, G; Pavillard, V; Rostagno, P | 1 |
Fujikawa, R; Fukushima, J; Goya, T; Koshiishi, Y; Miya, T; Nogami, H | 1 |
Attar, A; Bloch, F; Bruneval, P; Duong Van Huyen, JP; Kreft, C; Levoir, D; Molina, T | 1 |
Britten, CD; Eckhardt, SG; Hilsenbeck, SG; MacDonald, JR; Mangold, G; Marty, J; Rowinsky, EK; Von Hoff, DD; Weitman, S | 1 |
Berger, NA; Whitacre, CM; Willson, JK; Zborowska, E | 1 |
Cvitkovic, E; Goldwasser, F; Raymond, E; Zeghari-Squalli, N | 1 |
Bugat, R; Canal, P; Chatelut, E; Chevreau, P; Frétigny, E; Guichard, S; Hennebelle, I; Lochon, I; Selves, J; Terret, C | 1 |
Chen, AY; Choy, H; Rothenberg, ML | 1 |
Ebuchi, M; Irie, T; Kure, M; Maruyama, M; Nagahama, T; Yoshida, T | 1 |
Armand, JP; Bexon, A; Bonnay, M; Ducreux, M; Mahjoubi, M; Méry-Mignard, D; Rougier, P; Seitz, JF; Ychou, M | 1 |
Joel, SP; te Poele, RH | 1 |
Gliniak, B; Le, T | 1 |
Al-Zoubi, A; Boucher, J; Savarese, D | 1 |
Ford, HE; Jackman, AL; Kimbell, R | 1 |
Hotta, T; Ishimoto, K; Iwahashi, M; Matsuda, K; Tanaka, H; Tani, M; Tanimura, H; Tsunoda, T; Yamaue, H | 1 |
Grivicich, I; Mans, DR; Peters, GJ; Schwartsmann, G | 1 |
Baars, JJ; Huibregtse, K; Pinedo, HM; Stieltjes, H; Van der Vijgh, WJ; van Groeningen, CJ | 1 |
Bigg, DC; Bronckart, Y; Chaboteaux, C; da Costa, PM; Decaestecker, C; Gordover, L; Harper, L; Kiss, R; Lavergne, O; Lesueur-Ginot, L; Malonne, H; Philippart, P | 1 |
Hisano, C; Ishikawa, T; Kaji, Y; Maruyama, T; Masumoto, N; Nakamura, M; Nakano, S; Niho, Y; Ohkuma, K | 1 |
Bugat, R; Canal, P; Chatelut, E; Guichard, S; Hennebelle, I; Terret, C | 1 |
Boven, E; Hausheer, FH; Pinedo, HM; Schlüper, HM; Van Hattum, AH | 1 |
Graeven, U; Schmiegel, W | 1 |
Boige, V; Borrini, F; Ducreux, M; Fallik, D; Jacob, S; Praz, F; Sabourin, JC | 1 |
Akamatsu, T; Fujimoto, K; Honda, T; Kaneki, T; Kawashima, A; Koizumi, T; Kubo, K; Tsushima, K | 1 |
Ebuchi, M; Maruyama, M; Nagahama, T; Yuasa, Y | 1 |
Kobayashi, A; Yamaguchi, M | 1 |
Ahmed, F; Cook, T; Gupta, E; Rubin, E; Sinko, P; Vyas, V | 1 |
Dubreuil, A; Etienne, MC; Fischel, JL; Formento, P; Milano, G; Rostagno, P | 1 |
Aoki, S; Hamamatsu, C; Hirata, K; Hirayama, T; Kawasaki, H; Matsunaga, T; Nakagawa, N; Nakayama, I; Oono, K; Sasaki, K; Shibata, K; Takaoka, A; Takasaka, H; Yabana, T; Yamamoto, Y | 1 |
Astrow, AB; Macdonald, JS | 1 |
Burger, RA; Danks, MK; Harris, LC; Iyengar, RV; Krull, EJ; Pawlik, CA; Phelps, DA; Potter, PM | 1 |
Benedetti, F; Bertino, J; Fong, Y; Gonen, M; Jarnagin, W; Kemeny, N; Paty, P; Saltz, L; Schwartz, L; Stockman, J; Sullivan, D; Tong, W | 1 |
Choufani, EB; Hartshorn, KL; Lazar, HL | 1 |
Boyd, G; Cummings, J; Jodrell, DI; Smyth, JF | 1 |
Arnould, S; Bugat, R; Canal, P; Guichard, S; Hennebelle, I | 1 |
Baba, H; Ebuchi, M; Kure, N; Maruyama, M; Nagahama, T; Toukairin, Y | 1 |
Fukumoto, S; Habara, K; Iwasaki, T; Kamigaki, T; Ku, Y; Kunimoto, Y; Kuroda, Y; Nakamura, T; Nakamura, Y; Tamura, T | 1 |
Bécouarn, Y; Bekradda, M; Coudert, B; Gamelin, E; Germa, C; Krisch, C; Mignard, D; Mousseau, M; Négrier, S; Pierga, JY; Provençal, J; Raoul, JL; Rixe, O | 1 |
Araki, Y; Hayashi, A; Ishibashi, N; Kishimoto, Y; Konishi, J; Matono, K; Mituoka, M; Miyagi, Y; Nakagawa, M; Nozoe, Y; Ogata, Y; Sasatomi, T; Shirouzu, K | 1 |
Gonen, M; Jung, C; Motwani, M; Schwartz, GK; Shah, MA; She, Y; Sirotnak, FM | 1 |
Abrams, SI; Bergmann-Leitner, ES | 1 |
Blumenthal, RD; Goldenberg, DM; Lew, W; Modrak, DE; Rodriguez, MD | 1 |
Reutova, EV | 1 |
Dove, A | 1 |
Agrawal, S; Nan, L; Wang, H; Wang, S; Yu, D; Zhang, R | 1 |
Cerna, C; Davidson, KK; Heise, C; Izbicka, E; Kirn, D; Lawrence, RA; Petit, T; Von Hoff, DD | 1 |
Boyd, G; Cummings, J; Jodrell, DI; Macpherson, JS; Smith, G; Smyth, JF; Wolf, H | 1 |
Boyd, G; Burchell, B; Cummings, J; Ethell, BT; Jodrell, DI; Macpherson, JS; Smyth, JF | 1 |
Benchalal, M; Fingerhut, A; Fouere, S; Yahchouchy-Chouillard, E | 1 |
Dimitrakopoulos, A; Gennatas, K; Giannopoulos, A; Kosmas, Ch; Koufos, Ch; Macheras, A; Margaris, H; Papalambros, E; Papastratis, G; Polyzos, A; Tsavaris, NB; Tsipras, H; Vadiaka, M | 1 |
Aikawa, M; Dupree, K; Escandón, E; Fox, JA; Lowe, J; Sinicropi, D; Totpal, K; Xiang, H | 1 |
Agrawal, S; Ball, R; Chen, SF; Dexter, DL; Hollister, BA; Kandimalla, ER; Lombardi, G; Lucas, T; Yu, D | 1 |
Agrawal, S; Hang, J; Kandimalla, ER; Li, M; Shi, Z; Wang, H; Yu, D; Zhang, R | 1 |
Fujita, M; Kawasaki, M; Shibata, J; Tani, T | 1 |
de Bruijn, P; Loos, WJ; Mathijssen, RH; Nooter, K; Sparreboom, A; Verweij, J | 1 |
Fujita, M; Kobayashi, I; Miyamoto, Y; Morishita, Y; Owada, S; Taguchi, T; Takeshita, M | 1 |
Eguchi, K; Karato, A; Kojima, A; Kunikane, H; Ohe, Y; Ohmatsu, H; Okamoto, H; Sasaki, Y; Shinkai, T; Tamura, T | 1 |
36 review(s) available for irinotecan and Cancer of Colon
Article | Year |
---|---|
Phase II Study of Third-Line Panitumumab Rechallenge in Patients with Metastatic Wild-Type KRAS Colorectal Cancer Who Obtained Clinical Benefit from First-Line Panitumumab-Based Chemotherapy: JACCRO CC-09.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Clinical Trials, Phase II as Topic; Colonic Neoplasms; Colorectal Neoplasms; Humans; Irinotecan; Multicenter Studies as Topic; Panitumumab; Prospective Studies; Proto-Oncogene Proteins p21(ras) | 2021 |
Trifluridine/tipiracil: an emerging strategy for the management of gastrointestinal cancers.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Clinical Trials as Topic; Colonic Neoplasms; Docetaxel; Drug Combinations; Fluorouracil; Gastrointestinal Neoplasms; Humans; Immunotherapy; Indoles; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Pyrrolidines; Quality of Life; Taxoids; Thymine; Trifluridine; Uracil | 2018 |
Colon cancer: update on adjuvant therapy.
Topics: Age Factors; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic | 2008 |
The role of capecitabine in the management of tumors of the digestive system.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Cholangiocarcinoma; Colonic Neoplasms; Deoxycytidine; Digestive System Neoplasms; Docetaxel; Esophageal Neoplasms; Fluorouracil; Gallbladder Neoplasms; Humans; Irinotecan; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Rectal Neoplasms; Stomach Neoplasms; Taxoids; Treatment Outcome; Vascular Endothelial Growth Factor A | 2009 |
Oxaliplatin or irinotecan as adjuvant therapy for colon cancer: the results are in.
Topics: Antineoplastic Agents; Camptothecin; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colonic Neoplasms; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic | 2009 |
Efficacy and safety of bevacizumab plus capecitabine and irinotecan regimen for metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colonic Neoplasms; Deoxycytidine; Disease-Free Survival; Fatigue; Female; Fluorouracil; Gastrointestinal Diseases; Hematologic Diseases; Humans; Hypertension; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Proteins; Rectal Neoplasms; Retrospective Studies; Vascular Endothelial Growth Factor A | 2010 |
Evolving treatment of advanced colon cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colonic Neoplasms; Deoxycytidine; Disease Progression; Fluorouracil; Humans; Irinotecan; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin | 2009 |
Molecular predictive and prognostic markers in colon cancer.
Topics: Camptothecin; Colonic Neoplasms; Dihydrouracil Dehydrogenase (NADP); ErbB Receptors; Genes, ras; Genomic Instability; Humans; Irinotecan; Loss of Heterozygosity; Organoplatinum Compounds; Oxaliplatin; Polymorphism, Genetic; Prognosis; Thymidylate Synthase | 2010 |
Metastatic colorectal cancer: from improved survival to potential cure.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Catheter Ablation; Colonic Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Male; Medical Oncology; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Time Factors; Treatment Outcome | 2010 |
Maintenance therapy in colon cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colonic Neoplasms; Disease Progression; Disease-Free Survival; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Survival Rate | 2010 |
Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; Colonic Neoplasms; Disease-Free Survival; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Proportional Hazards Models; Pyrimidines; Research Design; Time Factors; Treatment Outcome | 2011 |
[A case of irinotecan or panitumumab-induced interstitial pneumonia successfully treated by steroid pulse therapy].
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Diseases, Interstitial; Male; Methylprednisolone; Middle Aged; Organoplatinum Compounds; Panitumumab; Tomography, X-Ray Computed | 2012 |
[Recent advances in chemotherapy for digestive cancers with special references to gastric and colonic cancers].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Colonic Neoplasms; Docetaxel; Drug Administration Schedule; Drug Combinations; Drug Delivery Systems; Fluorouracil; Humans; Irinotecan; Oxonic Acid; Paclitaxel; Pyridines; Stomach Neoplasms; Taxoids; Tegafur | 2003 |
Second-line treatment in advanced colon cancer: are multiple phase II trials informative enough to guide clinical practice?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Colonic Neoplasms; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Practice Guidelines as Topic; Reproducibility of Results | 2003 |
[Chemotherapy for colon cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colonic Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Tegafur; Treatment Outcome; Uracil | 2003 |
Intergroup trial fails to demonstrate a benefit with the addition of irinotecan to bolus 5-fluorouracil/leucovorin in stage III colon cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Survival Rate | 2004 |
Advances in colon cancer chemotheapy: nursing implications.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Chemotherapy, Adjuvant; Colonic Neoplasms; Community Health Nursing; Deoxycytidine; Drug Monitoring; Fluorouracil; Home Infusion Therapy; Humans; Irinotecan; Nurse's Role; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Treatment Outcome | 2005 |
Adjuvant therapy in colon cancer: which treatment in 2005?
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Survival Rate | 2005 |
Have we made progress in pharmacogenomics? The implementation of molecular markers in colon cancer.
Topics: Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Camptothecin; Colonic Neoplasms; Fluorouracil; Forecasting; Gene Expression Profiling; Genomics; Humans; Irinotecan; Loss of Heterozygosity; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics | 2005 |
Recent data with anti-epidermal growth factor receptor antibodies and irinotecan in colon cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cetuximab; Colonic Neoplasms; Combined Modality Therapy; ErbB Receptors; Humans; Irinotecan; Panitumumab | 2005 |
[Progression of adjuvant chemotherapy for colon cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Leucovorin; Levamisole; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin | 2005 |
Adjuvant therapy for colon cancer 2005: new options in the twenty-first century.
Topics: Antineoplastic Agents; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Fluorouracil; History, 20th Century; History, 21st Century; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin | 2006 |
[Molecular targets in colon cancer].
Topics: Angiogenesis Inhibitors; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Camptothecin; Cetuximab; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Colonic Neoplasms; Drug Delivery Systems; ErbB Receptors; Gefitinib; Humans; Imatinib Mesylate; Indoles; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Phthalazines; Piperazines; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolones; Receptors, Platelet-Derived Growth Factor; Receptors, Somatomedin; Signal Transduction; Sirolimus; Sunitinib | 2006 |
[Adjuvant treatment of colorectal cancer].
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Colorectal Neoplasms; Deoxycytidine; Drug Combinations; Fluorouracil; Humans; Irinotecan; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Tegafur; Uracil | 2006 |
[Up to date chemotherapy for colon cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Drug Administration Schedule; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Neoplasm Staging; Organoplatinum Compounds; Survival Rate | 2007 |
[Standard chemotherapy for colonic neoplasms].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Tegafur; Uracil | 2007 |
Adjuvant treatment of colon cancer: past, present and future.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Levamisole; Organoplatinum Compounds; Oxaliplatin; Survival Rate | 2007 |
[Adjuvant chemotherapy for colorectal cancer in Japan-current state and problem areas].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Europe; Evidence-Based Medicine; Fluorouracil; Humans; Irinotecan; Japan; Leucovorin; Neoplasm Staging; Oxonic Acid; Practice Guidelines as Topic; Rectal Neoplasms; Tegafur; United States; Uracil | 2007 |
[Bevacizumab (Avastin)].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Colonic Neoplasms; Drug Administration Schedule; Drug Approval; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Lung Neoplasms; Male; Organoplatinum Compounds; Oxaliplatin; Rectal Neoplasms; Vascular Endothelial Growth Factor A | 2007 |
[Development of new anti-cancer agents in Europe].
Topics: Antineoplastic Agents; Camptothecin; Colonic Neoplasms; Europe; Female; France; Humans; Irinotecan; Japan; Lung Neoplasms; Ovarian Neoplasms; Uterine Cervical Neoplasms | 1996 |
Topoisomerase-I inhibitors in the management of colon cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Colonic Neoplasms; Enzyme Inhibitors; Humans; Irinotecan; Topoisomerase I Inhibitors; Topotecan | 1996 |
[Drug clinics. How I treat. II. Therapeutic approaches to metastatic colorectal cancer].
Topics: Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Colonic Neoplasms; Enzyme Inhibitors; Fluorouracil; Hospitalization; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Quality of Life; Quinazolines; Rectal Neoplasms; Thiophenes; Thymidylate Synthase; Topoisomerase I Inhibitors | 1998 |
DNA topoisomerase I-targeting drugs as radiation sensitizers.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Cycle; Colonic Neoplasms; Combined Modality Therapy; DNA Damage; DNA Repair; DNA Topoisomerases, Type I; Enzyme Inhibitors; Female; Head and Neck Neoplasms; Humans; Irinotecan; Lung Neoplasms; Neoplasms; Ovarian Neoplasms; Radiation-Sensitizing Agents; Topotecan | 1999 |
Combination of raltitrexed with other cytotoxic agents: rationale and preclinical observations.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Fluorouracil; Humans; Irinotecan; Quinazolines; Thiophenes; Tumor Cells, Cultured | 1999 |
[Colon carcinoma. Consensus of therapeutic strategies].
Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colonic Neoplasms; Colorectal Neoplasms; Dose-Response Relationship, Drug; Fluorouracil; Germany; Humans; Incidence; Irinotecan; Leucovorin; Lymphatic Metastasis; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Prodrugs | 2000 |
Adjuvant therapy of colon cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Survival Rate | 2001 |
54 trial(s) available for irinotecan and Cancer of Colon
Article | Year |
---|---|
Impact of omitting fluorouracil from FOLFIRI plus bevacizumab as second-line chemotherapy for patients with metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Neutropenia; Rectal Neoplasms; Retrospective Studies | 2023 |
First-line fluoropyrimidine plus bevacizumab followed by irinotecan-escalation versus initial fluoropyrimidine, irinotecan and bevacizumab in patients with metastatic colorectal cancer - Final survival and per-protocol analysis of the randomised XELAVIRI
Topics: Aged; Antimetabolites; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Randomized Controlled Trials as Topic; Rectal Neoplasms | 2022 |
Minimal Residual Disease-Directed Adjuvant Therapy for Patients With Early-Stage Colon Cancer: CIRCULATE-US.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Circulating Tumor DNA; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colonic Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm, Residual; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prospective Studies | 2022 |
Economic evaluation of encorafenib with cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer in France: a cost-effectiveness analysis using data from the BEACON CRC randomised controlled trial.
Topics: Adult; Bevacizumab; Cetuximab; Colonic Neoplasms; Cost-Benefit Analysis; France; Humans; Irinotecan; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Rectal Neoplasms | 2022 |
Trastuzumab Combined with Irinotecan in Patients with HER2-Positive Metastatic Colorectal Cancer: A Phase II Single-Arm Study and Exploratory Biomarker Analysis.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colonic Neoplasms; Female; Humans; Irinotecan; Phosphatidylinositol 3-Kinases; Rectal Neoplasms; Trastuzumab | 2023 |
Multicentre single-arm phase II trial evaluating the safety and effiCacy of Panitumumab and iRinOtecan in NeoRAS Wild-type mEtaStatic colorectal cancer patientS (C-PROWESS trial): study protocol.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Colonic Neoplasms; Colorectal Neoplasms; ErbB Receptors; Humans; Irinotecan; Multicenter Studies as Topic; Panitumumab; Progression-Free Survival; Proto-Oncogene Proteins p21(ras); Rectal Neoplasms | 2022 |
Trifluridine/tipiracil+bevacizumab (BEV) vs. fluoropyrimidine-irinotecan+BEV as second-line therapy for metastatic colorectal cancer: a randomised noninferiority trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colonic Neoplasms; Colorectal Neoplasms; Drug Combinations; Frontotemporal Dementia; Humans; Irinotecan; Pyrrolidines; Rectal Neoplasms; Thymine; Trifluridine | 2023 |
Suvemcitug as second-line treatment of advanced or metastatic solid tumors and with FOLFIRI for pretreated metastatic colorectal cancer: phase Ia/Ib open label, dose-escalation trials.
Topics: Antibodies, Monoclonal, Humanized; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Vascular Endothelial Growth Factor A | 2023 |
Bevacizumab, Irinotecan, and Biweekly Trifluridine/Tipiracil for Metastatic Colorectal Cancer: MODURATE, a Phase Ib Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colonic Neoplasms; Colorectal Neoplasms; Drug Combinations; Humans; Irinotecan; Rectal Neoplasms; Trifluridine; Uracil | 2023 |
Modeling Tumor Growth Using Partly Conditional Survival Models: A Case Study in Colorectal Cancer.
Topics: Colonic Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin | 2023 |
Maintenance Therapy With Cetuximab After FOLFIRI Plus Cetuximab for RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial.
Topics: Aged; Cetuximab; Colonic Neoplasms; Disease Progression; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Rectal Neoplasms | 2023 |
Detection of KRAS mutations in liquid biopsies from metastatic colorectal cancer patients using droplet digital PCR, Idylla, and next generation sequencing.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Capecitabine; Circulating Tumor DNA; Colonic Neoplasms; DNA Mutational Analysis; Female; Gene Frequency; High-Throughput Nucleotide Sequencing; Humans; Irinotecan; Liquid Biopsy; Male; Middle Aged; Oxaliplatin; Polymerase Chain Reaction; Proto-Oncogene Proteins p21(ras) | 2020 |
The predictive and prognostic value of sex in early-stage colon cancer: a pooled analysis of 33,345 patients from the ACCENT database.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Sex Factors; Survival Rate; Young Adult | 2013 |
Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Class I Phosphatidylinositol 3-Kinases; Colonic Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Microsatellite Instability; Middle Aged; Multivariate Analysis; Mutation; Neoplasm Staging; Phosphatidylinositol 3-Kinases; Polymerase Chain Reaction; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins | 2013 |
A phase II study of combined chemotherapy with 5-week cycles of S-1 and CPT-11 plus bevacizumab in patients with metastatic colon cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Drug Combinations; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Tegafur | 2013 |
CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colectomy; Colonic Neoplasms; CpG Islands; Disease-Free Survival; DNA Methylation; DNA Mismatch Repair; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Staging; Phenotype; Proportional Hazards Models; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Young Adult | 2014 |
MRE11-deficiency associated with improved long-term disease free survival and overall survival in a subset of stage III colon cancer patients in randomized CALGB 89803 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Disease-Free Survival; DNA-Binding Proteins; Female; Fluorouracil; Follow-Up Studies; Genetic Association Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; MRE11 Homologue Protein; Polymorphism, Single Nucleotide; Prognosis; Treatment Outcome; Young Adult | 2014 |
Improving the therapeutic index in cancer therapy by using antibody-drug conjugates designed with a moderately cytotoxic drug.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Bevacizumab; Camptothecin; Cell Line, Tumor; Colonic Neoplasms; Female; Humans; Immunoconjugates; Irinotecan; Mice; Mice, Nude; Rabbits | 2015 |
Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with irinotecan: results of an open-label, phase 1 study.
Topics: Adenocarcinoma; Adult; Aged; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Colonic Neoplasms; Diarrhea; Disease Progression; Dose-Response Relationship, Drug; Febrile Neutropenia; Female; Hematologic Diseases; Humans; Irinotecan; Male; Middle Aged; Neoplasm Proteins; Neoplasms; Proto-Oncogene Proteins c-bcl-2; Salvage Therapy; Sulfonamides; Treatment Outcome | 2015 |
Prospective analysis of UGT1A1 promoter polymorphism for irinotecan dose escalation in metastatic colorectal cancer patients treated with bevacizumab plus FOLFIRI as the first-line setting: study protocol for a randomized controlled trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Fluorouracil; Glucuronosyltransferase; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Outcome Assessment, Health Care; Polymorphism, Genetic; Promoter Regions, Genetic; Prospective Studies | 2016 |
[Irinotecan plus fuorouracil/leucovorin (FOLFIRI) as a second line chemotherapy for refractory or metastatic colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Disease Progression; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neutropenia; Prospective Studies; Rectal Neoplasms; Remission Induction; Survival Rate; Vomiting; Young Adult | 2008 |
Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Carboxylesterase; Chromatography, High Pressure Liquid; Colonic Neoplasms; Female; Glucuronides; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Polymerase Chain Reaction; Polymorphism, Genetic; Promoter Regions, Genetic | 2008 |
A phase I study of combination therapy with S-1 and irinotecan (CPT-11) in patients with advanced colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Injections, Intravenous; Irinotecan; Male; Middle Aged; Oxonic Acid; Rectal Neoplasms; Tegafur | 2009 |
A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Recurrence; Risk Assessment | 2009 |
Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Microsatellite Instability; Middle Aged; Neoplasm Staging; Prognosis; Prospective Studies; Survival Analysis; Young Adult | 2009 |
Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Staging | 2009 |
Tissue biomarker development in a multicentre trial context: a feasibility study on the PETACC3 stage II and III colon cancer adjuvant treatment trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; Fluorouracil; Glucuronosyltransferase; Humans; Irinotecan; Microsatellite Instability; Oligonucleotide Array Sequence Analysis; Polymorphism, Single Nucleotide; Prospective Studies; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins; Smad4 Protein; Telomerase; Tumor Suppressor Protein p53 | 2009 |
[Efficacy of FORFIRI regimen on oxaliplatin-based chemotherapy-failed advanced colorectal cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Disease Progression; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Neutropenia; Rectal Neoplasms; Remission Induction; Salvage Therapy; Survival Rate; Vomiting; Young Adult | 2009 |
KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Colonic Neoplasms; Disease-Free Survival; Female; Genes, ras; Humans; Irinotecan; Male; Microsatellite Repeats; Middle Aged; Mutation; Oncogene Protein p21(ras); Proportional Hazards Models; Treatment Outcome | 2009 |
Phase III trial of irinotecan plus infusional 5-fluorouracil/folinic acid versus irinotecan plus oxaliplatin as first-line treatment of advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Rectal Neoplasms; Young Adult | 2011 |
[Evaluation of bevacizumab combined with irinotecan-based regimen as the first-line treatment for patients with metastatic colorectal cancer].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; CA-19-9 Antigen; Camptothecin; Carcinoembryonic Antigen; Colonic Neoplasms; Diarrhea; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Humans; Hypertension; Irinotecan; Leucovorin; Male; Middle Aged; Neutropenia; Rectal Neoplasms; Remission Induction; Retrospective Studies; Survival Rate; Young Adult | 2010 |
A randomized phase III trial of adjuvant chemotherapy with irinotecan, leucovorin and fluorouracil versus leucovorin and fluorouracil for stage II and III colon cancer: a Hellenic Cooperative Oncology Group study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Dose-Response Relationship, Drug; Female; Fluorouracil; Greece; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Staging; Treatment Outcome; Young Adult | 2011 |
Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Proportional Hazards Models; Proto-Oncogene Proteins B-raf | 2012 |
Effectiveness of liver metastasectomies in patients with metastatic colorectal cancer treated with FIr-B/FOx triplet chemotherapy plus bevacizumab.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Combined Modality Therapy; Disease-Free Survival; Female; Fluorouracil; Hepatectomy; Humans; Irinotecan; Liver Neoplasms; Male; Metastasectomy; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2012 |
Microsatellite instability and Beta2-Microglobulin mutations as prognostic markers in colon cancer: results of the FOGT-4 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Biomarkers, Tumor; Camptothecin; Colonic Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Microsatellite Instability; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Proportional Hazards Models; Prospective Studies; Treatment Outcome | 2012 |
Anti-EGFR (cetuximab) combined with irinotecan for treatment of elderly patients with metastatic colorectal cancer (mCRC).
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Camptothecin; Cetuximab; Colonic Neoplasms; Diarrhea; ErbB Receptors; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Neoplasm Metastasis; Rectal Neoplasms; Skin Diseases; Treatment Outcome | 2012 |
Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Chemotherapy, Adjuvant; Chromosomes, Human, Pair 18; Colonic Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Immunohistochemistry; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Loss of Heterozygosity; Male; Microsatellite Instability; Middle Aged; Multivariate Analysis; Mutation; Neoplasm Staging; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins; Research Design; Smad4 Protein | 2012 |
High-dose, single-agent irinotecan as first-line therapy in the treatment of metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Camptothecin; Colonic Neoplasms; Diarrhea; Drug Administration Schedule; Enzyme Inhibitors; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Male; Middle Aged; Neoplasm Proteins; Neutropenia; Prodrugs; Rectal Neoplasms; Remission Induction; Safety; Topoisomerase I Inhibitors; Treatment Outcome | 2002 |
A Phase II study of irinotecan in combination with 120-h infusion of 5-fluorouracil in patients with metastatic colorectal carcinoma: Japan Clinical Oncology Group Study (JCOG9703).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Administration Schedule; Feasibility Studies; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Rectal Neoplasms | 2003 |
Phase I and pharmacokinetic study of intravenous irinotecan plus oral ciclosporin in patients with fuorouracil-refractory metastatic colon cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Cyclosporine; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasm Staging; Treatment Outcome | 2003 |
Two different schedules of irinotecan (CPT-11) in patients with advanced colorectal carcinoma relapsing after a 5-fluorouracil and leucovorin combination. A randomized study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Karnofsky Performance Status; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Rectal Neoplasms; Topoisomerase I Inhibitors | 2003 |
Combined topoisomerase I inhibition for the treatment of metastatic colon cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Diarrhea; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Maximum Tolerated Dose; Nausea; Neoplasm Metastasis; Neoplasm Staging; Neutropenia; Patient Selection; Remission Induction; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome; Vomiting | 2004 |
Two schedules of second-line irinotecan for metastatic colon carcinoma.
Topics: Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma; Colonic Neoplasms; Cost Savings; Drug Administration Schedule; Female; Health Care Costs; Humans; Irinotecan; Male; Middle Aged; Quality of Life | 2004 |
A phase I-II, dose-escalating trial of ZD9331 in combination with irinotecan (CPT11) in previously pretreated metastatic colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Quinazolines; Rectal Neoplasms | 2004 |
Phase II study of irinotecan, 5-fluorouracil and leucovorin as first-line therapy for advanced colorectal cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Leukopenia; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Rectal Neoplasms; Survival Analysis; Treatment Outcome | 2005 |
Multicenter phase II study of oral capecitabine plus irinotecan as first-line chemotherapy in advanced colorectal cancer: a Korean Cancer Study Group trial.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colonic Neoplasms; Deoxycytidine; Diarrhea; Disease Progression; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Male; Middle Aged; Neutropenia; Prodrugs; Rectal Neoplasms; Remission Induction; Survival Rate; Topoisomerase I Inhibitors; Treatment Outcome | 2005 |
[Clinical evaluation of chemotherapy with irinotecan (CPT-11), l-leucovorin (l-LV), 5-fluorouracil (5-FU), and UFT for metastatic or recurrent colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Administration Schedule; Drug Combinations; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Nausea; Rectal Neoplasms; Survival Rate; Tegafur; Uracil; Vomiting, Anticipatory | 2005 |
TIMP-1 is significantly associated with objective response and survival in metastatic colorectal cancer patients receiving combination of irinotecan, 5-fluorouracil, and folinic acid.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Carcinoembryonic Antigen; Colonic Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Neoplasm Metastasis; Odds Ratio; Rectal Neoplasms; Survival Analysis; Tissue Inhibitor of Metalloproteinase-1; Treatment Outcome | 2007 |
[Effect of chemotherapy using irinotecan (CPT-11) against recurrent colorectal cancer].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colonic Neoplasms; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Rectal Neoplasms | 1995 |
Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colonic Neoplasms; Diarrhea; Disease Progression; Drug Administration Schedule; Female; Fever; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neutropenia; Rectal Neoplasms; Remission Induction | 1997 |
Phase I study of hepatic arterial infusion of floxuridine and dexamethasone with systemic irinotecan for unresectable hepatic metastases from colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Carcinoma; Colonic Neoplasms; Cryosurgery; Dexamethasone; Female; Floxuridine; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Tomography, X-Ray Computed | 2001 |
Randomized multicenter phase II study comparing a combination of fluorouracil and folinic acid and alternating irinotecan and oxaliplatin with oxaliplatin and irinotecan in fluorouracil-pretreated metastatic colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Rectal Neoplasms; Survival Rate; Treatment Outcome | 2001 |
Irinotecan (CPT-11) in patients with advanced colon carcinoma relapsing after 5-fluorouracil-leucovorin combination.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colonic Neoplasms; Cost-Benefit Analysis; Drug Costs; Drug Resistance, Neoplasm; Female; Fluorouracil; Health Status; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Treatment Outcome | 2002 |
Phase I study and pharmacokinetics of CPT-11 with 5-day continuous infusion.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; Diarrhea; Drug Evaluation; Esophageal Neoplasms; Humans; Irinotecan; Leukopenia; Lung Neoplasms; Middle Aged; Pharyngeal Neoplasms | 1992 |
454 other study(ies) available for irinotecan and Cancer of Colon
Article | Year |
---|---|
Synthesis of water-soluble (aminoalkyl)camptothecin analogues: inhibition of topoisomerase I and antitumor activity.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cattle; Cell Line; Colonic Neoplasms; DNA, Superhelical; Drug Evaluation, Preclinical; Drug Screening Assays, Antitumor; Humans; Indicators and Reagents; Leukemia L1210; Lung Neoplasms; Melanoma, Experimental; Mice; Molecular Structure; Plasmids; Structure-Activity Relationship; Thymus Gland; Topoisomerase I Inhibitors; Transplantation, Heterologous | 1991 |
Discovery of 3-alkoxyamino-5-(pyridin-2-ylamino)pyrazine-2-carbonitriles as selective, orally bioavailable CHK1 inhibitors.
Topics: Administration, Oral; Aminopyridines; Animals; Antineoplastic Agents; Checkpoint Kinase 1; Child; Colonic Neoplasms; DNA Damage; Drug Design; Humans; Mice; Mice, Nude; Mice, Transgenic; N-Myc Proto-Oncogene Protein; Neuroblastoma; Nuclear Proteins; Oncogene Proteins; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2012 |
Antitumor Activity of Americanin A Isolated from the Seeds of Phytolacca americana by Regulating the ATM/ATR Signaling Pathway and the Skp2-p27 Axis in Human Colon Cancer Cells.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; CDC2 Protein Kinase; Checkpoint Kinase 1; Checkpoint Kinase 2; Colonic Neoplasms; Dioxins; G2 Phase Cell Cycle Checkpoints; HCT116 Cells; Humans; Mice; Mice, Nude; Molecular Structure; Phytolacca americana; Protein Kinases; Seeds; Signal Transduction; Tumor Suppressor Protein p53 | 2015 |
Amorfrutin C Induces Apoptosis and Inhibits Proliferation in Colon Cancer Cells through Targeting Mitochondria.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; bcl-2-Associated X Protein; Caspases; Cell Cycle Checkpoints; Cell Proliferation; Colonic Neoplasms; Drug Screening Assays, Antitumor; Female; G1 Phase Cell Cycle Checkpoints; Glycyrrhiza; HT29 Cells; Humans; Inhibitory Concentration 50; Male; Membrane Potential, Mitochondrial; Mitochondria; Molecular Structure; Morocco; Peroxisome Proliferator-Activated Receptors; Plant Roots; Reactive Oxygen Species; Salicylates; Structure-Activity Relationship | 2016 |
Lamellarin-inspired potent topoisomerase I inhibitors with the unprecedented benzo[g][1]benzopyrano[4,3-b]indol-6(13H)-one scaffold.
Topics: Animals; Antineoplastic Agents; Cattle; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Coumarins; Drug Design; Drug Screening Assays, Antitumor; Humans; Indoles; Male; Mice, Inbred BALB C; Molecular Structure; Structure-Activity Relationship; Topoisomerase I Inhibitors | 2019 |
A single microbubble formulation carrying 5-fluorouridine, Irinotecan and oxaliplatin to enable FOLFIRINOX treatment of pancreatic and colon cancer using ultrasound targeted microbubble destruction.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Mice; Microbubbles; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome; Uridine | 2021 |
Improved Survival over Time After Resection of Colorectal Liver Metastases and Clinical Impact of Multigene Alteration Testing in Patients with Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Hepatectomy; Humans; Irinotecan; Liver Neoplasms; Mutation; Oxaliplatin; Prognosis; Rectal Neoplasms; Survival Rate | 2022 |
Downregulation of PHLPP induced by endoplasmic reticulum stress promotes eIF2α phosphorylation and chemoresistance in colon cancer.
Topics: Activating Transcription Factor 4; Autophagy; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; Down-Regulation; Drug Resistance, Neoplasm; Endoplasmic Reticulum Stress; Eukaryotic Initiation Factor-2; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Nuclear Proteins; Phosphoprotein Phosphatases; Phosphorylation; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Binding; Signal Transduction; Tunicamycin | 2021 |
Comparison of
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Glucuronosyltransferase; Humans; Irinotecan; Leucovorin; Retrospective Studies | 2022 |
A Comparison of Folinic Acid, Fluorouracil and Irinotecan (FOLFIRI) plus Bevacizumab and FOLFIRI plus Aflibercept as Second-line Treatment for Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Rectal Neoplasms | 2022 |
Single cell mass spectrometry studies reveal metabolomic features and potential mechanisms of drug-resistant cancer cell lines.
Topics: Cell Line, Tumor; Colonic Neoplasms; Humans; Irinotecan; Mass Spectrometry; Metabolomics; Neoplastic Stem Cells; Reactive Oxygen Species; Stearoyl-CoA Desaturase | 2022 |
Orally delivered solid lipid nanoparticles of irinotecan coupled with chitosan surface modification to treat colon cancer: Preparation, in-vitro and in-vivo evaluations.
Topics: Animals; Chitosan; Colonic Neoplasms; Drug Carriers; Irinotecan; Lipids; Liposomes; Male; Nanoparticles; Particle Size; Rats; Rats, Wistar; Tissue Distribution | 2022 |
Presenting a bioactive nanotherapeutic agent for colon cancer treatment.
Topics: Antineoplastic Agents; Cell Line, Tumor; Colonic Neoplasms; Drug Carriers; Drug Delivery Systems; Humans; Irinotecan; Nanoparticles; Polymers | 2022 |
A novel irinotecan derivative ZBH-1207 with different anti-tumor mechanism from CPT-11 against colon cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Caspase 3; Cell Line, Tumor; Colonic Neoplasms; Humans; Irinotecan; Poly(ADP-ribose) Polymerase Inhibitors | 2022 |
AKT inhibition sensitizes EVI1 expressing colon cancer cells to irinotecan therapy by regulating the Akt/mTOR axis.
Topics: Animals; Cell Line, Tumor; Colonic Neoplasms; Irinotecan; Mice; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; TOR Serine-Threonine Kinases; Transcription Factors | 2022 |
Safety and efficacy of irinotecan, oxaliplatin, and capecitabine (XELOXIRI) regimen with or without targeted drugs in patients with metastatic colorectal cancer: a retrospective cohort study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Longitudinal Studies; Organoplatinum Compounds; Oxaliplatin; Rectal Neoplasms; Retrospective Studies | 2022 |
Targeted delivery of irinotecan to colon cancer cells using epidermal growth factor receptor-conjugated liposomes.
Topics: Antineoplastic Agents; Cell Line, Tumor; Colonic Neoplasms; Drug Delivery Systems; ErbB Receptors; Humans; Irinotecan; Liposomes | 2022 |
Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM).
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Oxaliplatin; Retrospective Studies; Treatment Outcome | 2022 |
Real-world overall survival of patients receiving cetuximab in later lines of treatment for metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Rectal Neoplasms; Retrospective Studies | 2022 |
Ursolic and oleanolic acids in combination therapy inhibit migration of colon cancer cells through down-regulation of the uPA/uPAR-dependent MMPs pathway.
Topics: Cadherins; Colonic Neoplasms; Down-Regulation; Humans; Irinotecan; Matrix Metalloproteinase 2; Oleanolic Acid; Ursolic Acid | 2022 |
Surprising efficacy twist of two established cytostatics revealed by a-la-carte 3D cell spheroid preparation protocol.
Topics: Adenocarcinoma; Cell Line, Tumor; Colonic Neoplasms; Cytostatic Agents; Fluorouracil; Humans; Irinotecan; Spheroids, Cellular; Tumor Microenvironment | 2022 |
Association between a single nucleotide polymorphism in the R3HCC1 gene and irinotecan toxicity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Neutropenia; Pancreatic Neoplasms; Polymorphism, Single Nucleotide; Rectal Neoplasms | 2023 |
Real-world first-line treatment of patients with BRAF
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colonic Neoplasms; Colorectal Neoplasms; Female; Humans; Irinotecan; Male; Proto-Oncogene Proteins B-raf; Retrospective Studies | 2022 |
Curcumin Suppresses the Progression of Colorectal Cancer by Improving Immunogenic Cell Death Caused by Irinotecan.
Topics: Animals; Colonic Neoplasms; Curcumin; HMGB1 Protein; Immunogenic Cell Death; Irinotecan; Mice | 2022 |
Irinotecan-gut microbiota interactions and the capability of probiotics to mitigate Irinotecan-associated toxicity.
Topics: Animals; Colonic Neoplasms; Diarrhea; Escherichia coli; Gastrointestinal Microbiome; Glucuronidase; Irinotecan; Mice; Reactive Oxygen Species; RNA, Ribosomal, 16S | 2023 |
Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild-type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and
Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Circulating Tumor DNA; Colonic Neoplasms; Colorectal Neoplasms; Humans; Irinotecan; Prospective Studies; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Rectal Neoplasms | 2023 |
Fluoropyrimidine-induced hand-foot syndrome and cardiotoxicity: recommendations for the use of the oral fluoropyrimidine S-1 in metastatic colorectal cancer.
Topics: Capecitabine; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Hand-Foot Syndrome; Humans; Immunologic Factors; Irinotecan | 2023 |
Hepatic arterial infusion with nanoliposomal irinotecan leads to significant regression of tumor size of colorectal liver metastases in a CC531 rat model.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Hepatic Artery; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Rats | 2023 |
Cytotoxic properties of unfractionated and fractionated bromelain alone or in combination with chemotherapeutic agents in colorectal cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Bromelains; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Colorectal Neoplasms; Humans; Irinotecan | 2023 |
Combination of Irinotecan and Melatonin with the Natural Compounds Wogonin and Celastrol for Colon Cancer Treatment.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Colonic Neoplasms; Humans; Irinotecan; Melatonin | 2023 |
Prospective Series of Transarterial Chemoembolization of Metastatic Colorectal Cancer to the Liver with 30-60 μm Microspheres Loaded with Irinotecan.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Colonic Neoplasms; Colorectal Neoplasms; Humans; Irinotecan; Liver Neoplasms; Microspheres; Middle Aged; Prospective Studies; Rectal Neoplasms | 2023 |
Single-organ pulmonary metastasis is a favorable prognostic factor in metastatic colorectal cancer patients treated with FOLFIRI and vascular endothelial growth factor inhibitors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Lung Neoplasms; Neoplasm Metastasis; Prognosis; Rectal Neoplasms; Retrospective Studies; Vascular Endothelial Growth Factor A | 2023 |
Treatment of metastatic colorectal cancer with BRAF V600E mutation: A multicenter real-world study in China.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cetuximab; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Mutation; Proto-Oncogene Proteins B-raf; Rectal Neoplasms; Vemurafenib | 2023 |
CD44 mediated colon cancer targeting mutlifaceted lignin nanoparticles: Synthesis, in vitro characterization and in vivo efficacy studies.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Colonic Neoplasms; Hyaluronan Receptors; Hyaluronic Acid; Irinotecan; Lignin; Mice; Nanoparticles; Tissue Distribution | 2023 |
Nineteen-year, real-world experience of first-line combination chemotherapy in patients with metastatic colorectal cancer: a propensity score analysis from southern Thailand.
Topics: Colonic Neoplasms; Drug Therapy, Combination; Humans; Irinotecan; Oxaliplatin; Propensity Score; Rectal Neoplasms; Retrospective Studies; Thailand | 2023 |
Label-free drug response evaluation of human derived tumor spheroids using three-dimensional dynamic optical coherence tomography.
Topics: Algorithms; Breast Neoplasms; Colonic Neoplasms; Drug Evaluation; Female; Humans; Irinotecan; Paclitaxel; Tomography, Optical Coherence | 2023 |
Effects of concomitant use of THC and irinotecan on tumour growth and biochemical markers in a syngeneic mouse model of colon cancer.
Topics: Animals; Biomarkers; Colonic Neoplasms; Dronabinol; Humans; Irinotecan; Male; Mice; Quality of Life | 2023 |
Caffeine enhances chemosensitivity to irinotecan in the treatment of colorectal cancer.
Topics: Adenocarcinoma; Caffeine; Camptothecin; Cell Line, Tumor; Colonic Neoplasms; Colorectal Neoplasms; DNA; Humans; Irinotecan | 2023 |
[Modulation of Expression of Drug Metabolizing Enzymes and Augmentation of Anti-cancer Drug Effects: Through Epigenetics and Three-dimensional Cancer Cell Culture Systems].
Topics: Antineoplastic Agents; Cell Culture Techniques; Colonic Neoplasms; Cytochrome P-450 CYP1A2; Decitabine; DNA; Epigenesis, Genetic; Fluorouracil; Humans; Irinotecan; Methyltransferases; Pharmaceutical Preparations | 2023 |
Targeting Heterogeneous Tumors Using a Multifunctional Molecular Prodrug.
Topics: Animals; Cell Line, Tumor; Colonic Neoplasms; Drug Delivery Systems; Drug Liberation; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Mice; Mice, Nude; Prodrugs; Xenograft Model Antitumor Assays | 2019 |
Theranostic Nanoplatform with Hydrogen Sulfide Activatable NIR Responsiveness for Imaging-Guided On-Demand Drug Release.
Topics: Animals; Apoptosis; Cell Proliferation; Colonic Neoplasms; Drug Liberation; Humans; Hydrogen Sulfide; Irinotecan; Mice; Nanoparticles; Phototherapy; Theranostic Nanomedicine; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2019 |
KRAS codon 12 and 13 mutations may guide the selection of irinotecan or oxaliplatin in first-line treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Colonic Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Mutation; Oxaliplatin; Proto-Oncogene Proteins p21(ras) | 2019 |
Ganciclovir reduces irinotecan-induced intestinal toxicity by inhibiting NLRP3 activation.
Topics: Animals; Antiviral Agents; Apoptosis; Biomarkers; Cell Proliferation; Colonic Neoplasms; Diarrhea; Ganciclovir; Gene Expression Regulation; Humans; Inflammation; Intestinal Diseases; Irinotecan; Male; Mice; Mice, Inbred BALB C; Mice, Nude; NLR Family, Pyrin Domain-Containing 3 Protein; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2020 |
Antagonistic Effects of CAPE (a Component of Propolis) on the Cytotoxicity and Genotoxicity of Irinotecan and SN38 in Human Gastrointestinal Cancer Cells In Vitro.
Topics: Antineoplastic Agents; Antioxidants; Apoptosis; Caffeic Acids; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colonic Neoplasms; Cytotoxins; DNA Damage; Drug Synergism; HCT116 Cells; HT29 Cells; Humans; Hydrogen Peroxide; Irinotecan; Lymphocytes; Mutagens; Oxidative Stress; Phenylethyl Alcohol; Propolis; Topoisomerase I Inhibitors | 2020 |
6-Shogaol enhances the anticancer effect of 5-fluorouracil, oxaliplatin, and irinotecan via increase of apoptosis and autophagy in colon cancer cells in hypoxic/aglycemic conditions.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Catechols; Cell Hypoxia; Cell Line, Tumor; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Humans; Immunosuppressive Agents; Irinotecan; Oxaliplatin; Topoisomerase I Inhibitors | 2020 |
Synchronous Primary Pancreatic Ductal Carcinoma and Colonic Adenocarcinoma Present in a Patient With History of Skin Squamous Cell Carcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Carcinoma, Squamous Cell; Colonic Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasms, Multiple Primary; Oxaliplatin; Pancreatic Neoplasms; Skin Neoplasms | 2020 |
CTDSP1 inhibitor rabeprazole regulates DNA-PKcs dependent topoisomerase I degradation and irinotecan drug resistance in colorectal cancer.
Topics: Cell Line, Tumor; Colonic Neoplasms; Colorectal Neoplasms; DNA; DNA Topoisomerases, Type I; DNA-Activated Protein Kinase; Drug Resistance; Drug Resistance, Neoplasm; Humans; Irinotecan; Phosphoprotein Phosphatases; Proton Pump Inhibitors; Rabeprazole; Retrospective Studies; Topoisomerase I Inhibitors | 2020 |
WGCNA reveals key gene modules regulated by the combined treatment of colon cancer with PHY906 and CPT11.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Colonic Neoplasms; Drugs, Chinese Herbal; Gene Expression Regulation, Neoplastic; Gene Ontology; Humans; Irinotecan; Mice; Oligonucleotide Array Sequence Analysis; Reproducibility of Results; Transcription Factors; Xenograft Model Antitumor Assays | 2020 |
Cryptotanshinone alleviates chemotherapy-induced colitis in mice with colon cancer via regulating fecal-bacteria-related lipid metabolism.
Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Bacteria; Colitis; Colon; Colonic Neoplasms; Feces; Fluorouracil; Gastrointestinal Microbiome; Irinotecan; Lipid Metabolism; Male; Mice, Inbred BALB C; Phenanthrenes; RNA, Ribosomal, 16S | 2021 |
Significance of aldo-keto reductase 1C3 and ATP-binding cassette transporter B1 in gain of irinotecan resistance in colon cancer cells.
Topics: Aldehydes; Aldo-Keto Reductase Family 1 Member C3; ATP Binding Cassette Transporter, Subfamily B; Cell Line, Tumor; Colonic Neoplasms; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Up-Regulation | 2020 |
Dual deficiency of DPD and UGT1A1 in a case of colon cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Dihydropyrimidine Dehydrogenase Deficiency; Female; Fluorouracil; Glucuronosyltransferase; Humans; Irinotecan; Leucovorin; Middle Aged; Mutation; Tomography, X-Ray Computed | 2020 |
Green synthesis of methoxy-poly(ethylene glycol)-block-poly(l-lactide-co-glycolide) copolymer using zinc proline as a biocompatible initiator for irinotecan delivery to colon cancer in vivo.
Topics: Colonic Neoplasms; Dioxanes; Drug Carriers; Humans; Irinotecan; Nanoparticles; Particle Size; Pharmaceutical Preparations; Polyethylene Glycols; Proline; Zinc | 2021 |
A novel patient-derived orthotopic xenograft (PDOX) mouse model of highly-aggressive liver metastasis for identification of candidate effective drug-combinations.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Bevacizumab; Body Weight; Colonic Neoplasms; Fluorouracil; Humans; Irinotecan; Liver Neoplasms, Experimental; Mice, Nude; Phenylurea Compounds; Proof of Concept Study; Pyridines; Xenograft Model Antitumor Assays | 2020 |
Identification of PARP-1 in cancer stem cells of gastrointestinal cancers: A preliminary study.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; Colonic Neoplasms; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Fluorouracil; Gastrointestinal Neoplasms; Gemcitabine; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Irinotecan; Liver Neoplasms; Mice; Neoplastic Stem Cells; Pancreatic Neoplasms; Phthalazines; Piperazines; Poly (ADP-Ribose) Polymerase-1; Xenograft Model Antitumor Assays | 2021 |
SHP2-Mediated Inhibition of DNA Repair Contributes to cGAS-STING Activation and Chemotherapeutic Sensitivity in Colon Cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell Proliferation; Colonic Neoplasms; DNA Damage; DNA Repair; Female; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Lovastatin; Membrane Proteins; Mice; Mice, Inbred BALB C; Mice, Nude; Nucleotidyltransferases; Poly (ADP-Ribose) Polymerase-1; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2021 |
Chemotherapy agents stimulate dendritic cells against human colon cancer cells through upregulation of the transporter associated with antigen processing.
Topics: Antigen Presentation; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 2; ATP Binding Cassette Transporter, Subfamily B, Member 3; B7-H1 Antigen; Cell Line, Tumor; Colonic Neoplasms; Dendritic Cells; Gene Expression Regulation, Neoplastic; Histocompatibility Antigens Class I; Humans; Immediate-Early Proteins; Interferon-gamma; Irinotecan; Killer Cells, Natural; Membrane Transport Proteins; Phagocytosis; Up-Regulation | 2021 |
SENP1 participates in Irinotecan resistance in human colon cancer cells.
Topics: Cell Line, Tumor; Cell Movement; Cell Proliferation; Colonic Neoplasms; Cysteine Endopeptidases; Drug Resistance, Neoplasm; Glycolysis; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Irinotecan; Signal Transduction; SUMO-1 Protein; Sumoylation; Topoisomerase I Inhibitors | 2021 |
Green tea catechins in combination with irinotecan attenuates tumorigenesis and treatment-associated toxicity in an inflammation-associated colon cancer mice model.
Topics: Animals; Carcinogenesis; Catechin; Colonic Neoplasms; Humans; Inflammation; Irinotecan; Mice; Tea | 2021 |
Effect of antitumor drugs in low concentrationson the biological, immunophenotypic and cytogenetic characteristics of human colon cancer cells in vitro.
Topics: Antineoplastic Agents; Apoptosis; Cadherins; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cisplatin; Colonic Neoplasms; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Synergism; Endonucleases; Epithelial-Mesenchymal Transition; HT29 Cells; Humans; Hyaluronan Receptors; Immunohistochemistry; Immunophenotyping; Interferons; Irinotecan; Snail Family Transcription Factors; Time Factors; Vimentin | 2017 |
Curcumin enhances the effects of irinotecan on colorectal cancer cells through the generation of reactive oxygen species and activation of the endoplasmic reticulum stress pathway.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Calcium; Camptothecin; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colonic Neoplasms; Curcumin; Drug Synergism; Drug Therapy, Combination; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Heat-Shock Proteins; Humans; Irinotecan; Reactive Oxygen Species; RNA Interference; RNA, Small Interfering; Transcription Factor CHOP | 2017 |
Resection of colorectal liver metastases after second-line chemotherapy: is it worthwhile? A LiverMetSurvey analysis of 6415 patients.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Catheter Ablation; Cetuximab; Colonic Neoplasms; Disease Progression; Disease-Free Survival; Female; Hepatectomy; Humans; Irinotecan; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Panitumumab; Postoperative Care; Preoperative Care; Prospective Studies; Rectal Neoplasms; Registries | 2017 |
Role of AXL in invasion and drug resistance of colon and breast cancer cells and its association with p53 alterations.
Topics: Animals; Axl Receptor Tyrosine Kinase; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; Doxorubicin; Fluorouracil; Gene Expression Regulation, Neoplastic; Gene Silencing; HCT116 Cells; HeLa Cells; Humans; Irinotecan; MCF-7 Cells; Mice, Knockout; Mutation; Neoplasm Invasiveness; Oligonucleotide Array Sequence Analysis; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; RNA, Small Interfering; Signal Transduction; Treatment Outcome; Tumor Suppressor Protein p53 | 2017 |
Epithelial-mesenchymal transition and cancer stem cell-like phenotype induced by Twist1 contribute to acquired resistance to irinotecan in colon cancer.
Topics: Camptothecin; Cell Movement; Cell Proliferation; Colonic Neoplasms; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Neoplasm Invasiveness; Neoplastic Stem Cells; Nuclear Proteins; RNA, Small Interfering; Transfection; Twist-Related Protein 1 | 2017 |
Sub-100nm, long tumor retention SN-38-loaded photonic micelles for tri-modal cancer therapy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Colonic Neoplasms; Combined Modality Therapy; Drug Delivery Systems; HT29 Cells; Humans; Hydrophobic and Hydrophilic Interactions; Irinotecan; Male; Mice; Mice, Nude; Micelles; Nanoparticles; Particle Size; Photons; Photosensitizing Agents; Phototherapy; Rats; Rats, Sprague-Dawley; Time Factors; Xenograft Model Antitumor Assays | 2017 |
Long-term survival in a patient with low-level inflammatory markers and liver metastasis, converted resectable by TACE.
Topics: Adenocarcinoma; Adult; Biomarkers; Camptothecin; Capecitabine; Chemoembolization, Therapeutic; Colectomy; Colonic Neoplasms; Fluorouracil; Hepatectomy; Humans; Inflammation Mediators; Irinotecan; Leucovorin; Liver Neoplasms; Male; Microspheres; Organoplatinum Compounds; Oxaliplatin; Remission Induction | 2017 |
Some chemotherapeutics-treated colon cancer cells display a specific phenotype being a combination of stem-like and senescent cell features.
Topics: Antineoplastic Agents; Cellular Senescence; Colonic Neoplasms; Cyclin D1; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Fluorouracil; HCT116 Cells; Humans; Hyaluronan Receptors; Irinotecan; Neoplastic Stem Cells; Oxaliplatin | 2018 |
Liposomal
Topics: Animals; Bevacizumab; Camptothecin; Colonic Neoplasms; Copper Radioisotopes; HT29 Cells; Humans; Irinotecan; Liposomes; Mice; Mice, SCID; Positron-Emission Tomography; Vascular Endothelial Growth Factor A | 2017 |
Monophosphorylation by deoxycytidine kinase affects apparent cellular uptake of decitabine in HCT116 colon cancer cells.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Camptothecin; Colonic Neoplasms; Cytarabine; Decitabine; Deoxycytidine; Deoxycytidine Kinase; Equilibrative Nucleoside Transporter 1; Etoposide; Gemcitabine; HCT116 Cells; Humans; Irinotecan; Phosphorylation | 2017 |
Irinotecan and Oxaliplatin Might Provide Equal Benefit as Adjuvant Chemotherapy for Patients with Resectable Synchronous Colon Cancer and Liver-confined Metastases: A Nationwide Database Study.
Topics: Aged; Antineoplastic Agents; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Databases, Factual; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Organoplatinum Compounds; Outcome Assessment, Health Care; Oxaliplatin; Proportional Hazards Models; Retrospective Studies; Taiwan | 2017 |
Wee1 inhibition can suppress tumor proliferation and sensitize p53 mutant colonic cancer cells to the anticancer effect of irinotecan.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; DNA Damage; Enzyme Inhibitors; Humans; Irinotecan; Mutation; Nuclear Proteins; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Pyrimidinones; Tumor Suppressor Protein p53 | 2018 |
Chemotherapy diminishes lipid storage capacity of adipose tissue in a preclinical model of colon cancer.
Topics: Adipocytes; Adipose Tissue; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Size; Colonic Neoplasms; Disease Models, Animal; Fatty Acids; Fatty Acids, Monounsaturated; Fatty Acids, Omega-3; Female; Fluorouracil; Humans; Irinotecan; Lipogenesis; Mitochondria; Mitochondrial Proteins; Phospholipids; Proteome; Rats; Rats, Inbred F344; Triglycerides | 2017 |
Curcumin reverses irinotecan resistance in colon cancer cell by regulation of epithelial-mesenchymal transition.
Topics: Antineoplastic Agents; Apoptosis; Cadherins; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Curcumin; Drug Interactions; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Humans; Irinotecan; Vimentin | 2018 |
Overexpression of Nitrogen Permease Regulator Like-2 (NPRL2) Enhances Sensitivity to Irinotecan (CPT-11) in Colon Cancer Cells by Activating the DNA Damage Checkpoint Pathway.
Topics: Apoptosis; Camptothecin; Cell Cycle Checkpoints; Cell Movement; Colonic Neoplasms; DNA Damage; Down-Regulation; G2 Phase; Gene Expression Regulation, Neoplastic; HCT116 Cells; Histones; Humans; Irinotecan; Lentivirus; Membrane Potential, Mitochondrial; Mitosis; Neoplasm Invasiveness; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Transduction, Genetic; Tumor Suppressor Proteins | 2018 |
Posterior Reversible Encephalopathy Syndrome after a Variety of Combined Chemotherapies Containing Bevacizumab for Metastatic Colon Cancer.
Topics: Adult; Antineoplastic Agents, Immunological; Bevacizumab; Camptothecin; Capecitabine; Colonic Neoplasms; Female; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Posterior Leukoencephalopathy Syndrome; Treatment Outcome | 2018 |
Fisetin mediated apoptotic cell death in parental and Oxaliplatin/irinotecan resistant colorectal cancer cells in vitro and in vivo.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colonic Neoplasms; Colorectal Neoplasms; Drug Resistance, Neoplasm; Flavonoids; Flavonols; Irinotecan; Male; Mice, Nude; Oxaliplatin; Xenograft Model Antitumor Assays | 2018 |
Butyrate, a dietary fiber derivative that improves irinotecan effect in colon cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Butyrates; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colon; Colonic Neoplasms; Dietary Fiber; Drug Synergism; Fermentation; Gastrointestinal Microbiome; Histone Deacetylases; Humans; Inhibitory Concentration 50; Irinotecan; Mice; Mice, Inbred BALB C; Neoplasm Transplantation | 2018 |
Ethanolic Extract of Traditional Chinese Medicine (TCM) Gamboge Inhibits Colon Cancer
Topics: Animals; Apoptosis; Camptothecin; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Ethanol; Fluorouracil; Garcinia; Humans; Immunohistochemistry; Irinotecan; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Plant Extracts; Random Allocation; Wnt Signaling Pathway; Xenograft Model Antitumor Assays | 2018 |
Survival of patients with non-resectable, chemotherapy-resistant colorectal cancer liver metastases undergoing conventional lipiodol-based transarterial chemoembolization (cTACE) palliatively versus neoadjuvantly prior to percutaneous thermal ablation.
Topics: Ablation Techniques; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoembolization, Therapeutic; Cisplatin; Colonic Neoplasms; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Ethiodized Oil; Female; Gemcitabine; Humans; Hyperthermia, Induced; Irinotecan; Laser Therapy; Liver Neoplasms; Male; Microwaves; Middle Aged; Mitomycin; Neoadjuvant Therapy; Palliative Care; Prognosis; Rectal Neoplasms; Retrospective Studies; Survival Rate; Treatment Outcome; Young Adult | 2018 |
Curcumin attenuates resistance to irinotecan via induction of apoptosis of cancer stem cells in chemoresistant colon cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Camptothecin; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Curcumin; Drug Resistance, Neoplasm; Humans; Irinotecan; Neoplastic Stem Cells; Spheroids, Cellular | 2018 |
KDM5c inhibits multidrug resistance of colon cancer cell line by down-regulating ABCC1.
Topics: Antineoplastic Agents; Cell Line, Tumor; Colonic Neoplasms; DNA Fragmentation; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Histone Demethylases; Humans; Inhibitory Concentration 50; Irinotecan; Multidrug Resistance-Associated Proteins; Oxaliplatin; Polymerase Chain Reaction; RNA, Messenger | 2018 |
A molecular basis for the synergy between 17‑allylamino‑17‑demethoxy geldanamycin with Capecitabine and Irinotecan in human colorectal cancer cells through VEFG and MMP-9 gene expression.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Camptothecin; Capecitabine; Colonic Neoplasms; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Gene Expression; Gene Expression Regulation, Neoplastic; HT29 Cells; Humans; Irinotecan; Lactams, Macrocyclic; Matrix Metalloproteinase 9; Neovascularization, Pathologic; Vascular Endothelial Growth Factor A | 2019 |
Pharmacological inhibition of bacterial β-glucuronidase prevents irinotecan-induced diarrhea without impairing its antitumor efficacy in vivo.
Topics: Animals; Antineoplastic Agents, Phytogenic; Bacterial Proteins; Cell Line, Tumor; Colonic Neoplasms; Diarrhea; Escherichia coli; Eubacterium; Glucuronidase; HEK293 Cells; Humans; Irinotecan; Male; Mice, Inbred BALB C; Peptostreptococcus; Quinolines | 2019 |
E-Cadherin in Colorectal Cancer: Relation to Chemosensitivity.
Topics: Adenocarcinoma; Antigens, CD; Antineoplastic Agents; Cadherins; Colonic Neoplasms; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Fluorouracil; Gene Expression Regulation, Neoplastic; HCT116 Cells; HT29 Cells; Humans; Immunohistochemistry; Irinotecan; Oxaliplatin; Tumor Cells, Cultured | 2019 |
A facile approach to fabricate self-assembled magnetic nanotheranostics for drug delivery and imaging.
Topics: Animals; Colonic Neoplasms; Contrast Media; Drug Carriers; Ferric Compounds; HT29 Cells; Humans; Hydrophobic and Hydrophilic Interactions; Irinotecan; Magnetic Resonance Imaging; Magnetite Nanoparticles; Mice; Microscopy, Confocal; Particle Size; Theranostic Nanomedicine; Transplantation, Heterologous | 2018 |
The influence of trapping agents on the antitumor efficacy of irinotecan liposomes: head-to-head comparison of ammonium sulfate, sulfobutylether-β-cyclodextrin and sucrose octasulfate.
Topics: Ammonium Sulfate; Animals; Antineoplastic Agents; beta-Cyclodextrins; Colonic Neoplasms; Delayed-Action Preparations; Drug Liberation; HT29 Cells; Humans; Irinotecan; Liposomes; Male; Mice, Nude; Rats, Sprague-Dawley; Sucrose; Topoisomerase I Inhibitors | 2018 |
Improved Efficacy and Reduced Toxicity Using a Custom-Designed Irinotecan-Delivering Silicasome for Orthotopic Colon Cancer.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Colonic Neoplasms; Irinotecan; Mice; Mice, Inbred C57BL; Nanocapsules; Silicon Dioxide | 2019 |
The risk of adverse events of CPT- 11.
Topics: Colonic Neoplasms; Glucuronosyltransferase; Humans; Irinotecan; Polymorphism, Genetic; Risk Factors | 2016 |
CXCL2/CXCR2 axis induces cancer stem cell characteristics in CPT-11-resistant LoVo colon cancer cells via Gαi-2 and Gαq/11.
Topics: Carcinogenesis; Cell Cycle; Cell Line, Tumor; Chemokine CXCL2; Colonic Neoplasms; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; GTP-Binding Protein alpha Subunit, Gi2; GTP-Binding Protein alpha Subunits, Gq-G11; Humans; Irinotecan; Neoplastic Stem Cells; Receptors, Interleukin-8B; RNA, Small Interfering; Signal Transduction; Up-Regulation | 2019 |
A Novel Anti-EGFR mAb Ame55 with Lower Toxicity and Better Efficacy than Cetuximab When Combined with Irinotecan.
Topics: Animals; Antibodies, Monoclonal; Antibody Affinity; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cetuximab; CHO Cells; Colonic Neoplasms; Cricetulus; Drug Development; Drug Synergism; ErbB Receptors; Female; Humans; Irinotecan; Macaca fascicularis; Male; Mice, Nude; Xenograft Model Antitumor Assays | 2019 |
Synergy between dihydromyricetin intervention and irinotecan chemotherapy delays the progression of colon cancer in mouse models.
Topics: Animals; Chloride Channels; Colonic Neoplasms; Disease Models, Animal; Disease Progression; Drug Synergism; Flavonols; Humans; Irinotecan; Male; Mice; Mice, Inbred C57BL; Mitochondrial Proteins | 2019 |
Vision loss after chemotherapy: an irinotecan-induced retinopathy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Female; Humans; Irinotecan; Middle Aged; Retinal Diseases; Vision Disorders | 2019 |
Integration of elicited expert information via a power prior in Bayesian variable selection: Application to colon cancer data.
Topics: Aged; Aged, 80 and over; Bayes Theorem; Clinical Decision-Making; Colonic Neoplasms; Dose-Response Relationship, Drug; Electronic Health Records; Expert Testimony; Female; Humans; Irinotecan; Logistic Models; Male; Neoplasm Metastasis; Precision Medicine; Research Design; Topoisomerase I Inhibitors | 2020 |
A new herbal formula BP10A exerted an antitumor effect and enhanced anticancer effect of irinotecan and oxaliplatin in the colon cancer PDTX model.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Death; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Drugs, Chinese Herbal; Humans; Irinotecan; Male; Mice, Inbred BALB C; Mice, Nude; Oxaliplatin; Phytotherapy; Xenograft Model Antitumor Assays | 2019 |
Anticancer activity of polymeric nanoparticles containing linoleic acid-SN38 (LA-SN38) conjugate in a murine model of colorectal cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; Cell Survival; Colonic Neoplasms; Drug Screening Assays, Antitumor; HCT116 Cells; HT29 Cells; Humans; Irinotecan; Linoleic Acid; Male; Mice; Nanoparticles; Neoplasms, Experimental; Optical Imaging; Particle Size; Polymers; Rats; Rats, Sprague-Dawley; Surface Properties; Tissue Distribution; Tumor Cells, Cultured | 2019 |
Phage-guided modulation of the gut microbiota of mouse models of colorectal cancer augments their responses to chemotherapy.
Topics: Animals; Antineoplastic Agents; Bacteria; Bacteriophages; Butyrates; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Colorectal Neoplasms; Dextrans; Disease Models, Animal; Drug Therapy; Fusobacterium nucleatum; Gastrointestinal Microbiome; Immunoglobulins; Irinotecan; Male; Mice; Mice, Inbred C57BL; Nanoparticles | 2019 |
Novel lipophilic SN38 prodrug forming stable liposomes for colorectal carcinoma therapy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Colonic Neoplasms; Drug Liberation; Female; HT29 Cells; Humans; Irinotecan; Lipids; Liposomes; Mice, Nude; Molecular Dynamics Simulation; Nanoparticles; Prodrugs; Rats, Sprague-Dawley; Solubility; Tissue Distribution; Xenograft Model Antitumor Assays | 2019 |
Utilization of quantitative in vivo pharmacology approaches to assess combination effects of everolimus and irinotecan in mouse xenograft models of colorectal cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Colonic Neoplasms; Drug Synergism; Everolimus; Female; Humans; Immunosuppressive Agents; Irinotecan; Metabolome; Mice; Mice, Nude; Mutation; Neoplasm Transplantation; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins; Sirolimus; Transplantation, Heterologous; Xenograft Model Antitumor Assays | 2013 |
Selecting regimens in advanced colon cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin | 2004 |
Cell diameter measurements obtained with a handheld cell counter could be used as a surrogate marker of G2/M arrest and apoptosis in colon cancer cell lines exposed to SN-38.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Count; Cell Proliferation; Cell Size; Cell Survival; Colonic Neoplasms; Cytological Techniques; Dose-Response Relationship, Drug; G2 Phase Cell Cycle Checkpoints; HCT116 Cells; HT29 Cells; Humans; Irinotecan; Microscopy, Fluorescence; Reproducibility of Results | 2013 |
Influence of MLH1 on colon cancer sensitivity to poly(ADP-ribose) polymerase inhibitor combined with irinotecan.
Topics: Adaptor Proteins, Signal Transducing; Apoptosis; Camptothecin; Checkpoint Kinase 1; Colonic Neoplasms; Gene Expression Regulation, Neoplastic; HCT116 Cells; Humans; Irinotecan; MutL Protein Homolog 1; Nuclear Proteins; Phosphorylation; Poly(ADP-ribose) Polymerase Inhibitors; Protein Kinases; Topoisomerase I Inhibitors | 2013 |
MSH3 mismatch repair protein regulates sensitivity to cytotoxic drugs and a histone deacetylase inhibitor in human colon carcinoma cells.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Benzofurans; Camptothecin; Cell Death; Cell Nucleus; Cell Survival; Colonic Neoplasms; DNA Damage; DNA Mismatch Repair; DNA-Binding Proteins; Drug Screening Assays, Antitumor; Fluorescent Antibody Technique; Fluorouracil; Gene Knockdown Techniques; HCT116 Cells; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Irinotecan; MutL Protein Homolog 1; MutS Homolog 3 Protein; Nuclear Proteins; Organoplatinum Compounds; Oxaliplatin; Rad51 Recombinase | 2013 |
Severe irinotecan-induced toxicity in a patient with UGT1A1 28 and UGT1A1 6 polymorphisms.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Diarrhea; Dose-Response Relationship, Drug; Fluorouracil; Glucuronosyltransferase; Heterozygote; Humans; Irinotecan; Leucovorin; Male; Neutropenia; Polymorphism, Genetic; Severity of Illness Index; Treatment Outcome | 2013 |
[A case of metastatic colon cancer effectively treated by XELOX and IRIS].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colonic Neoplasms; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Oxaloacetates; Oxonic Acid; Tegafur; Tomography, X-Ray Computed | 2013 |
Partial response after transcatheter arterial infusion chemotherapy in a patient with systemic chemotherapy-resistant unresectable colon cancer and hepatic metastasis: (case report).
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Liver Failure; Liver Neoplasms; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prognosis; Remission Induction; Tomography, X-Ray Computed | 2013 |
Dual roles for splice variants of the glucuronidation pathway as regulators of cellular metabolism.
Topics: Alternative Splicing; Antineoplastic Agents; Camptothecin; Catalase; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; Gene Expression Profiling; Gene Knockdown Techniques; Glucuronosyltransferase; Humans; Irinotecan; Isoenzymes; Oxidative Stress; Peroxiredoxins; Reactive Oxygen Species; RNA, Small Interfering | 2014 |
A circadian clock transcription model for the personalization of cancer chronotherapy.
Topics: Animals; ARNTL Transcription Factors; Camptothecin; Chronotherapy; Circadian Clocks; Colonic Neoplasms; Female; Gene Expression Regulation, Neoplastic; Irinotecan; Liver Neoplasms, Experimental; Male; Mice; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Inbred DBA; Models, Biological; Nuclear Receptor Subfamily 1, Group D, Member 1; Period Circadian Proteins; Precision Medicine; RNA, Messenger; Topoisomerase I Inhibitors | 2013 |
Different effects of epigenetic modifiers on the cytotoxicity induced by 5-fluorouracil, irinotecan or oxaliplatin in colon cancer cells.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Camptothecin; Cell Line, Tumor; Colonic Neoplasms; Decitabine; DNA; DNA Modification Methylases; Drug Synergism; Epigenesis, Genetic; Fluorouracil; HCT116 Cells; Histone Deacetylase Inhibitors; HT29 Cells; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin | 2014 |
Berberine enhances chemosensitivity to irinotecan in colon cancer via inhibition of NF‑κB.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; bcl-X Protein; Berberine; Camptothecin; Colonic Neoplasms; Down-Regulation; Doxorubicin; Fluorouracil; HCT116 Cells; Humans; Inhibitor of Apoptosis Proteins; Irinotecan; NF-kappa B; RNA Interference; RNA, Small Interfering; Survivin; Transcription Factor RelA | 2014 |
Trends in treatment and survival in older patients presenting with stage IV colorectal cancer.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Female; Humans; Irinotecan; Male; Medicare; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Rectal Neoplasms; Registries; Survival Rate; Time Factors; United States | 2014 |
IL-33 targeting attenuates intestinal mucositis and enhances effective tumor chemotherapy in mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Blotting, Western; Camptothecin; Cell Line, Tumor; Colonic Neoplasms; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Humans; Interleukin-1 Receptor-Like 1 Protein; Interleukin-33; Irinotecan; Mice; Mice, Inbred BALB C; Mucositis; Receptors, Interleukin; Recombinant Proteins | 2014 |
Irinotecan-induced immune thrombocytopenia.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Bevacizumab; Camptothecin; Colonic Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Middle Aged; Platelet Count; Thrombocytopenia | 2014 |
The sirtuin inhibitor tenovin-6 upregulates death receptor 5 and enhances cytotoxic effects of 5-fluorouracil and oxaliplatin in colon cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Caco-2 Cells; Camptothecin; Colonic Neoplasms; Drug Synergism; Female; Fluorouracil; HCT116 Cells; HT29 Cells; Humans; Irinotecan; Mice; Mice, Inbred BALB C; Mice, Nude; Organoplatinum Compounds; Oxaliplatin; Random Allocation; Receptors, TNF-Related Apoptosis-Inducing Ligand; Sirtuin 1; Sirtuin 2; Sirtuins; Up-Regulation; Xenograft Model Antitumor Assays | 2013 |
Curable patient with metastatic colorectal cancer: balancing effective therapies and toxicities.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colectomy; Colonic Neoplasms; Colonoscopy; Female; Fluorouracil; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Magnetic Resonance Imaging; Neoadjuvant Therapy; Positron-Emission Tomography | 2014 |
The use of Olaparib (AZD2281) potentiates SN-38 cytotoxicity in colon cancer cells by indirect inhibition of Rad51-mediated repair of DNA double-strand breaks.
Topics: Animals; Camptothecin; Cell Line, Tumor; Colonic Neoplasms; Disease Models, Animal; DNA Breaks, Double-Stranded; DNA Mismatch Repair; DNA Repair; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Profiling; Gene Knockdown Techniques; Humans; Irinotecan; Mice; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerases; Rad51 Recombinase; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
A systemic analysis of S-1 regimens for treatment of patients with colon cancer.
Topics: Adolescent; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Tegafur; Treatment Outcome | 2014 |
Resistance to irinotecan (CPT-11) activates epidermal growth factor receptor/nuclear factor kappa B and increases cellular metastasis and autophagy in LoVo colon cancer cells.
Topics: Autophagy; beta Catenin; Camptothecin; Cell Cycle; Cell Line, Tumor; Colonic Neoplasms; ErbB Receptors; Humans; I-kappa B Kinase; Irinotecan; Neoplasm Metastasis; NF-kappa B; Signal Transduction; Topoisomerase I Inhibitors; Wnt Proteins | 2014 |
Chemosensitivity of resistant colon cancer cell lines to lobaplatin, heptaplatin, and dicycloplatin.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Cell Line, Tumor; Cisplatin; Colonic Neoplasms; Cyclobutanes; Dose-Response Relationship, Drug; Drug Combinations; Drug Resistance, Neoplasm; Enzyme-Linked Immunosorbent Assay; Glutamates; Humans; Inhibitory Concentration 50; Irinotecan; Malonates; Organoplatinum Compounds; Oxaliplatin | 2014 |
Development and validation of an ultra-high performance LC-MS/MS assay for intracellular SN-38 in human solid tumour cell lines: comparison with a validated HPLC-fluorescence method.
Topics: Acetonitriles; Camptothecin; Cell Line, Tumor; Chromatography, High Pressure Liquid; Colonic Neoplasms; Drug Stability; HCT116 Cells; HT29 Cells; Humans; Intracellular Space; Irinotecan; Least-Squares Analysis; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Fluorescence; Tandem Mass Spectrometry | 2014 |
The power of genes: a case of unusually severe systemic toxicity after localized hepatic chemoembolization with irinotecan-eluted microspheres for metastatic colon cancer.
Topics: Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Chemoembolization, Therapeutic; Colonic Neoplasms; Female; Glucuronosyltransferase; Humans; Irinotecan; Liver Neoplasms; Microspheres; Mutation; Neutropenia; Polymorphism, Genetic | 2014 |
Hyaluronic acid decorated lipid nanocarrier for MDR modulation and CD-44 targeting in colon adenocarcinoma.
Topics: Adenocarcinoma; Camptothecin; Colonic Neoplasms; Coumarins; Drug Delivery Systems; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; HT29 Cells; Humans; Hyaluronan Receptors; Hyaluronic Acid; Irinotecan; Lipids; Nanoparticles; Thiazoles | 2015 |
Preclinical activity of nanoliposomal irinotecan is governed by tumor deposition and intratumor prodrug conversion.
Topics: Animals; Antineoplastic Agents; Camptothecin; Carcinoma; Colonic Neoplasms; Female; HT29 Cells; Humans; Irinotecan; Liposomes; Mice; Mice, Inbred NOD; Mice, SCID; Prodrugs; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2014 |
Aspirin and COX-2 inhibitor use in patients with stage III colon cancer.
Topics: Adult; Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Cyclooxygenase 2 Inhibitors; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Odds Ratio; Prospective Studies; Sex Factors; Treatment Outcome | 2015 |
Synthesis and biological evaluation of novel 10-substituted-7-ethyl-10-hydroxycamptothecin (SN-38) prodrugs.
Topics: Animals; Camptothecin; Cell Death; Cell Line, Tumor; Cell Proliferation; Cholinesterase Inhibitors; Colonic Neoplasms; Drug Stability; Humans; Hydrogen-Ion Concentration; Irinotecan; Mice, Nude; Prodrugs; Xenograft Model Antitumor Assays | 2014 |
Irinophore C™, a lipid nanoparticulate formulation of irinotecan, improves vascular function, increases the delivery of sequentially administered 5-FU in HT-29 tumors, and controls tumor growth in patient derived xenografts of colon cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Blood Vessels; Camptothecin; Cell Line, Tumor; Chemistry, Pharmaceutical; Colonic Neoplasms; Drug Delivery Systems; Fluorouracil; HT29 Cells; Humans; Irinotecan; Mice; Mice, Inbred NOD; Mice, SCID; Nanostructures; Regional Blood Flow; Xenograft Model Antitumor Assays | 2015 |
The number of intestinal bacteria is not critical for the enhancement of antitumor activity and reduction of intestinal toxicity of irinotecan by the Chinese herbal medicine PHY906 (KD018).
Topics: Animals; Anti-Bacterial Agents; Antineoplastic Agents, Phytogenic; Bacteria; Camptothecin; Colonic Neoplasms; Drugs, Chinese Herbal; Female; Granulocyte Colony-Stimulating Factor; Humans; Intestinal Mucosa; Intestines; Irinotecan; Mice; Neutrophil Infiltration; Phytotherapy; Receptors, G-Protein-Coupled; RNA, Messenger; Tumor Necrosis Factor-alpha; Weight Loss | 2014 |
Prognostic factors and the role of adjuvant chemotherapy in post-curative surgery for Dukes B and C colon cancers and survival outcomes: a Malaysian experience.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Lymphatic Metastasis; Malaysia; Male; Middle Aged; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Postoperative Period; Prognosis; Retrospective Studies; Survival Rate; Young Adult | 2015 |
Oral delivery of nanoparticles containing anticancer SN38 and hSET1 antisense for dual therapy of colon cancer.
Topics: Administration, Oral; Animals; Camptothecin; Cell Line, Tumor; Chitosan; Colonic Neoplasms; Disease Models, Animal; Drug Carriers; Drug Liberation; Drug Stability; Histone-Lysine N-Methyltransferase; Humans; Irinotecan; Mice; Nanoparticles; Oligonucleotides, Antisense; Spectroscopy, Fourier Transform Infrared; Xenograft Model Antitumor Assays | 2015 |
Functional-segregated coumarin-containing telodendrimer nanocarriers for efficient delivery of SN-38 for colon cancer treatment.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Colonic Neoplasms; Coumarins; Dendrimers; Drug Carriers; Humans; Irinotecan; Molecular Dynamics Simulation; Nanostructures | 2015 |
Development of an oral nanotherapeutics using redox nanoparticles for treatment of colitis-associated colon cancer.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Azoxymethane; Camptothecin; Cell Line, Tumor; Colitis; Colonic Neoplasms; Dextrans; Drug Delivery Systems; Drug Screening Assays, Antitumor; Endoscopy; Free Radical Scavengers; Inflammation; Irinotecan; Male; Mice; Mice, Inbred ICR; Nanomedicine; Nanoparticles; Neoplasms, Experimental; Nitrogen Oxides; Oxidation-Reduction; Reactive Oxygen Species; Sulfates | 2015 |
Inhibition of JNK Sensitizes Hypoxic Colon Cancer Cells to DNA-Damaging Agents.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Hypoxia; Cell Line, Tumor; Colonic Neoplasms; DNA Damage; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Female; Fluorouracil; Genes, Dominant; HT29 Cells; Humans; Immunohistochemistry; Irinotecan; Mice; Mice, SCID; Mitogen-Activated Protein Kinase 8; Organoplatinum Compounds; Oxaliplatin; Protein Kinase Inhibitors; Transfection; Xenograft Model Antitumor Assays | 2015 |
Association between mismatch repair gene and irinotecan-based chemotherapy in metastatic colon cancer.
Topics: Adaptor Proteins, Signal Transducing; Aged; Camptothecin; Colonic Neoplasms; Disease-Free Survival; DNA Mismatch Repair; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; HCT116 Cells; Humans; Irinotecan; Male; Middle Aged; MutL Protein Homolog 1; MutS Homolog 2 Protein; Nuclear Proteins; Prognosis; Thymidylate Synthase; Treatment Outcome | 2015 |
SW480 colorectal cancer cells that naturally express Lgr5 are more sensitive to the most common chemotherapeutic agents than Lgr5-negative SW480 cells.
Topics: Antineoplastic Agents; Camptothecin; Cell Adhesion; Cell Count; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Humans; Irinotecan; Neoplastic Stem Cells; Organoplatinum Compounds; Oxaliplatin; Receptors, G-Protein-Coupled; Transfection | 2015 |
Vatalanib sensitizes ABCB1 and ABCG2-overexpressing multidrug resistant colon cancer cells to chemotherapy under hypoxia.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Cell Hypoxia; Cell Line, Tumor; Colonic Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; HEK293 Cells; Humans; Irinotecan; Isoenzymes; Neoplasm Proteins; Phthalazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Recombinant Proteins | 2015 |
Topoisomerase-I PS506 as a Dual Function Cancer Biomarker.
Topics: Amino Acid Sequence; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Colonic Neoplasms; DNA Topoisomerases, Type I; Female; Gene Expression; Humans; Irinotecan; Lung; Lung Neoplasms; Molecular Sequence Data; Neoplasms; Ovarian Neoplasms; Phosphorylation; Serine; Topotecan | 2015 |
An anti-EpCAM antibody EpAb2-6 for the treatment of colon cancer.
Topics: Animals; Antibodies, Monoclonal; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Camptothecin; Cell Adhesion Molecules; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Synergism; Epithelial Cell Adhesion Molecule; Flow Cytometry; Fluorouracil; HCT116 Cells; Humans; Irinotecan; Leucovorin; Mice, Inbred NOD; Mice, SCID; Molecular Targeted Therapy; Vitamin B Complex; Xenograft Model Antitumor Assays | 2015 |
Fasting protects against the side effects of irinotecan treatment but does not affect anti-tumour activity in mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carboxylesterase; Carboxylic Ester Hydrolases; Cell Line, Tumor; Colonic Neoplasms; Diarrhea; Fasting; Glucuronides; Irinotecan; Leukopenia; Liver; Male; Mice, Inbred BALB C; RNA, Messenger; Treatment Outcome; Tumor Burden; Weight Loss | 2016 |
Identification of novel, in vivo active Chk1 inhibitors utilizing structure guided drug design.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Cell Cycle; Cell Line, Tumor; Checkpoint Kinase 1; Colonic Neoplasms; Drug Design; Drug Synergism; Female; Humans; Indoles; Irinotecan; Mice; Mice, Nude; Protein Kinase Inhibitors; Protein Kinases; Pyridones; Structure-Activity Relationship; Xenograft Model Antitumor Assays | 2015 |
Anti-cancer effects of 2-oxoquinoline derivatives on the HCT116 and LoVo human colon cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Caspase 3; Cell Line, Tumor; Colonic Neoplasms; Extracellular Signal-Regulated MAP Kinases; Fluorouracil; HCT116 Cells; Humans; Irinotecan; JNK Mitogen-Activated Protein Kinases; Myeloid Cell Leukemia Sequence 1 Protein; p38 Mitogen-Activated Protein Kinases; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-bcl-2; Quinolones | 2015 |
Synergistic Effect of SN-38 in Combination with Cetuximab on Angiogenesis and Cancer Cell Invasion.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Camptothecin; Cell Adhesion; Cell Cycle; Cell Movement; Cell Proliferation; Cells, Cultured; Cetuximab; Colonic Neoplasms; Drug Synergism; Flow Cytometry; Human Umbilical Vein Endothelial Cells; Humans; Irinotecan; Neoplasm Invasiveness; Neovascularization, Pathologic; Phosphorylation; Signal Transduction | 2015 |
Development and characterization of pH responsive polymeric nanoparticles of SN-38 for colon cancer.
Topics: Camptothecin; Cell Line, Tumor; Colonic Neoplasms; Drug Carriers; Humans; Hydrogen-Ion Concentration; Irinotecan; Nanoparticles | 2016 |
DNA Topoisomerase I Gene Copy Number and mRNA Expression Assessed as Predictive Biomarkers for Adjuvant Irinotecan in Stage II/III Colon Cancer.
Topics: Antineoplastic Agents, Phytogenic; Biomarkers; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; DNA Topoisomerases, Type I; Female; Gene Dosage; Gene Expression; Humans; In Situ Hybridization, Fluorescence; Irinotecan; Kaplan-Meier Estimate; Male; Neoplasm Staging; Prognosis; RNA, Messenger; Topoisomerase I Inhibitors | 2016 |
Chemotherapeutic agents attenuate CXCL12-mediated migration of colon cancer cells by selecting for CXCR4-negative cells and increasing peptidase CD26.
Topics: Animals; Camptothecin; Carcinogenesis; Cell Lineage; Cell Movement; Chemokine CXCL12; Colonic Neoplasms; Dipeptidyl Peptidase 4; Fluorouracil; Gene Expression Regulation, Neoplastic; HT29 Cells; Humans; Hyaluronan Receptors; Irinotecan; Mice; Neoplasm Metastasis; Receptors, CXCR4; Xenograft Model Antitumor Assays | 2015 |
Radiation and SN38 treatments modulate the expression of microRNAs, cytokines and chemokines in colon cancer cells in a p53-directed manner.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Chemokines; Chemoradiotherapy; Colonic Neoplasms; Computational Biology; Cytokines; Databases, Genetic; Dose-Response Relationship, Drug; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; HCT116 Cells; Heterozygote; Humans; Inhibitory Concentration 50; Irinotecan; MicroRNAs; Mutation; Radiation Dosage; Signal Transduction; Time Factors; Transfection; Tumor Suppressor Protein p53 | 2015 |
Arsenic sulfide combined with JQ1, chemotherapy agents, or celecoxib inhibit gastric and colon cancer cell growth.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenicals; Azepines; Camptothecin; Celecoxib; Cell Line, Tumor; Cisplatin; Colonic Neoplasms; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; p38 Mitogen-Activated Protein Kinases; Stomach Neoplasms; Sulfides; Triazoles; Tumor Suppressor Protein p53 | 2015 |
Regorafenib as a potential adjuvant chemotherapy agent in disseminated small colon cancer: Drug selection outcome of a novel screening system using nanoimprinting 3-dimensional culture with HCT116-RFP cells.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Cell Culture Techniques; Chemotherapy, Adjuvant; Colonic Neoplasms; Drug Screening Assays, Antitumor; Fluorouracil; HCT116 Cells; Humans; Irinotecan; Luminescent Proteins; Mice; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Phenylurea Compounds; Pyridines; Red Fluorescent Protein; Xenograft Model Antitumor Assays | 2016 |
Synthesis and Antitumor Properties of BQC-Glucuronide, a Camptothecin Prodrug for Selective Tumor Activation.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; Female; Glucuronidase; Glucuronides; Humans; Irinotecan; Mice; Mice, Inbred BALB C; Prodrugs; Topotecan | 2016 |
Complete regression of xenograft tumors using biodegradable mPEG-PLA-SN38 block copolymer micelles.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; Drug Carriers; Drug Liberation; Female; HCT116 Cells; Hepatocytes; Humans; Hydrophobic and Hydrophilic Interactions; Inhibitory Concentration 50; Injections, Subcutaneous; Irinotecan; Mice; Mice, Nude; Micelles; Particle Size; Polyesters; Polyethylene Glycols; Structure-Activity Relationship; Treatment Outcome; Xenograft Model Antitumor Assays | 2016 |
Characterization of DNA topoisomerase I in three SN-38 resistant human colon cancer cell lines reveals a new pair of resistance-associated mutations.
Topics: Benzodioxoles; Binding Sites; Camptothecin; Cell Line, Tumor; Chromosome Deletion; Colonic Neoplasms; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Epirubicin; Etoposide; Gene Dosage; Guanidines; HCT116 Cells; HT29 Cells; Humans; Hydrazones; Irinotecan; Isoquinolines; Mutation | 2016 |
Inhibition of NF-κB and metastasis in irinotecan (CPT-11)-resistant LoVo colon cancer cells by thymoquinone via JNK and p38.
Topics: Antineoplastic Agents, Phytogenic; Benzoquinones; Camptothecin; Cell Line, Tumor; Cell Movement; Colonic Neoplasms; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Humans; Irinotecan; JNK Mitogen-Activated Protein Kinases; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; p38 Mitogen-Activated Protein Kinases; Phosphatidylinositol 3-Kinases; Transcription Factor RelA | 2017 |
Cell Line Derived 5-FU and Irinotecan Drug-Sensitivity Profiles Evaluated in Adjuvant Colon Cancer Trial Data.
Topics: Camptothecin; Cell Line, Tumor; Chemotherapy, Adjuvant; Clinical Trials as Topic; Cohort Studies; Colonic Neoplasms; Disease-Free Survival; Drug Evaluation, Preclinical; Fluorouracil; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Prognosis | 2016 |
Expression of an Oncogenic BARD1 Splice Variant Impairs Homologous Recombination and Predicts Response to PARP-1 Inhibitor Therapy in Colon Cancer.
Topics: Antineoplastic Agents; BRCA1 Protein; Cell Line, Tumor; Colonic Neoplasms; Homologous Recombination; Humans; Irinotecan; Oxaliplatin; Poly(ADP-ribose) Polymerase Inhibitors; Protein Splicing; Tumor Suppressor Proteins; Ubiquitin-Protein Ligases; Ubiquitination | 2016 |
Drug penetration and metabolism in 3D cell cultures treated in a 3D printed fluidic device: assessment of irinotecan via MALDI imaging mass spectrometry.
Topics: Camptothecin; Cell Culture Techniques; Colonic Neoplasms; HCT116 Cells; Humans; Irinotecan; Lab-On-A-Chip Devices; Printing, Three-Dimensional; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Spheroids, Cellular | 2016 |
Colonic perforation following endoscopic mucosal resection in a patient on bevacizumab treatment.
Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Diseases; Colonic Neoplasms; Colonic Polyps; Colonoscopy; Endoscopic Mucosal Resection; Female; Fluorouracil; Humans; Intestinal Perforation; Irinotecan; Leucovorin | 2016 |
Primary cultures of human colon cancer as a model to study cancer stem cells.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Camptothecin; Cell Line, Tumor; Colonic Neoplasms; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Irinotecan; Mice; Neoplastic Stem Cells; Octamer Transcription Factor-3; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2016 |
Prognostic Significance of MicroRNA-21 Expression in Patients with Unresectable Metastatic Colon Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; MicroRNAs; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prognosis; Real-Time Polymerase Chain Reaction | 2016 |
Late-stage inhibition of autophagy enhances calreticulin surface exposure.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autophagy; Autophagy-Related Protein-1 Homolog; Beclin-1; Calreticulin; Camptothecin; Cell Membrane; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Endoplasmic Reticulum Stress; Enzyme Inhibitors; Fluorouracil; HCT116 Cells; Humans; Intracellular Signaling Peptides and Proteins; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Phosphorylation; Protein Transport; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Signal Transduction; Time Factors; TOR Serine-Threonine Kinases | 2016 |
Side-Effects of Irinotecan (CPT-11), the Clinically Used Drug for Colon Cancer Therapy, Are Eliminated in Experimental Animals Treated with Latex Proteins from Calotropis procera (Apocynaceae).
Topics: Animals; Apocynaceae; Calotropis; Camptothecin; Colonic Neoplasms; Disease Models, Animal; Irinotecan; Latex; Male; Mice | 2017 |
TNF Signaling through RIP1 Kinase Enhances SN38-Induced Death in Colon Adenocarcinoma.
Topics: Adenocarcinoma; Animals; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colonic Neoplasms; Drug Resistance, Neoplasm; Drug Synergism; Female; HCT116 Cells; HT29 Cells; Humans; Irinotecan; Mice; Receptor-Interacting Protein Serine-Threonine Kinases; Signal Transduction; Tumor Necrosis Factor-alpha | 2017 |
[A case of interstitial pneumonia induced by S-1/irinotecan combination therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Combinations; Humans; Irinotecan; Liver Neoplasms; Lung Diseases, Interstitial; Male; Oxonic Acid; Tegafur; Tomography, X-Ray Computed; Treatment Failure | 2008 |
Efficacy of the combined use of bevacizumab and irinotecan as a postoperative adjuvant chemotherapy in colon carcinoma.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bevacizumab; Camptothecin; Cell Proliferation; Chemotherapy, Adjuvant; Colonic Neoplasms; Humans; Immunoenzyme Techniques; Irinotecan; Lung Neoplasms; Male; Neovascularization, Pathologic; Postoperative Care; Rats; Rats, Inbred F344; Rats, Nude; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2008 |
Synergism of CPT-11 and Apo2L/TRAIL against two differentially sensitive human colon tumor xenografts.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Camptothecin; Colonic Neoplasms; Combined Modality Therapy; Drug Synergism; Gene Expression Regulation, Neoplastic; Genetic Therapy; Humans; Immunoenzyme Techniques; In Situ Nick-End Labeling; Irinotecan; Mice; Mice, SCID; Receptors, TNF-Related Apoptosis-Inducing Ligand; TNF-Related Apoptosis-Inducing Ligand; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2008 |
Thymidine selectively enhances growth suppressive effects of camptothecin/irinotecan in MSI+ cells and tumors containing a mutation of MRE11.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Colonic Neoplasms; DNA-Binding Proteins; Humans; Irinotecan; Mice; Mice, Nude; Microsatellite Instability; MRE11 Homologue Protein; Mutation; Thymidine; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays | 2008 |
[Three cases with liver metastasis from gastric or colon cancer successfully treated with S-1 combined with CPT- 11].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Combinations; Female; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2008 |
Synchronous hepatic metastases from colon cancer: changing treatment strategies and results of surgical intervention.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Carcinoembryonic Antigen; Colonic Neoplasms; Combined Modality Therapy; Female; Humans; Irinotecan; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Retrospective Studies; Survival Rate; Treatment Outcome | 2009 |
Can cetuximab affect paraneoplastic myopathy?
Topics: Adenocarcinoma; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Candidiasis; Cetuximab; Colonic Neoplasms; Humans; Irinotecan; Klebsiella Infections; Liver Neoplasms; Male; Methylprednisolone; Middle Aged; Muscular Diseases; Paraneoplastic Syndromes; Tuberculosis | 2009 |
Marked activity of irinotecan and rapamycin combination toward colon cancer cells in vivo and in vitro is mediated through cooperative modulation of the mammalian target of rapamycin/hypoxia-inducible factor-1alpha axis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Colonic Neoplasms; Glycolysis; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Irinotecan; Male; MAP Kinase Signaling System; Mice; Phosphatidylinositol 3-Kinases; Protein Kinases; Proto-Oncogene Proteins c-akt; Sirolimus; TOR Serine-Threonine Kinases; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2009 |
Single and combined supplementation of glutamine and n-3 polyunsaturated fatty acids on host tolerance and tumour response to 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin (CPT-11)/5-fluorouracil chemotherapy in rats bearing Ward colo
Topics: Animals; Antineoplastic Agents, Phytogenic; Body Weight; Camptothecin; Colonic Neoplasms; Combined Modality Therapy; Diarrhea; Dietary Supplements; Fatty Acids, Omega-3; Female; Fluorouracil; Glutamine; Immune Tolerance; Irinotecan; Leukocyte Count; Nutritional Status; Rats; Rats, Inbred F344; Treatment Failure; Xenograft Model Antitumor Assays | 2009 |
Dual chemotherapy and photodynamic therapy in an HT-29 human colon cancer xenograft model using SN-38-loaded chlorin-core star block copolymer micelles.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; Female; HT29 Cells; Humans; Immunohistochemistry; Irinotecan; Mice; Mice, Inbred BALB C; Micelles; Molecular Structure; Photochemotherapy; Polymers; Porphyrins; Xenograft Model Antitumor Assays | 2009 |
Successful and well-tolerated second line therapy with cetuximab, irinotecan, and raltitrexed in progressive liver disease due to metastatic colon cancer.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colonic Neoplasms; Humans; Irinotecan; Liver Diseases; Liver Neoplasms; Male; Quinazolines; Thiophenes | 2008 |
A novel sulindac derivative that does not inhibit cyclooxygenases but potently inhibits colon tumor cell growth and induces apoptosis with antitumor activity.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Cell Division; Cell Line, Tumor; Colonic Neoplasms; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Drug Screening Assays, Antitumor; Humans; Irinotecan; Male; Maximum Tolerated Dose; Mice; Mice, Nude; Models, Molecular; Neoplasm Proteins; Protein Conformation; Sulindac; Xenograft Model Antitumor Assays | 2009 |
Molecular mechanisms of sequence-dependent antitumor effects of SN-38 and 5-fluorouracil combination therapy against colon cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Camptothecin; Cell Proliferation; Colonic Neoplasms; Dose-Response Relationship, Drug; Flow Cytometry; Fluorouracil; G1 Phase; G2 Phase; Humans; Irinotecan; Thymidylate Synthase; Tumor Cells, Cultured | 2009 |
The dual EGFR/HER-2 tyrosine kinase inhibitor lapatinib sensitizes colon and gastric cancer cells to the irinotecan active metabolite SN-38.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Camptothecin; Cell Cycle; Cell Proliferation; Chromatography, Liquid; Colonic Neoplasms; Colony-Forming Units Assay; Drug Synergism; ErbB Receptors; Flow Cytometry; Humans; Irinotecan; Lapatinib; Male; Mass Spectrometry; Mice; Mice, Inbred BALB C; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2009 |
Upregulation of glycolytic enzymes in proteins secreted from human colon cancer cells with 5-fluorouracil resistance.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Colonic Neoplasms; Down-Regulation; Drug Resistance, Neoplasm; Female; Fluorouracil; Glycolysis; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Proteins; Proteome; Pyruvate Kinase; Reproducibility of Results; Up-Regulation | 2009 |
Acquired Fanconi syndrome after treatment with capecitabine, irinotecan, and bevacizumab.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colonic Neoplasms; Deoxycytidine; Fanconi Syndrome; Female; Fluorouracil; Humans; Irinotecan | 2009 |
[A case of hyperammonemia with encephalopathy related to FOLFIRI chemotherapy for advanced colon cancer].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Consciousness Disorders; Fluorouracil; Humans; Hyperammonemia; Irinotecan; Leucovorin; Male; Middle Aged | 2009 |
Differentiation-related gene-1 decreases Bim stability by proteasome-mediated degradation.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Camptothecin; Colonic Neoplasms; DNA, Antisense; Down-Regulation; GTP-Binding Proteins; HCT116 Cells; Humans; Irinotecan; Membrane Proteins; Proteasome Endopeptidase Complex; Protein Binding; Proto-Oncogene Proteins; RNA, Small Interfering | 2009 |
Irinotecan use during pregnancy.
Topics: Adult; Antineoplastic Agents, Phytogenic; Camptothecin; Colonic Neoplasms; Female; Humans; Irinotecan; Krukenberg Tumor; Ovarian Neoplasms; Pregnancy; Pregnancy Complications, Neoplastic; Prenatal Care | 2009 |
[A case of advanced colon cancer treated with preoperative chemotherapy (IRIS) leading to clinical complete response].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Humans; Irinotecan; Lymphatic Metastasis; Male; Preoperative Care; Rectal Neoplasms; Tegafur; Treatment Outcome | 2009 |
[Effectiveness of S-1 plus CPT-11 therapy for an elderly patient with recurrent colon cancer].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colectomy; Colonic Neoplasms; Humans; Irinotecan; Lymph Node Excision; Male; Neoplasm Recurrence, Local; Tegafur | 2009 |
[Clinical significance of a transient increase in carcinoembryonic antigen and carbohydrate antigen 19-9 in patients with metastatic colorectal cancer receiving chemotherapy].
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Capecitabine; Carcinoembryonic Antigen; Child; Colonic Neoplasms; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Rectal Neoplasms; Remission Induction; Young Adult | 2009 |
CEACAM5-targeted therapy of human colonic and pancreatic cancer xenografts with potent labetuzumab-SN-38 immunoconjugates.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Carcinoembryonic Antigen; Carcinoma; Colonic Neoplasms; Drug Delivery Systems; Female; GPI-Linked Proteins; Humans; Immunoconjugates; Irinotecan; Mice; Mice, Nude; Models, Biological; Pancreatic Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2009 |
The role of protein kinase C in the synergistic interaction of safingol and irinotecan in colon cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Camptothecin; Cell Adhesion; Cell Survival; Colonic Neoplasms; Drug Synergism; HT29 Cells; Humans; Irinotecan; Protein Kinase C; Sphingosine | 2009 |
Cytotoxic effects of cardiac glycosides in colon cancer cells, alone and in combination with standard chemotherapeutic drugs.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cardenolides; Colonic Neoplasms; Digitoxin; Digoxin; Drug Screening Assays, Antitumor; HT29 Cells; Humans; Irinotecan; NF-kappa B; Proscillaridin; Strophanthins | 2009 |
[Huge ascending colon carcinoma, treated successfully with S-1 plus CPT-11, followed by significant tumor reduction and curative resection--a case report].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colectomy; Colonic Neoplasms; Colonoscopy; Combined Modality Therapy; Drug Combinations; Female; Humans; Irinotecan; Oxonic Acid; Tegafur; Tomography, X-Ray Computed | 2009 |
[Efficacy of cetuximab combined with chemotherapy on advanced colorectal cancer: a report of 53 cases].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colonic Neoplasms; Combined Modality Therapy; Diarrhea; Exanthema; Female; Follow-Up Studies; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Prognosis; Proportional Hazards Models; Rectal Neoplasms; Remission Induction; Retrospective Studies | 2009 |
[Combination with SN-38 on human colon cancer LoVo cells].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Bevacizumab; Camptothecin; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Irinotecan; RNA, Messenger; Signal Transduction; Time Factors; Vascular Endothelial Growth Factor A | 2009 |
[A case of advanced right colonic cancer successfully treated by surgery and post operative chemotherapy].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Combined Modality Therapy; Drug Combinations; Fluorouracil; Humans; Irinotecan; Leucovorin; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Organoplatinum Compounds; Oxonic Acid; Postoperative Period; Tegafur | 2009 |
En bloc resection for right colon cancer directly invading duodenum or pancreatic head.
Topics: Adult; Aged; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; Duodenal Neoplasms; Duodenum; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreas; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome | 2009 |
Expression of HSP27, HSP72 and MRP proteins in in vitro co-culture of colon tumour cell spheroids with normal cells after incubation with rhTGF- beta1 and/or CPT-11.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B; Camptothecin; Coculture Techniques; Colonic Neoplasms; HSP27 Heat-Shock Proteins; HSP72 Heat-Shock Proteins; Humans; Interleukin-6; Irinotecan; Nitric Oxide; Recombinant Proteins; Spheroids, Cellular; Transforming Growth Factor beta1; Tumor Cells, Cultured | 2009 |
Gene expression profile of colon cancer cell lines treated with SN-38.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Colonic Neoplasms; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Oligonucleotide Array Sequence Analysis | 2010 |
[Allicin enhances cytotoxicity of CPT-11 to colon cancer LoVo cell in vitro].
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Disulfides; Humans; Irinotecan; Models, Biological; Sulfinic Acids | 2009 |
Irinotecan in the adjuvant treatment of colon cancer: is the story finished or does personalized therapy open new opportunities?
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; Colonic Neoplasms; Disease-Free Survival; Humans; Irinotecan; Patient Selection; Precision Medicine; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2010 |
Cytotoxic drugs up-regulate epidermal growth factor receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFR-targeted antibody-dependent cell-mediated-cytotoxicity (ADCC).
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Agents; Blotting, Western; Camptothecin; Cell Line, Tumor; Cetuximab; Colonic Neoplasms; Deoxycytidine; Drug Synergism; ErbB Receptors; Fluorouracil; Gemcitabine; Genes, ras; Humans; Irinotecan; Killer Cells, Lymphokine-Activated; Mutation; Panitumumab; Up-Regulation | 2010 |
[A case of fluoropyrimidine-resistant recurrent colon cancer successfully treated with weekly administration of irinotecan].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoembryonic Antigen; Colonic Neoplasms; Drug Resistance, Neoplasm; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Neoplasm Staging; Recurrence; Tegafur; Tomography, X-Ray Computed; Uracil | 2010 |
Glutathione modulators reverse the pro-tumour effect of growth factors enhancing WiDr cell response to chemotherapeutic agents.
Topics: Antineoplastic Combined Chemotherapy Protocols; Buthionine Sulfoximine; Camptothecin; Cell Growth Processes; Cell Line, Tumor; Colonic Neoplasms; Drug Synergism; Epidermal Growth Factor; Fluorouracil; Glutathione; Hepatocyte Growth Factor; Humans; Intercellular Signaling Peptides and Proteins; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Pyrrolidonecarboxylic Acid; Thiazolidines; Vascular Endothelial Growth Factor A | 2010 |
Detailed distribution of NK012, an SN-38-incorporating micelle, in the liver and its potent antitumor effects in mice bearing liver metastases.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Proliferation; Chromatography, High Pressure Liquid; Colonic Neoplasms; Disease Models, Animal; Humans; Irinotecan; Kaplan-Meier Estimate; Liver; Liver Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Micelles; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2010 |
Irinotecan overcomes the resistance to 5-fluorouracil in human colon cancer xenografts by down-regulation of intratumoral thymidylate synthase.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Camptothecin; Colonic Neoplasms; Down-Regulation; Drug Combinations; Drug Resistance, Neoplasm; Fluorouracil; Humans; Irinotecan; Mice; Mice, Nude; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Prodrugs; Tegafur; Thymidylate Synthase; Xenograft Model Antitumor Assays | 2010 |
Acute thrombocytopenia: an unusual complication occurring after drug-eluting microspheres transcatheter hepatic chemoembolization.
Topics: Acute Disease; Adenocarcinoma; Antineoplastic Agents; Camptothecin; Chemoembolization, Therapeutic; Colonic Neoplasms; Follow-Up Studies; Humans; Irinotecan; Leukocyte Count; Liver Neoplasms; Male; Microspheres; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Platelet Count; Sigmoid Neoplasms; Thrombocytopenia | 2011 |
High antimetastatic efficacy of MEN4901/T-0128, a novel camptothecin carboxymethyldextran conjugate.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Body Weight; Camptothecin; Colonic Neoplasms; Dextrans; Dose-Response Relationship, Drug; Green Fluorescent Proteins; HT29 Cells; Humans; Irinotecan; Mice; Mice, Nude; Prodrugs; Topotecan; Xenograft Model Antitumor Assays | 2011 |
Effects of the HDAC inhibitor CG2 in combination with irinotecan, 5-fluorouracil, or oxaliplatin on HCT116 colon cancer cells and xenografts.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Colonic Neoplasms; Dose-Response Relationship, Drug; Fluorouracil; HCT116 Cells; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Irinotecan; Mice; Mice, Nude; Models, Biological; Naphthalenes; Organoplatinum Compounds; Oxaliplatin; Xenograft Model Antitumor Assays | 2010 |
The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Cell Proliferation; Colonic Neoplasms; Drug Synergism; Female; HCT116 Cells; Histone Deacetylase Inhibitors; HT29 Cells; Humans; Hydroxamic Acids; Irinotecan; Mice; Mice, Nude; Prodrugs; Random Allocation; Sulfonamides; Topoisomerase I Inhibitors; Tumor Burden; Whole Body Imaging; Xenograft Model Antitumor Assays | 2011 |
[Risk associated with severe hematological toxicity in patients with advanced or recurrent colonic cancer receiving combination chemotherapy of S-1 and irinotecan hydrochloride].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Combinations; Female; Hematologic Diseases; Humans; Irinotecan; Male; Neoplasm Recurrence, Local; Oxonic Acid; Risk Factors; Tegafur | 2010 |
Targeting the p38 MAPK pathway inhibits irinotecan resistance in colon adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Resistance, Neoplasm; Drug Synergism; Female; Fluorouracil; HCT116 Cells; Humans; Imidazoles; Immunohistochemistry; Irinotecan; Isoenzymes; Leucovorin; MAP Kinase Signaling System; Mice; Mice, Nude; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Pyridines; Xenograft Model Antitumor Assays | 2011 |
[Efficacy of cetuximab combined with chemotherapy for patients with advanced colorectal cancer and unclear K-ras status].
Topics: Acneiform Eruptions; Adenocarcinoma; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colonic Neoplasms; Diarrhea; Disease-Free Survival; Female; Follow-Up Studies; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Organoplatinum Compounds; Oxaliplatin; ras Proteins; Rectal Neoplasms; Remission Induction; Survival Rate | 2010 |
Irinotecan and DNA-PKcs inhibitors synergize in killing of colon cancer cells.
Topics: Acridones; Antineoplastic Agents; Camptothecin; Cell Cycle Checkpoints; Cell Survival; Chromones; Cisplatin; Colonic Neoplasms; Comet Assay; DNA-Activated Protein Kinase; Drug Synergism; HCT116 Cells; HT29 Cells; Humans; Irinotecan; Morpholines; Organoplatinum Compounds; Protein Kinase Inhibitors; Pyridines; Topoisomerase I Inhibitors | 2012 |
A patient with metastatic colon cancer to the liver presenting with cardiac arrest status post receiving combination irinotecan-panitumumab: a case report.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Heart Arrest; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Panitumumab | 2010 |
DNA damage persistence as determinant of tumor sensitivity to the combination of Topo I inhibitors and telomere-targeting agents.
Topics: Acridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Cell Cycle; Cell Survival; Cells, Cultured; Colonic Neoplasms; DNA Damage; Drug Synergism; G-Quadruplexes; HCT116 Cells; HT29 Cells; Humans; Irinotecan; Male; Mice; Mice, Nude; Telomere; Topoisomerase I Inhibitors; Treatment Outcome; Xenograft Model Antitumor Assays | 2011 |
[Analysis of gene expression patterns in an irinotecan-resistance colon cancer cell by cDNA microarray].
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Colonic Neoplasms; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glutathione Transferase; Humans; Irinotecan; Oligonucleotide Array Sequence Analysis; Transcriptome; Zinc Fingers | 2011 |
[A case of drug-induced interstitial pneumonia caused by S-1 and CPT-11 combination therapy for advanced colon cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Combinations; Fatal Outcome; Female; Humans; Irinotecan; Lung Diseases, Interstitial; Neoplasm Staging; Oxonic Acid; Tegafur; Tomography, X-Ray Computed | 2011 |
Cytotoxic T lymphocytes efficiently recognize human colon cancer stem-like cells.
Topics: Animals; Antigens; Antineoplastic Agents; Benzimidazoles; Camptothecin; Cell Line, Tumor; Colonic Neoplasms; Etoposide; Humans; Irinotecan; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Transplantation; Neoplastic Stem Cells; Peptides; T-Lymphocytes, Cytotoxic | 2011 |
Differentiated human colorectal cancer cells protect tumor-initiating cells from irinotecan.
Topics: Adenocarcinoma; Aldehyde Dehydrogenase; Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biomarkers, Tumor; Blotting, Western; Camptothecin; Cell Differentiation; Colonic Neoplasms; Cyclosporins; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Flow Cytometry; Humans; Irinotecan; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplastic Stem Cells; Spheroids, Cellular; Time Factors; Topoisomerase I Inhibitors; Tumor Burden; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2011 |
Interaction of a traditional Chinese Medicine (PHY906) and CPT-11 on the inflammatory process in the tumor microenvironment.
Topics: Animals; Camptothecin; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Drug Interactions; Drugs, Chinese Herbal; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Immunity; Immunohistochemistry; Inflammation; Irinotecan; Liver; Macrophages; Medicine, Chinese Traditional; Mice; Organ Size; Polymerase Chain Reaction; Reproducibility of Results; RNA, Messenger; Signal Transduction; Spleen; Tumor Microenvironment | 2011 |
Anti-tumor activity of liposome encapsulated fluoroorotic acid as a single agent and in combination with liposome irinotecan.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Survival; Colonic Neoplasms; Drug Combinations; Drug Compounding; Drug Synergism; HT29 Cells; Humans; Irinotecan; Liposomes; Maximum Tolerated Dose; Mice; Mice, Inbred BALB C; Mice, Nude; Orotic Acid; Particle Size; Survival Analysis; Treatment Outcome; Xenograft Model Antitumor Assays | 2011 |
Overcoming hypoxia-induced apoptotic resistance through combinatorial inhibition of GSK-3β and CDK1.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Camptothecin; CDC2 Protein Kinase; Cell Hypoxia; Cell Line, Tumor; Colonic Neoplasms; Drug Synergism; Fluorouracil; Gene Expression Regulation, Neoplastic; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Inhibitor of Apoptosis Proteins; Irinotecan; Mice; Mice, Nude; Neoplasm Proteins; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-myb; Pyrimidines; Recombinant Proteins; RNA, Small Interfering; Thiazoles; TNF-Related Apoptosis-Inducing Ligand; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2011 |
Association between deficient mismatch repair system and efficacy to irinotecan-containing chemotherapy in metastatic colon cancer.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Disease-Free Survival; DNA Mismatch Repair; Female; Humans; Irinotecan; Male; Microsatellite Instability; Middle Aged; MutL Protein Homolog 1; MutS Homolog 2 Protein; Nuclear Proteins; Prognosis; Treatment Outcome | 2011 |
Fatal infusion reaction to cetuximab: the need for predictive risk factors and safer patient selection.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Cetuximab; Colonic Neoplasms; Fatal Outcome; Genotype; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Patient Selection; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Risk Factors | 2011 |
Irinotecan induces steroid and xenobiotic receptor (SXR) signaling to detoxification pathway in colon cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma; Cell Line, Tumor; Colonic Neoplasms; Drug Evaluation, Preclinical; Gene Expression Regulation, Neoplastic; HCT116 Cells; Hep G2 Cells; Humans; Inactivation, Metabolic; Irinotecan; Pregnane X Receptor; Receptors, Cytoplasmic and Nuclear; Receptors, Steroid; Signal Transduction; Up-Regulation; Xenobiotics | 2011 |
Comparative effectiveness of different chemotherapeutic regimens on survival of people aged 66 and older with stage III colon cancer: a "real world" analysis using Surveillance, Epidemiology, and End Results-Medicare data.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Comparative Effectiveness Research; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Organoplatinum Compounds; Oxaliplatin; Proportional Hazards Models; Retrospective Studies; SEER Program; Survival Analysis; Treatment Outcome; United States | 2011 |
Identification of a potent epigenetic biomarker for resistance to camptothecin and poor outcome to irinotecan-based chemotherapy in colon cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Caco-2 Cells; Camptothecin; Case-Control Studies; Cell Line, Tumor; Colonic Neoplasms; DNA Methylation; DNA-Binding Proteins; Drug Resistance, Neoplasm; Female; Fluorouracil; Gene Knockdown Techniques; HCT116 Cells; Humans; Irinotecan; Male; Membrane Proteins; Middle Aged; Organoplatinum Compounds; Oxaliplatin; RNA, Messenger | 2012 |
MC70 potentiates doxorubicin efficacy in colon and breast cancer in vitro treatment.
Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biphenyl Compounds; Breast Neoplasms; Camptothecin; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Colonic Neoplasms; Doxorubicin; Drug Synergism; Female; Genomics; Humans; Irinotecan; Kinetics; Multidrug Resistance-Associated Proteins; Necrosis; Neoplasm Proteins; Signal Transduction; Tetrahydroisoquinolines; Topotecan | 2011 |
MicroRNA-451 is involved in the self-renewal, tumorigenicity, and chemoresistance of colorectal cancer stem cells.
Topics: Antineoplastic Agents; Blotting, Western; Camptothecin; Cell Line; Colonic Neoplasms; Cyclooxygenase 2; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Irinotecan; MicroRNAs; Neoplastic Stem Cells; Reverse Transcriptase Polymerase Chain Reaction | 2011 |
Comparative and cost-effectiveness of oxaliplatin-based or irinotecan-based regimens compared with 5-fluorouracil/leucovorin alone among US elderly stage IV colon cancer patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Cost-Benefit Analysis; Disease-Free Survival; Female; Fluorouracil; Health Care Costs; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Quality-Adjusted Life Years; Survival Analysis | 2012 |
Pharmacokinetics and antitumor efficacy of XMT-1001, a novel, polymeric topoisomerase I inhibitor, in mice bearing HT-29 human colon carcinoma xenografts.
Topics: Acetals; Animals; Camptothecin; Chromatography, Liquid; Colonic Neoplasms; DNA Topoisomerases, Type I; Female; Humans; Irinotecan; Mice; Mice, Nude; Polymers; Tandem Mass Spectrometry; Tissue Distribution; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2012 |
The role of autophagic cell death and apoptosis in irinotecan-treated p53 null colon cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Autophagy; Camptothecin; Cell Line, Tumor; Colonic Neoplasms; HCT116 Cells; HT29 Cells; Humans; Irinotecan; Tumor Suppressor Protein p53 | 2013 |
Combination of gastrin-releasing peptide antagonist with cytotoxic agents produces synergistic inhibition of growth of human experimental colon cancers.
Topics: Animals; Antineoplastic Agents; Bombesin; Camptothecin; Cell Cycle Checkpoints; Cell Line, Tumor; Colonic Neoplasms; Drug Synergism; Drug Therapy, Combination; Fluorouracil; Gastrin-Releasing Peptide; HCT116 Cells; HT29 Cells; Humans; Irinotecan; Male; Mice; Mice, Nude; Peptide Fragments; Receptors, Bombesin; Transplantation, Heterologous | 2012 |
Gef gene therapy enhances the therapeutic efficacy of cytotoxics in colon cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Bacterial Toxins; Camptothecin; Cell Survival; Colonic Neoplasms; Combined Modality Therapy; Escherichia coli Proteins; Fluorouracil; Genetic Therapy; Humans; Irinotecan; Membrane Proteins; Organoplatinum Compounds; Oxaliplatin | 2012 |
Colon cancer cell chemosensitisation by fish oil emulsion involves apoptotic mitochondria pathway.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Camptothecin; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; Combined Modality Therapy; Dietary Supplements; Drug Resistance, Neoplasm; Emulsions; Fatty Acids, Omega-3; Fish Oils; Fluorouracil; Food-Drug Interactions; Humans; Irinotecan; Membrane Potential, Mitochondrial; Mitochondria; Organoplatinum Compounds; Oxaliplatin; Triglycerides | 2013 |
The synergistic effects of low-dose irinotecan and TRAIL on TRAIL-resistant HT-29 colon carcinoma in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; bcl-2-Associated X Protein; Camptothecin; Carcinoma; Caspase 9; Cell Survival; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Female; HT29 Cells; Humans; Irinotecan; Mice; Mice, Nude; Receptors, TNF-Related Apoptosis-Inducing Ligand; TNF-Related Apoptosis-Inducing Ligand; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Mitogen-activated protein kinase (MEK/ERK) inhibition sensitizes cancer cells to centromere-associated protein E inhibition.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Biomarkers, Tumor; Bridged Bicyclo Compounds, Heterocyclic; Camptothecin; Cell Line, Tumor; Cell Proliferation; Chromosomal Proteins, Non-Histone; Colonic Neoplasms; Dacarbazine; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Irinotecan; Lung Neoplasms; M Phase Cell Cycle Checkpoints; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 3; Neuroblastoma; Pancreatic Neoplasms; RNA Interference; RNA, Small Interfering; Sarcosine; Temozolomide | 2013 |
Current stages of adjuvant treatment of colon cancer.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Chemotherapy, Adjuvant; Colonic Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Staging; Organoplatinum Compounds; Survival Analysis | 2012 |
The PARP inhibitor ABT-888 synergizes irinotecan treatment of colon cancer cell lines.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzimidazoles; Blotting, Western; Camptothecin; Cell Proliferation; Colonic Neoplasms; Drug Synergism; Flow Cytometry; Humans; Irinotecan; Poly(ADP-ribose) Polymerase Inhibitors; Tumor Cells, Cultured | 2013 |
GHRH antagonist when combined with cytotoxic agents induces S-phase arrest and additive growth inhibition of human colon cancer.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cisplatin; Colonic Neoplasms; Fluorouracil; Growth Hormone-Releasing Hormone; HCT116 Cells; HT29 Cells; Humans; Irinotecan; Mice; Mice, Nude; S Phase Cell Cycle Checkpoints; Sermorelin; Transplantation, Heterologous | 2012 |
Bevacizumab-containing chemotherapy is safe in patients with unresectable metastatic colorectal cancer and a synchronous asymptomatic primary tumor.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colonic Neoplasms; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Neoplasms, Multiple Primary; Organoplatinum Compounds; Oxaliplatin; Prognosis; Rectal Neoplasms; Retrospective Studies; Survival Rate; Young Adult | 2013 |
KRAS mutation is a predictor of oxaliplatin sensitivity in colon cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; DNA-Binding Proteins; Endonucleases; Fluorouracil; Humans; Irinotecan; Mutation; Organoplatinum Compounds; Oxaliplatin; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins | 2012 |
Polymorphisms of the UDP-glucuronosyl transferase 1A genes are associated with adverse events in cancer patients receiving irinotecan-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Colonic Neoplasms; Diarrhea; Drug-Related Side Effects and Adverse Reactions; Female; Genetic Predisposition to Disease; Glucuronosyltransferase; Humans; Irinotecan; Isoenzymes; Lung Neoplasms; Male; Middle Aged; Neoplasms; Neutropenia; Pharmacogenetics; Polymorphism, Genetic; Stomach Neoplasms | 2013 |
KML001 displays vascular disrupting properties and irinotecan combined antitumor activities in a murine tumor model.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenites; Camptothecin; Cell Line, Tumor; Colonic Neoplasms; DNA Damage; Drug Synergism; Human Umbilical Vein Endothelial Cells; Humans; Irinotecan; Mice; Neoplasms, Experimental; Neovascularization, Pathologic; Sodium Compounds; Telomere | 2013 |
Concurrent chemotherapy inhibits herpes simplex virus-1 replication and oncolysis.
Topics: Camptothecin; Cell Line, Tumor; Colonic Neoplasms; Combined Modality Therapy; Fluorouracil; Herpesvirus 1, Human; Humans; Irinotecan; Methotrexate; NF-kappa B; Oncolytic Virotherapy; Oncolytic Viruses; Pancreatic Neoplasms; Transcriptional Activation; Tumor Necrosis Factor-alpha; Virus Replication | 2013 |
Irinotecan during pregnancy in metastatic colon cancer.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cesarean Section; Colectomy; Colonic Neoplasms; Disease Progression; Female; Fluorouracil; Gestational Age; Humans; Infant, Newborn; Irinotecan; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Male; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Treatment Failure | 2012 |
Combined colonic cancer treatment with vitamin D analogs and irinotecan or oxaliplatin.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Camptothecin; Cell Line, Tumor; Colonic Neoplasms; Dihydroxycholecalciferols; Female; HT29 Cells; Humans; Irinotecan; Mice; Mice, Inbred C57BL; Neoplasms, Experimental; Organoplatinum Compounds; Oxaliplatin; Signal Transduction; Vitamin D; Xenograft Model Antitumor Assays | 2013 |
Pemetrexed disodium combined with oxaliplatin, SN38, or 5-fluorouracil, based on the quantitation of drug interactions in human HT29 colon cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Division; Cell Survival; Colonic Neoplasms; DNA, Neoplasm; Drug Interactions; Female; Fluorouracil; Glutamates; Guanine; HT29 Cells; Humans; Irinotecan; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Neoplasms, Experimental; Organoplatinum Compounds; Oxaliplatin; Pemetrexed; Transplantation, Heterologous | 2002 |
Drg1, a novel target for modulating sensitivity to CPT-11 in colon cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Colonic Neoplasms; DNA, Antisense; DNA, Complementary; Drug Synergism; Flavonoids; GTP-Binding Proteins; Humans; Irinotecan; Male; Mice; Mice, Nude; Piperidines; Prodrugs; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2002 |
Cellular effects of CPT-11 on colon carcinoma cells: dependence on p53 and hMLH1 status.
Topics: Adaptor Proteins, Signal Transducing; Apoptosis; Blotting, Western; Caffeine; Camptothecin; Carrier Proteins; CDC2 Protein Kinase; Cell Cycle; Colonic Neoplasms; Drug Resistance, Neoplasm; Flow Cytometry; Gene Deletion; Humans; Irinotecan; MutL Protein Homolog 1; Neoplasm Proteins; Nuclear Proteins; Phosphorylation; Proto-Oncogene Proteins c-bcl-2; Time Factors; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2002 |
Contribution of apoptosis in the cytotoxicity of the oxaliplatin-irinotecan combination in the HT29 human colon adenocarcinoma cell line.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Cycle; Cell Division; Cell Survival; Colonic Neoplasms; Drug Interactions; Flow Cytometry; HT29 Cells; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Peptide Hydrolases; Poly(ADP-ribose) Polymerases | 2002 |
Secreted and tumour targeted human carboxylesterase for activation of irinotecan.
Topics: Animals; Antigens, Neoplasm; Antineoplastic Agents, Phytogenic; Blotting, Western; Camptothecin; Carboxylesterase; Carboxylic Ester Hydrolases; Cell Adhesion Molecules; Cell Division; Chlorocebus aethiops; Colonic Neoplasms; COS Cells; Drug Screening Assays, Antitumor; Gene Expression Regulation; Humans; Immunoenzyme Techniques; Irinotecan; Lymphokines; Plasmids; Polymerase Chain Reaction; Prodrugs; Sialoglycoproteins; Tumor Cells, Cultured | 2002 |
Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Camptothecin; Colonic Neoplasms; Drug Synergism; Fluorouracil; Humans; Immunohistochemistry; Irinotecan; Membrane Glycoproteins; Mice; Mice, SCID; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha; Xenograft Model Antitumor Assays | 2002 |
Augmented anti-metastatic efficacy of a selective matrix metalloproteinase inhibitor, MMI-166, in combination with CPT-11.
Topics: Animals; Antineoplastic Agents; Camptothecin; Colonic Neoplasms; Disease Models, Animal; Humans; Irinotecan; Liver Neoplasms; Matrix Metalloproteinase Inhibitors; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Sulfonamides; Transplantation, Heterologous | 2002 |
[Two patients with recurrent colon cancer who underwent surgery following a combination of irinotecan and UFT].
Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colectomy; Colonic Neoplasms; Combined Modality Therapy; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Leucovorin; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Tegafur; Uracil | 2002 |
Combination of 5-fluorouracil and irinotecan on modulation of thymidylate synthase and topoisomerase I expression and cell cycle regulation in human colon cancer LoVo cells: clinical relevance.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Cycle; Colonic Neoplasms; Dose-Response Relationship, Drug; Fluorouracil; Humans; In Vitro Techniques; Irinotecan; Thymidylate Synthase; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 2002 |
Prognostic role of serum vascular endothelial growth factor, basic fibroblast growth factor and nitric oxide in patients with colorectal carcinoma.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Carcinoembryonic Antigen; Chemotherapy, Adjuvant; Cisplatin; Colonic Neoplasms; Colorectal Neoplasms; Disease-Free Survival; Endothelial Growth Factors; Female; Fibroblast Growth Factor 2; Fluorouracil; Follow-Up Studies; Humans; Intercellular Signaling Peptides and Proteins; Irinotecan; Leucovorin; Life Tables; Lymphokines; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Nitrates; Nitric Oxide; Organoplatinum Compounds; Oxaliplatin; Prognosis; Proportional Hazards Models; Rectal Neoplasms; Survival Analysis; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2002 |
Weekly hepatic arterial infusion of 5-fluorouracil and subsequent systemic chemotherapy for liver metastases from colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colonic Neoplasms; Drug Administration Schedule; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Leukopenia; Liver Neoplasms; Male; Middle Aged; Nausea; Rectal Neoplasms; Retrospective Studies; Survival Analysis; Thrombocytopenia; Vomiting, Anticipatory | 2003 |
Irinotecan (CPT11) plus high-dose 5-fluorouracil (5-FU) and leucovorin (LV) as salvage therapy for metastatic colorectal cancer (MCRC) after failed oxaliplatin plus 5-FU and LV: a pilot study in Taiwan.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Leucovorin; Leukopenia; Middle Aged; Nausea; Pilot Projects; Rectal Neoplasms; Salvage Therapy; Survival Analysis; Treatment Outcome; Vomiting, Anticipatory | 2003 |
[A case of irinotecan-resistant colon cancer responding to chronotherapy with oxaliplatin, 5-FU, l-LV].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Chronotherapy; Colonic Neoplasms; Drug Evaluation; Drug Resistance, Neoplasm; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Organoplatinum Compounds; Oxaliplatin | 2003 |
[A case of colon cancer with liver metastases and lymph node metastases successfully treated with surgery followed by CPT-11 and 5-FU chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Aorta, Abdominal; Camptothecin; Colonic Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Gastrectomy; Humans; Irinotecan; Liver Neoplasms; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Middle Aged | 2003 |
Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11.
Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal; Camptothecin; Cell Division; Colonic Neoplasms; Endothelial Growth Factors; HT29 Cells; Humans; Intercellular Signaling Peptides and Proteins; Irinotecan; Lymphokines; Mice; Mice, Nude; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2003 |
Epidermal growth factor receptor inhibition induces trichomegaly.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colonic Neoplasms; Diagnosis, Differential; ErbB Receptors; Eyelashes; Female; Humans; Irinotecan; Liver Neoplasms; Neoplasm Metastasis | 2003 |
Second-line chemotherapy with low-dose CPT-11 and cisplatin for colorectal cancer resistant to 5-FU-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Colonic Neoplasms; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Remission Induction | 2003 |
Advances in colon cancer.
Topics: Camptothecin; Colonic Neoplasms; Drug Combinations; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Pyridines; Treatment Outcome | 2003 |
PG490-88, a derivative of triptolide, causes tumor regression and sensitizes tumors to chemotherapy.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Cycle; Colonic Neoplasms; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Diterpenes; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; Epoxy Compounds; Humans; Irinotecan; Lung Neoplasms; Mice; Mice, Nude; Phenanthrenes; Transplantation, Heterologous; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2003 |
Carboxylesterases expressed in human colon tumor tissue and their role in CPT-11 hydrolysis.
Topics: Blotting, Northern; Blotting, Western; Brain; Camptothecin; Carboxylesterase; Carboxylic Ester Hydrolases; Cell Line, Tumor; Colon; Colonic Neoplasms; DNA Topoisomerases, Type I; Electrophoresis, Polyacrylamide Gel; Female; Humans; Hydrolases; Hydrolysis; Irinotecan; Liver; Male; Reverse Transcriptase Polymerase Chain Reaction; RNA; Umbelliferones | 2003 |
A prodrug strategy using ONYX-015-based replicating adenoviruses to deliver rabbit carboxylesterase to tumor cells for conversion of CPT-11 to SN-38.
Topics: Adenoviridae; Animals; Camptothecin; Carboxylesterase; Colonic Neoplasms; Female; Humans; Irinotecan; Mice; Mice, Nude; Prodrugs; Rabbits; Transgenes; Virus Replication; Xenograft Model Antitumor Assays | 2003 |
Ex vivo analysis of topotecan: advancing the application of laboratory-based clinical therapeutics.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; In Vitro Techniques; Irinotecan; Lethal Dose 50; Lung Neoplasms; Male; Neoplasms; Prostatic Neoplasms; Topotecan; Tumor Cells, Cultured | 2003 |
Enhancement of in vivo antitumor activity of classical anticancer agents by combination with the new, glutathione-interacting DNA minor groove-binder, brostallicin.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Colonic Neoplasms; DNA; Doxorubicin; Female; Glutathione; Glutathione Transferase; Guanidines; Irinotecan; Leukemia L1210; Lung Neoplasms; Mice; Mice, Inbred DBA; Mice, Nude; Pyrroles; Transplantation, Heterologous | 2003 |
[Experimental study on intraperitoneal versus intravenous CPT-11 for peritoneal seeding and liver metastasis].
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Colonic Neoplasms; Female; Infusions, Intravenous; Injections, Intraperitoneal; Irinotecan; Liver Neoplasms; Mice; Mice, Inbred BALB C; Peritoneal Neoplasms | 2003 |
[A case of resected spinal metastasis following colectomy and hepatectomy for descending colon carcinoma].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colectomy; Colonic Neoplasms; Combined Modality Therapy; Drug Administration Schedule; Fluorouracil; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Spinal Neoplasms | 2003 |
Requirement of p53 targets in chemosensitization of colonic carcinoma to death ligand therapy.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Apoptosis Regulatory Proteins; Base Pair Mismatch; bcl-2-Associated X Protein; Camptothecin; Carcinoma; Caspase 8; Caspase 9; Caspase Inhibitors; Caspases; Cell Death; Cell Line; Cell Line, Tumor; Colonic Neoplasms; DNA Damage; DNA Repair; Enzyme Inhibitors; Etoposide; Flow Cytometry; Humans; Irinotecan; Luciferases; Membrane Glycoproteins; Mice; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; RNA, Small Interfering; Time Factors; TNF-Related Apoptosis-Inducing Ligand; Transcription, Genetic; Transfection; Tumor Necrosis Factor-alpha; Tumor Suppressor Protein p53 | 2003 |
Thrombospondin-1 plus irinotecan: a novel antiangiogenic-chemotherapeutic combination that inhibits the growth of advanced human colon tumor xenografts in mice.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Division; Cells, Cultured; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; HT29 Cells; Humans; Irinotecan; Kinetics; Mice; Mice, Nude; Thrombospondin 1; Xenograft Model Antitumor Assays | 2004 |
Glucuronidation as a mechanism of intrinsic drug resistance in colon cancer cells: contribution of drug transport proteins.
Topics: Anthraquinones; Antigens, CD; Antineoplastic Agents, Phytogenic; Biological Transport; Camptothecin; Carrier Proteins; Colonic Neoplasms; Drug Interactions; Drug Resistance; Glucuronides; HT29 Cells; Humans; Irinotecan; Membrane Glycoproteins; Membrane Transport Proteins; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Propionates; Quinolines; Tetraspanin 29; Tumor Cells, Cultured; Tyrosine | 2004 |
Perioperative complications in patients undergoing major liver resection with or without neoadjuvant chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Colonic Neoplasms; Female; Fluorouracil; Folic Acid; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Postoperative Complications; Retrospective Studies | 2003 |
Glucuronidation as a mechanism of intrinsic drug resistance in human colon cancer: reversal of resistance by food additives.
Topics: Anthraquinones; Biopsy; Camptothecin; Catalysis; Cell Line, Tumor; Colonic Neoplasms; Drug Resistance, Neoplasm; Enzyme Inhibitors; Food Additives; Glucuronides; Glucuronosyltransferase; Humans; Irinotecan; Isoenzymes; Propofol; Topoisomerase I Inhibitors; Tyrosine | 2003 |
Biweekly irinotecan plus bolus 5-fluorouracil and folinic acid in patients with advanced stage colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Rectal Neoplasms; Survival Analysis | 2003 |
Chemoembolization of rat liver metastasis with irinotecan and quantification of tumor cell reduction.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Chemoembolization, Therapeutic; Colonic Neoplasms; Dose-Response Relationship, Drug; Fluorouracil; Irinotecan; Luminescent Measurements; Male; Microspheres; Rats; Rats, Inbred Strains | 2004 |
Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents.
Topics: Antineoplastic Agents; Camptothecin; Cell Division; Cell Line, Tumor; Colonic Neoplasms; Female; Fluorouracil; HCT116 Cells; Humans; Irinotecan; Models, Biological; Ovarian Neoplasms; Paclitaxel | 2004 |
Quantification of tumor tissue populations by multispectral analysis.
Topics: Adipose Tissue; Animals; Antineoplastic Agents, Phytogenic; Apoptosis Regulatory Proteins; Camptothecin; Cell Line, Tumor; Colonic Neoplasms; Disease Models, Animal; fas Receptor; Female; Humans; Irinotecan; Ligands; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Membrane Glycoproteins; Mice; Mice, Nude; Necrosis; Neoplasm Transplantation; Remission Induction; Skin Neoplasms; Time Factors; TNF-Related Apoptosis-Inducing Ligand; Topoisomerase I Inhibitors; Transplantation, Heterologous; Tumor Necrosis Factor-alpha | 2004 |
ABCG2 overexpression in colon cancer cells resistant to SN38 and in irinotecan-treated metastases.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Colon; Colonic Neoplasms; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Liver Neoplasms; Neoplasm Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm | 2004 |
[A case report of colon cancer with liver and lung metastases responding to combination chemotherapy with l-LV, 5-fluorouracil and CPT-11].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Administration Schedule; Drug Screening Assays, Antitumor; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Tumor Cells, Cultured | 2004 |
[A case of highly advanced ascending colon cancer with multiple bone and liver metastases and pleuritis carcinomatosa treated with pharmacokinetic modulating chemotherapy and low-dose CPT-11].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Pleurisy; Quality of Life; Tegafur; Uracil | 2004 |
Selective modulation of the therapeutic efficacy of anticancer drugs by selenium containing compounds against human tumor xenografts.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Camptothecin; Carcinoma, Squamous Cell; Cell Line, Tumor; Colonic Neoplasms; Cysteine; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; Irinotecan; Maximum Tolerated Dose; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms; Organoselenium Compounds; Radiation-Sensitizing Agents; Selenium; Selenocysteine; Selenomethionine; Time Factors | 2004 |
[A case of colon carcinoma with unresectable multiple liver metastases responding to various combined chemotherapies centering on hepatic arterial infusion therapy].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Colonic Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Hepatic Artery; Humans; Infusion Pumps, Implantable; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Liver Neoplasms; Quality of Life | 2004 |
The schedule-dependent enhanced cytotoxic activity of 7-ethyl-10-hydroxy-camptothecin (SN-38) in combination with Gefitinib (Iressa, ZD1839).
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Cell Cycle; Cell Division; Colonic Neoplasms; DNA Topoisomerases, Type I; Drug Synergism; ErbB Receptors; Gefitinib; HT29 Cells; Humans; Irinotecan; Quinazolines; Signal Transduction; Tumor Cells, Cultured | 2004 |
Two new drugs for colon cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Colonic Neoplasms; Colorectal Neoplasms; Humans; Irinotecan; Lung Neoplasms; Pancreatic Neoplasms | 2004 |
Complete remission of primary colon cancer in a metastatic patient treated with CPT-11 plus capecitabine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colonic Neoplasms; Deoxycytidine; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Treatment Outcome | 2004 |
Reactivation of hepatitis C virus after chemotherapy for colon cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Colonic Neoplasms; Fluorouracil; Hepatitis C; Humans; Immunocompromised Host; Irinotecan; Leucovorin; Male; Recurrence | 2004 |
Irinotecan chemotherapy associated with transient dysarthria and aphasia.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Aphasia; Camptothecin; Colonic Neoplasms; Dysarthria; Fluorouracil; Humans; Infusion Pumps; Irinotecan; Male | 2004 |
Effects of oxaliplatin and CPT-11 on cytotoxicity and nucleic acid incorporation of the fluoropyrimidines.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; Drug Synergism; Floxuridine; Fluorouracil; Humans; Irinotecan; Nucleic Acids; Organoplatinum Compounds; Oxaliplatin; Uridine | 2004 |
[A case of hepatic metastasis from colon cancer successfully treated with 5-FU, levofolinate (l-LV) and low-dose CPT-11].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colectomy; Colonic Neoplasms; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Remission Induction | 2004 |
Potentiation of cytotoxicity of topoisomerase i poison by concurrent and sequential treatment with the checkpoint inhibitor UCN-01 involves disparate mechanisms resulting in either p53-independent clonogenic suppression or p53-dependent mitotic catastroph
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Colonic Neoplasms; DNA Damage; DNA Replication; Drug Administration Schedule; Drug Synergism; Enzyme Inhibitors; G2 Phase; HCT116 Cells; Humans; Irinotecan; Microscopy, Fluorescence; Mitosis; S Phase; Staurosporine; Topoisomerase I Inhibitors; Transfection; Tumor Suppressor Protein p53 | 2004 |
[A case of metastatic liver tumor from colorectal carcinoma--continued arterial infusion chemotherapy through a microcatheter located in replaced right hepatic artery].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Catheters, Indwelling; Colonic Neoplasms; Combined Modality Therapy; Drug Administration Schedule; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Liver Neoplasms; Male | 2004 |
[A case of 5-FU-resistant recurrent colon cancer treated with low-dose CPT-11/CDDP on an outpatient basis].
Topics: Adult; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Fluorouracil; Humans; Irinotecan; Male; Quality of Life | 2004 |
Enhanced therapeutic efficacy of a novel liposome-based formulation of SN-38 against human tumor models in SCID mice.
Topics: Animals; Biomedical Enhancement; Camptothecin; Cell Line, Tumor; Clinical Trials, Phase I as Topic; Colonic Neoplasms; Disease Models, Animal; Drug Carriers; Female; HT29 Cells; Humans; Injections, Intravenous; Irinotecan; Liposomes; Mice; Mice, SCID; Technology, Pharmaceutical; Transplantation, Heterologous; Xenograft Model Antitumor Assays | 2004 |
[Successful treatment of liver metastasis and extrahepatic metastasis with hepatic arterial infusion of CDDP, CPT-11, and 5-FU].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Colonic Neoplasms; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Rectal Neoplasms | 2004 |
Carcinoembryonic antigen antibody inhibits lung metastasis and augments chemotherapy in a human colonic carcinoma xenograft.
Topics: Animals; Antibodies, Monoclonal; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Carcinoembryonic Antigen; Carcinoma, Signet Ring Cell; Cell Proliferation; Colonic Neoplasms; Combined Modality Therapy; Complement System Proteins; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Lung Neoplasms; Mice; Mice, Nude; Survival Rate; Transplantation, Heterologous | 2005 |
Elimination of hepatic metastases of colon cancer cells via p53-independent cross-talk between irinotecan and Apo2 ligand/TRAIL.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; bcl-X Protein; Camptothecin; Colonic Neoplasms; Drug Synergism; Female; HCT116 Cells; Humans; Irinotecan; Janus Kinase 2; Liver Neoplasms; Membrane Glycoproteins; Mice; Mice, Nude; Protein-Tyrosine Kinases; Proteins; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; TNF-Related Apoptosis-Inducing Ligand; Topoisomerase I Inhibitors; Transfection; Tumor Necrosis Factor-alpha; Tumor Suppressor Protein p53; X-Linked Inhibitor of Apoptosis Protein; Xenograft Model Antitumor Assays | 2004 |
Synergistic antitumor activity of capecitabine in combination with irinotecan.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cell Line, Tumor; Colonic Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Female; Fluorouracil; Irinotecan; Maximum Tolerated Dose; Mice; Mice, Nude; Neoplasm Transplantation; Quinazolines; Thiophenes | 2005 |
Importance of preclinical investigations of the integration of capecitabine into polychemotherapy regimens.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cell Line, Tumor; Colonic Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Female; Fluorouracil; Irinotecan; Maximum Tolerated Dose; Mice; Mice, Nude; Neoplasm Transplantation; Quinazolines; Thiophenes | 2005 |
Antitumour activity of XR5944 in vitro and in vivo in combination with 5-fluorouracil and irinotecan in colon cancer cell lines.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Fluorouracil; HCT116 Cells; HT29 Cells; Humans; Irinotecan; Mice; Mice, Nude; Phenazines; Transplantation, Heterologous | 2005 |
Inhibitory effects of asiatic acid and CPT-11 on growth of HT-29 cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Caspase 3; Caspases; Cell Division; Colonic Neoplasms; HT29 Cells; Humans; Irinotecan; Pentacyclic Triterpenes; Triterpenes | 2005 |
Adenoviral vector-mediated expression of a gene encoding secreted, EpCAM-targeted carboxylesterase-2 sensitises colon cancer spheroids to CPT-11.
Topics: Adenoviridae; Antineoplastic Agents, Phytogenic; Camptothecin; Carboxylesterase; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Genetic Vectors; Humans; Irinotecan; Ovarian Neoplasms | 2005 |
Dual inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation by AEE788 reduces growth and metastasis of human colon carcinoma in an orthotopic nude mouse model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Growth Processes; Colonic Neoplasms; ErbB Receptors; Growth Substances; HT29 Cells; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Irinotecan; Male; Mice; Mice, Nude; Neoplasm Metastasis; Phosphorylation; Platelet Endothelial Cell Adhesion Molecule-1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Purines; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; Xenograft Model Antitumor Assays | 2005 |
The irinotecan/5-fluorouracil combination induces apoptosis and enhances manganese superoxide dismutase activity in HT-29 human colon carcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Colonic Neoplasms; Drug Synergism; Electrophoresis, Polyacrylamide Gel; Flow Cytometry; Fluorouracil; HT29 Cells; Humans; Irinotecan; Superoxide Dismutase | 2005 |
Genome-wide expression analysis of therapy-resistant tumors reveals SPARC as a novel target for cancer therapy.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Colonic Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Mice; Mice, Nude; Neoplasms, Experimental; Oligonucleotide Array Sequence Analysis; Osteonectin; Transplantation, Heterologous | 2005 |
[Follicular drug reaction from cetuximab: a common side effect in the treatment of metastatic colon carcinoma].
Topics: Anaphylaxis; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colonic Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Eruptions; Folliculitis; Humans; Infusions, Intravenous; Irinotecan; Liver Neoplasms; Male; Middle Aged; Skin | 2006 |
[Second-line chemotherapy with bi-weekly CPT-11 and cisplatin for recurrent colorectal cancer resistant to 5-FU based chemotherapy].
Topics: Adult; Aged; Alopecia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Colonic Neoplasms; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Nausea; Neoplasm Recurrence, Local; Rectal Neoplasms | 2005 |
[Combination chemotherapy with oral TS-1 and low-dose CPT-11 by hepatic arterial infusion for multiple hepatic metastases from colon cancer--a case report].
Topics: Adenocarcinoma; Administration, Oral; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Hepatic Artery; Humans; Infusion Pumps, Implantable; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Male; Middle Aged; Oxonic Acid; Pyridines; Tegafur | 2005 |
Capecitabine as third line therapy in patients with advanced colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Capecitabine; Carcinoembryonic Antigen; Colonic Neoplasms; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Prodrugs; Rectal Neoplasms; Retrospective Studies; Survival Rate | 2005 |
Comparison between triple therapy with octreotide, galanin and serotonin vs. irinotecan or oxaliplatin in combination with 5-fluorouracil/leukovorin in human colon cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Body Weight; Camptothecin; Cell Proliferation; Colonic Neoplasms; Epidermal Growth Factor; Female; Fluorouracil; Galanin; Immunohistochemistry; In Situ Nick-End Labeling; Irinotecan; Leucovorin; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Octreotide; Organoplatinum Compounds; Oxaliplatin; Platelet Endothelial Cell Adhesion Molecule-1; Poly(ADP-ribose) Polymerases; Serotonin; Time Factors; Treatment Outcome; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2005 |
The radical scavenger edaravone enhances the anti-tumor effects of CPT-11 in murine colon cancer by increasing apoptosis via inhibition of NF-kappaB.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antipyrine; Apoptosis; Blotting, Western; Camptothecin; Caspase 3; Caspases; Cell Line, Tumor; Colonic Neoplasms; Disease Models, Animal; Edaravone; Electrophoretic Mobility Shift Assay; Free Radical Scavengers; In Situ Nick-End Labeling; Irinotecan; Lung Neoplasms; Male; Mice; NF-kappa B; Reactive Oxygen Species | 2005 |
Signaling through IFN regulatory factor-5 sensitizes p53-deficient tumors to DNA damage-induced apoptosis and cell death.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Colonic Neoplasms; DNA Damage; DNA-Binding Proteins; Drug Synergism; HCT116 Cells; Humans; Interferon Regulatory Factors; Interferon-beta; Irinotecan; Phosphorylation; Signal Transduction; Transcription Factors; Transfection; Tumor Suppressor Protein p53 | 2005 |
[Assessment of immunotoxicity of irinotecan determined by the novel method, by which productivity of TNF-alpha from whole blood is stimulated by lipopolysaccharide].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Biomarkers; Blood; Camptothecin; Colonic Neoplasms; Female; Humans; Immunologic Tests; Infusions, Intravenous; Irinotecan; Lipopolysaccharides; Male; Middle Aged; Monocytes; Stomach Neoplasms; Tumor Necrosis Factor-alpha | 2005 |
Regression of colorectal adenomas with intravenous cytotoxic chemotherapy in a patient with familial adenomatous polyposis.
Topics: Adenoma; Adenomatous Polyposis Coli; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Middle Aged; Treatment Outcome | 2005 |
Equivalent effect of DNA damage-induced apoptotic cell death or long-term cell cycle arrest on colon carcinoma cell proliferation and tumour growth.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Camptothecin; Cell Cycle; Cell Proliferation; Colonic Neoplasms; DNA Damage; Female; Flow Cytometry; Humans; Irinotecan; Mice; Mice, Inbred BALB C; Mice, Nude; Mutation; Necrosis; Ploidies; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2006 |
The epidermal growth factor receptor tyrosine kinase inhibitor gefitinib sensitizes colon cancer cells to irinotecan.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Camptothecin; Cell Cycle; Cell Line, Tumor; Colonic Neoplasms; Cyclin E; DNA Topoisomerases, Type II; DNA-Binding Proteins; Down-Regulation; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Irinotecan; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2005 |
[A case of colon cancer with multiple liver, lung and bone metastases successfully treated with combined weekly high-dose 5-FU (WHF) chemotherapy with UFT and CPT-11].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Colectomy; Colonic Neoplasms; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Fluorouracil; Humans; Infusion Pumps, Implantable; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Lung Neoplasms; Middle Aged; Tegafur; Uracil | 2005 |
Novel fluoro-substituted camptothecins: in vivo antitumor activity, reduced gastrointestinal toxicity and pharmacokinetic characterization.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; Female; Gastrointestinal Tract; Humans; Irinotecan; Male; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C3H; Mice, Nude; Ovarian Neoplasms; Prodrugs; Rats; Rats, Sprague-Dawley; Tumor Burden; Xenograft Model Antitumor Assays | 2006 |
Secondary acute promyelocytic leukemia following irinotecan and oxaliplatin for advanced colon cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Female; Humans; Irinotecan; Leukemia, Promyelocytic, Acute; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin | 2006 |
[A case of peritoneal dissemination disappeared by CPT-11 + TS-1 combination chemotherapy].
Topics: Administration, Oral; Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Combinations; Humans; Infusions, Intravenous; Irinotecan; Male; Neoplasm Seeding; Oxonic Acid; Peritoneal Neoplasms; Pyridines; Tegafur | 2005 |
[A case of metastatic colon cancer treated with oxaliplatin combination chemotherapy].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Floxuridine; Humans; Irinotecan; Liver Neoplasms; Male; Organoplatinum Compounds; Oxaliplatin; Quality of Life | 2005 |
Novel two-step resection for lesions between the middle hepatic vein and vena cava which allows the middle hepatic vein to be preserved.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Fluorouracil; Follow-Up Studies; Hepatectomy; Hepatic Veins; Humans; Irinotecan; Leucovorin; Liver; Liver Neoplasms; Liver Regeneration; Male; Rectal Neoplasms; Vena Cava, Inferior | 2006 |
Immunotherapy with dendritic cells and CpG oligonucleotides can be combined with chemotherapy without loss of efficacy in a mouse model of colon cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; CpG Islands; Dendritic Cells; Disease Models, Animal; Female; Fluorouracil; Humans; Immunotherapy; Irinotecan; Mice; Mice, Inbred BALB C; Oligonucleotides | 2006 |
DNA damage-induced expression of p53 suppresses mitotic checkpoint kinase hMps1: the lack of this suppression in p53MUT cells contributes to apoptosis.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Camptothecin; Carcinoma; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Colonic Neoplasms; DNA Damage; Flow Cytometry; Gene Expression Regulation, Neoplastic; HCT116 Cells; HeLa Cells; HT29 Cells; Humans; Irinotecan; Models, Biological; Neoplasm Proteins; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Suppressor Protein p53 | 2006 |
Transarterial chemoembolization with degradable starch microspheres, irinotecan, and mitomycin-C in patients with liver metastases.
Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoembolization, Therapeutic; Colonic Neoplasms; Disease Progression; Hepatic Artery; Humans; Injections, Intra-Arterial; Irinotecan; Liver Neoplasms; Male; Microspheres; Middle Aged; Mitomycin; Rectal Neoplasms; Remission Induction; Starch; Stomach Neoplasms; Topoisomerase I Inhibitors | 2006 |
Irinotecan/5-fluorouracil combination induces alterations in mitochondrial membrane potential and caspases on colon cancer cell lines.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Caspase 3; Caspase 8; Caspase 9; Caspases; Cell Line, Tumor; Colonic Neoplasms; Fluorouracil; HT29 Cells; Humans; Irinotecan; Membrane Potentials; Mitochondrial Membranes | 2005 |
Expression of drug pathway proteins is independent of tumour type.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Breast Neoplasms; Camptothecin; Colonic Neoplasms; Cytochrome P-450 Enzyme System; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Immunohistochemistry; Irinotecan; Lung Neoplasms; Lymphoma; Male; Melanoma; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Neoplasms; Ovarian Neoplasms; Prostatic Neoplasms; Tissue Array Analysis | 2006 |
The antitumor effect of a novel differentiation inducer, 2, 2-Bis (4-(4-amino-3-hydroxyphenoxy) phenyl) adamantane (DPA), in combinatory therapy on human colon cancer.
Topics: Adamantane; Animals; Antineoplastic Combined Chemotherapy Protocols; beta Catenin; Blotting, Western; Cadherins; Camptothecin; Carcinoembryonic Antigen; Catenins; Cell Adhesion Molecules; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cell Shape; Cell Survival; Colonic Neoplasms; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Delta Catenin; Dose-Response Relationship, Drug; Drug Synergism; Fibronectins; G1 Phase; HT29 Cells; Humans; Intracellular Signaling Peptides and Proteins; Irinotecan; Male; Mice; Mice, Inbred ICR; Mice, Nude; Phosphoproteins; Resting Phase, Cell Cycle; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2006 |
Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy.
Topics: Animals; Breast Neoplasms; Camptothecin; Colonic Neoplasms; Drug Delivery Systems; Drug Stability; Female; HT29 Cells; Humans; Irinotecan; Liposomes; Mice; Mice, Nude; Nanostructures; Rats; Rats, Sprague-Dawley; Xenograft Model Antitumor Assays | 2006 |
Novel missense mutation of the DNA topoisomerase I gene in SN-38-resistant DLD-1 cells.
Topics: Amino Acid Substitution; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Colonic Neoplasms; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Glycine; Humans; Irinotecan; Mutation, Missense; Protein Conformation; Serine | 2006 |
Postchemotherapy characteristics of hepatic colorectal metastases: remnants of uncertain malignant potential.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Colonic Neoplasms; DNA Repair; Follow-Up Studies; Gene Silencing; Hepatectomy; Humans; Irinotecan; Liver; Liver Neoplasms; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; O(6)-Methylguanine-DNA Methyltransferase; Organoplatinum Compounds; Oxaliplatin; Preoperative Care; Rectal Neoplasms; Remission Induction; Retrospective Studies; Topoisomerase I Inhibitors | 2006 |
Epigenetic inactivation of the premature aging Werner syndrome gene in human cancer.
Topics: Aging, Premature; Animals; Camptothecin; Cell Line, Tumor; Colonic Neoplasms; CpG Islands; DNA Helicases; DNA Methylation; Epigenesis, Genetic; Exodeoxyribonucleases; Female; Genes, Tumor Suppressor; Humans; Irinotecan; Mice; Mice, Nude; Promoter Regions, Genetic; RecQ Helicases; RNA, Messenger; Topoisomerase I Inhibitors; Werner Syndrome; Werner Syndrome Helicase | 2006 |
[Complete response to CPT-11 and UFT/LV combination therapy in a case with simultaneous multiple lung metastases from colon cancer].
Topics: Adenocarcinoma; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Administration Schedule; Drug Combinations; Female; Humans; Irinotecan; Leucovorin; Leukopenia; Lung Neoplasms; Middle Aged; Neoplasms, Multiple Primary; Neutropenia; Remission Induction; Tegafur; Uracil; Vomiting, Anticipatory | 2006 |
[A patient with hepatic, pulmonary, and nodal metastases of colon cancer responding to CPT-11/TS-1 therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colectomy; Colonic Neoplasms; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Oxonic Acid; Pyridines; Quality of Life; Tegafur | 2006 |
Inhibition of poly(ADP-ribose) polymerase prevents irinotecan-induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Proliferation; Colonic Neoplasms; Colony-Forming Units Assay; Dacarbazine; Diarrhea; Drug Synergism; Enzyme Inhibitors; Intestinal Diseases; Irinotecan; Organic Chemicals; Poly(ADP-ribose) Polymerase Inhibitors; Temozolomide; Topoisomerase I Inhibitors; Tumor Burden | 2006 |
The effects of the oral, pan-VEGF-R kinase inhibitor CEP-7055 and chemotherapy in orthotopic models of glioblastoma and colon carcinoma in mice.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carbazoles; Carcinoma; Colonic Neoplasms; Dacarbazine; Glioblastoma; Humans; Irinotecan; Mice; Mice, Nude; Neoplasm Metastasis; Receptors, Vascular Endothelial Growth Factor; Temozolomide; Xenograft Model Antitumor Assays | 2006 |
[Multiple hepatic metastases of colon cancer responding to combined therapy with TS-1 and CPT-11--a case report].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Administration Schedule; Drug Combinations; Female; Humans; Irinotecan; Liver Neoplasms; Oxonic Acid; Remission Induction; Tegafur | 2006 |
Molecular characterization of established human colon carcinoma cell lines (HCT-8) made resistant to 5-fluorouracil by different selection schedules.
Topics: Antineoplastic Agents; Camptothecin; Carcinoma; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Dihydrouracil Dehydrogenase (NADP); Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Oligonucleotide Array Sequence Analysis; Poly A; RNA, Messenger | 2005 |
[Evaluation of weekly low-dose CPT-11 combined with 5-FU/l-LV therapy for advanced and recurrent colorectal cancer--preliminary study].
Topics: Aged; Aged, 80 and over; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Leukopenia; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Quality of Life; Rectal Neoplasms | 2006 |
[A case of non-curatively resected colon cancer with liver and lymph node metastases treated by TS-1/CPT-11 combination therapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoembryonic Antigen; Colectomy; Colonic Neoplasms; Drug Administration Schedule; Drug Combinations; Humans; Irinotecan; Liver Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Oxonic Acid; Tegafur | 2006 |
Irinotecan cytotoxicity does not necessarily depend on the UGT1A1 polymorphism but on fluoropyrimidine: a molecular case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Female; Floxuridine; Fluorouracil; Glucuronosyltransferase; Humans; Irinotecan; Polymorphism, Genetic | 2006 |
Targeting the lymphotoxin-beta receptor with agonist antibodies as a potential cancer therapy.
Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal; Camptothecin; Cell Line, Tumor; Colonic Neoplasms; Combined Modality Therapy; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; Immunoglobulin G; Immunoglobulin M; Irinotecan; Lymphocytes, Tumor-Infiltrating; Lymphotoxin beta Receptor; Mice; Mice, Inbred BALB C; Mice, Nude; Random Allocation; Recombinant Fusion Proteins; Single-Blind Method; Uterine Cervical Neoplasms; Xenograft Model Antitumor Assays | 2006 |
Novel SN-38-incorporating polymeric micelles, NK012, eradicate vascular endothelial growth factor-secreting bulky tumors.
Topics: Animals; Camptothecin; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; Female; Irinotecan; Lung Neoplasms; Mice; Mice, Inbred BALB C; Micelles; Nanoparticles; Polyethylene Glycols; Polyglutamic Acid; Random Allocation; Tissue Distribution; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2006 |
Irinotecan-induced cytotoxicity to colon cancer cells in vitro is stimulated by pre-incubation with trifluorothymidine.
Topics: Antimetabolites; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Camptothecin; Cell Cycle; Cell Line, Tumor; Colonic Neoplasms; DNA Damage; Drug Synergism; Flow Cytometry; Humans; Irinotecan; Trifluridine | 2007 |
Searching for the Holy Grail of oncology.
Topics: Antineoplastic Agents; Camptothecin; Colonic Neoplasms; Diarrhea; Genetic Predisposition to Disease; Glucuronosyltransferase; Humans; Irinotecan; Neutropenia; Pharmacogenetics; Polymorphism, Single Nucleotide; Risk Assessment | 2006 |
Complete response of highly advanced colon cancer with multiple lymph node metastases to irinotecan combined with UFT: report of a case.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colonoscopy; Enzyme Inhibitors; Female; Follow-Up Studies; Humans; Irinotecan; Lymphatic Metastasis; Middle Aged; Prodrugs; Tegafur; Tomography, X-Ray Computed; Uracil | 2006 |
Targeting the expression of platelet-derived growth factor receptor by reactive stroma inhibits growth and metastasis of human colon carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Camptothecin; Carcinoma; Cecum; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Drug Synergism; Humans; Imatinib Mesylate; Irinotecan; Liver; Male; Mice; Mice, Nude; Pericytes; Piperazines; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Stromal Cells; Transplantation, Heterologous | 2006 |
Effect of combined therapy with low-dose 5-aza-2'-deoxycytidine and irinotecan on colon cancer cell line HCT-15.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Azacitidine; Camptothecin; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Cyclin-Dependent Kinase Inhibitor p16; Decitabine; DNA Methylation; Drug Therapy, Combination; Gene Expression Regulation, Neoplastic; Humans; In Situ Nick-End Labeling; Intracellular Signaling Peptides and Proteins; Irinotecan; Male; Membrane Proteins; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Proteins; Promoter Regions, Genetic; Proto-Oncogene Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Tumor Suppressor Protein p14ARF | 2007 |
[Experimental study of effect of epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in combination with irinotecan].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Cycle; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; DNA Topoisomerases, Type I; Drug Synergism; ErbB Receptors; Gefitinib; HT29 Cells; Humans; Inhibitory Concentration 50; Irinotecan; Mitogen-Activated Protein Kinase Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction | 2006 |
Short hairpin RNAs targeting Bcl-xL modulate senescence and apoptosis following SN-38 and irinotecan exposure in a colon cancer model.
Topics: Animals; Antimycin A; Antineoplastic Agents, Phytogenic; Apoptosis; bcl-X Protein; Camptothecin; Cell Death; Colonic Neoplasms; Down-Regulation; Doxorubicin; HCT116 Cells; Humans; Irinotecan; Mice; Proto-Oncogene Proteins c-bcl-2; RNA, Small Interfering; Transfection; Xenograft Model Antitumor Assays | 2007 |
Schedule-dependent cytotoxicity of 5-fluorouracil and irinotecan in a colon cancer cell line.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Camptothecin; Colonic Neoplasms; Drug Administration Schedule; Flow Cytometry; Fluorouracil; Humans; Irinotecan; Tumor Cells, Cultured | 2006 |
[Feasibility of modified FOLFIRI regimen for patients with refractory advanced or recurrent colorectal cancer].
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Administration Schedule; Feasibility Studies; Female; Fluorouracil; Humans; Infusion Pumps, Implantable; Infusions, Intravenous; Irinotecan; Leucovorin; Leukopenia; Male; Middle Aged; Neutropenia; Quality of Life; Rectal Neoplasms | 2007 |
[A retrospective study of irinotecan plus fluorouracil and l-leucovorin chemotherapy for advanced and metastatic colorectal cancer].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Rectal Neoplasms; Retrospective Studies | 2007 |
Adjuvant therapy for stage II and III colorectal cancer.
Topics: Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colonic Neoplasms; Deoxycytidine; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prodrugs; Rectal Neoplasms; Vitamin B Complex | 2007 |
Developing strategies for liver metastases from colorectal cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Catheter Ablation; Chemotherapy, Adjuvant; Colonic Neoplasms; Cryosurgery; Embolization, Therapeutic; Hepatectomy; Humans; Irinotecan; Liver Neoplasms; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Portal Vein; Rectal Neoplasms; Remission Induction; Survival Rate; Time Factors; Topoisomerase I Inhibitors | 2007 |
Panitumumab in metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Epidermal Growth Factor; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Panitumumab | 2007 |
[A case of ascending colon cancer with enlarged metastatic lymph nodes around superior mesenteric arterial root that responded dramatically to S-1 and CPT-11 combination chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colectomy; Colon, Ascending; Colonic Neoplasms; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Humans; Irinotecan; Lymph Nodes; Lymphatic Metastasis; Male; Mesenteric Artery, Superior; Middle Aged; Oxonic Acid; Remission Induction; Tegafur | 2007 |
Copper-transporting P-type ATPase, ATP7A, confers multidrug resistance and its expression is related to resistance to SN-38 in clinical colon cancer.
Topics: Adenocarcinoma; Adenosine Triphosphatases; Animals; Antineoplastic Agents, Phytogenic; Brefeldin A; Camptothecin; Cation Transport Proteins; Cell Membrane; CHO Cells; Cisplatin; Colonic Neoplasms; Copper; Copper-Transporting ATPases; Cricetinae; Cricetulus; Doxorubicin; Drug Interactions; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Golgi Apparatus; Humans; Irinotecan; Monensin; Transfection | 2007 |
Local and distant immune-mediated control of colon cancer growth with fusogenic membrane glycoproteins in combination with viral oncolysis.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cancer Vaccines; Cell Fusion; Cell Line, Tumor; Colonic Neoplasms; Combined Modality Therapy; Genetic Therapy; Humans; Irinotecan; Measles virus; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Oncolytic Virotherapy; T-Lymphocytes, Cytotoxic; Viral Fusion Proteins | 2007 |
Reversible grade 4 hyperbilirubinemia in a patient with UGT1A1 7/7 genotype treated with irinotecan and cetuximab.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colonic Neoplasms; Fluorouracil; Genotype; Glucuronosyltransferase; Humans; Hyperbilirubinemia; Irinotecan; Leucovorin; Liver Neoplasms; Male; Organoplatinum Compounds; Polymorphism, Genetic | 2007 |
Expression and characterization of a human carboxylesterase 2 splice variant.
Topics: Alternative Splicing; Antineoplastic Agents, Phytogenic; Base Sequence; Camptothecin; Carboxylesterase; Cloning, Molecular; Colon; Colonic Neoplasms; Humans; Irinotecan; Isoenzymes; Molecular Sequence Data; Prodrugs; Reverse Transcriptase Polymerase Chain Reaction; Topoisomerase I Inhibitors | 2007 |
A renewed call for equipoise.
Topics: Adenocarcinoma; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; Ethics, Medical; Fluorouracil; Humans; Irinotecan; Leucovorin; Leukemia; Randomized Controlled Trials as Topic; Recurrence; Treatment Outcome; Uncertainty | 2007 |
[Efficacy of CPT-11 combined 5-FU/CF (FOLFIRI) regimen on advanced colorectal cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Diarrhea; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Nausea; Neoplasm Staging; Neutropenia; Rectal Neoplasms; Remission Induction; Retrospective Studies; Survival Rate; Young Adult | 2007 |
Schedule-dependent cytotoxicity of 5-fluorouracil and irinotecan in p53 mutant human colon cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Colonic Neoplasms; Drug Administration Schedule; Fluorouracil; Gene Expression; Gene Expression Profiling; Humans; Irinotecan; Leucovorin; Mutation; Oligonucleotide Array Sequence Analysis; Tumor Cells, Cultured; Up-Regulation | 2007 |
Development and characterization of a model of liver metastasis using human colon cancer HCT-116 cells.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Adhesion; Cell Line, Tumor; Collagen Type II; Colonic Neoplasms; Female; Fibronectins; Floxuridine; Fluorouracil; Humans; Irinotecan; Laminin; Liver Neoplasms; Mice; Mice, Inbred C57BL; Mice, Nude; Models, Biological; Neoplasm Metastasis; Paclitaxel | 2007 |
Effect of betulinic acid on anticancer drug-resistant colon cancer cells.
Topics: Adenocarcinoma; Antineoplastic Agents; bcl-2-Associated X Protein; bcl-Associated Death Protein; Betulinic Acid; Camptothecin; Caspases; Cell Death; Cell Line, Tumor; Colonic Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Fluorouracil; Humans; Irinotecan; Mitochondria; Multidrug Resistance-Associated Proteins; Organoplatinum Compounds; Oxaliplatin; Pentacyclic Triterpenes; Triterpenes | 2007 |
Therapy of colon carcinoma: an oncology perspective. Interview with Piotr M. Czaykowski by Paul C. Adams.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoembryonic Antigen; Carcinoma; Colonic Neoplasms; Combined Modality Therapy; Fluorouracil; Humans; Irinotecan; Quinazolines; Rectal Neoplasms; Thiophenes | 2007 |
Investigation of two dosing schedules of vandetanib (ZD6474), an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, in combination with irinotecan in a human colon cancer xenograft model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Colonic Neoplasms; Drug Administration Schedule; ErbB Receptors; Female; Humans; Irinotecan; Magnetic Resonance Imaging; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Treatment Outcome | 2007 |
[Systemic treatment of peritoneal metastases].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Chemotherapy, Cancer, Regional Perfusion; Colonic Neoplasms; Combined Modality Therapy; Fluorouracil; Gastrointestinal Neoplasms; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Neoplasm Staging; Peritoneal Neoplasms; Prognosis; Quality of Life | 2007 |
Nutritional modulation of antitumor efficacy and diarrhea toxicity related to irinotecan chemotherapy in rats bearing the ward colon tumor.
Topics: Animals; Camptothecin; Colonic Neoplasms; Diarrhea; Diet; Fatty Acids, Omega-3; Female; Food-Drug Interactions; Glutamine; Irinotecan; Oligosaccharides; Probiotics; Rats | 2007 |
Comparative cytotoxicity of C-1311 in colon cancer in vitro and in vivo using the hollow fiber assay.
Topics: Aminoacridines; Animals; Antineoplastic Agents; Camptothecin; Capecitabine; Cell Line, Tumor; Cell Proliferation; Clinical Trials, Phase II as Topic; Colonic Neoplasms; Deoxycytidine; Drug Screening Assays, Antitumor; Fluorouracil; HT29 Cells; Humans; In Vitro Techniques; Irinotecan; Mice; Mice, Nude; Organoplatinum Compounds; Oxaliplatin; Paclitaxel | 2007 |
Inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation on tumor-associated endothelial cells leads to treatment of orthotopic human colon cancer in nude mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cecal Neoplasms; Cell Line, Tumor; Colonic Neoplasms; Endothelial Cells; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Humans; Irinotecan; Male; Mice; Mice, Nude; Neoplasm Proteins; Phosphorylation; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-akt; Purines; Signal Transduction; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2007 |
Pharmacological targeting of NF-kappaB potentiates the effect of the topoisomerase inhibitor CPT-11 on colon cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Survival; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug Synergism; Female; HT29 Cells; Humans; I-kappa B Kinase; Irinotecan; Mice; Mice, Nude; NF-kappa B; Protein Kinase Inhibitors; Pyrimidines; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2008 |
[An elderly case of recurrent colon cancer responding to weekly S-1 chemotherapy leading to partial response].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Combinations; Female; Humans; Irinotecan; Lung Neoplasms; Neoplasm Recurrence, Local; Oxonic Acid; Tegafur; Tomography, X-Ray Computed; Treatment Failure | 2008 |
Altered expression of cell proliferation-related and interferon-stimulated genes in colon cancer cells resistant to SN38.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colonic Neoplasms; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Humans; Inhibitory Concentration 50; Interferons; Irinotecan; Oligonucleotide Array Sequence Analysis; Time Factors | 2008 |
[A long survival case of advanced colon cancer with lung metastasis and cancerous pleuritis responding to CPT-11 and S-1 combination therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Combinations; Humans; Irinotecan; Lung Neoplasms; Male; Neoplasm Staging; Oxonic Acid; Pleurisy; Positron-Emission Tomography; Tegafur; Time Factors; Tomography, X-Ray Computed | 2008 |
Bolus oral glutamine protects rats against CPT-11-induced diarrhea and differentially activates cytoprotective mechanisms in host intestine but not tumor.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Camptothecin; Colon; Colonic Neoplasms; Cytoprotection; Diarrhea; Female; Glutamine; Irinotecan; Neoplasms, Experimental; Rats | 2008 |
The cyclin-dependent kinase inhibitor flavopiridol potentiates the effects of topoisomerase I poisons by suppressing Rad51 expression in a p53-dependent manner.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Colonic Neoplasms; Cyclin-Dependent Kinase 9; Down-Regulation; Drug Synergism; Flavonoids; HCT116 Cells; Humans; Irinotecan; Phosphorylation; Piperidines; Protein Kinase Inhibitors; Rad51 Recombinase; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Topoisomerase I Inhibitors; Tumor Suppressor Protein p53 | 2008 |
Treatment of human colon cancer xenografts with TRA-8 anti-death receptor 5 antibody alone or in combination with CPT-11.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Camptothecin; Cell Line, Tumor; Colonic Neoplasms; Drug Resistance, Neoplasm; Flow Cytometry; Fluorescent Antibody Technique; Humans; Irinotecan; Mice; Mice, Nude; Receptors, TNF-Related Apoptosis-Inducing Ligand; Tissue Distribution; Tomography, Emission-Computed, Single-Photon; Xenograft Model Antitumor Assays | 2008 |
[Multiple hepatic metastases and ovarian metastases of colon cancer responding to combined therapy with S-1 and CPT-11--a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Combinations; Female; Humans; Irinotecan; Liver Neoplasms; Middle Aged; Ovarian Neoplasms; Oxonic Acid; Tegafur; Tomography, X-Ray Computed | 2008 |
Phosphorylated epidermal growth factor receptor on tumor-associated endothelial cells is a primary target for therapy with tyrosine kinase inhibitors.
Topics: Animals; Apoptosis; Blotting, Western; Camptothecin; Cecum; Cell Proliferation; Colonic Neoplasms; Drug Therapy, Combination; Endothelial Cells; Enzyme Inhibitors; ErbB Receptors; Humans; Immunoenzyme Techniques; In Situ Nick-End Labeling; Irinotecan; Lymphatic Metastasis; Male; Mice; Mice, Nude; Necrosis; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Receptor, ErbB-2; RNA, Small Interfering; Topoisomerase I Inhibitors; Transforming Growth Factor alpha | 2008 |
Anticancer effect of SN-38 on colon cancer cell lines with different metastatic potential.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Camptothecin; Cell Proliferation; Colonic Neoplasms; DNA Topoisomerases, Type I; Flow Cytometry; G2 Phase; Humans; Immunoenzyme Techniques; Inhibitor of Apoptosis Proteins; Irinotecan; Microtubule-Associated Proteins; Neoplasm Proteins; S Phase; Survivin; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 2008 |
Recombinant human insulin-like growth factor-binding protein 3 inhibits tumor growth and targets the Akt pathway in lung and colon cancer models.
Topics: Animals; Antineoplastic Agents; Camptothecin; Carboplatin; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Down-Regulation; Drug Synergism; Female; Humans; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor Binding Proteins; Irinotecan; Lung Neoplasms; MAP Kinase Signaling System; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Proto-Oncogene Proteins c-akt; Recombinant Proteins; Signal Transduction; Transplantation, Heterologous | 2008 |
Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Colonic Neoplasms; Female; Humans; Irinotecan; Mice; Mice, Inbred CBA; Neoplasms, Experimental; Random Allocation; Rhabdomyosarcoma; Topoisomerase I Inhibitors; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured | 1995 |
[A model for sensitivity determination of anticancer agents against chemical-induced colon cancer in rats].
Topics: Animals; Camptothecin; Cell Division; Cisplatin; Colonic Neoplasms; Dimethylhydrazines; Drug Screening Assays, Antitumor; Irinotecan; Male; Rats; Rats, Sprague-Dawley | 1995 |
Identification and kinetics of a beta-glucuronide metabolite of SN-38 in human plasma after administration of the camptothecin derivative irinotecan.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Biotransformation; Camptothecin; Chromatography, High Pressure Liquid; Colonic Neoplasms; Female; Glucuronates; Glucuronidase; Humans; Irinotecan; Middle Aged; Time Factors | 1995 |
Establishment and characterization of human gastric and colonic xenograft lines resistant to CPT-11 (a new derivative of camptothecin).
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Division; Colonic Neoplasms; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Resistance; Humans; Irinotecan; Male; Mice; Mice, Nude; Stomach Neoplasms; Transplantation, Heterologous; Tumor Cells, Cultured | 1995 |
[Antitumor effect of camptothecin analog on liver metastatic model of human colon cancer in nude mice].
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Division; Colonic Neoplasms; Female; Humans; Irinotecan; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Tumor Cells, Cultured | 1994 |
Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor
Topics: Adolescent; Adult; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Child; Colonic Neoplasms; Drug Administration Schedule; Drug Resistance; Drug Screening Assays, Antitumor; Female; Humans; Irinotecan; Male; Melphalan; Mice; Mice, Inbred CBA; Neoplasm Transplantation; Rhabdomyosarcoma; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured; Vincristine | 1993 |
Irinotecan is an active agent in untreated patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Colonic Neoplasms; Diarrhea; Drug Administration Schedule; Female; Humans; Irinotecan; Liver; Lung; Male; Middle Aged; Neutropenia; Rectal Neoplasms; Remission Induction; Survival Analysis | 1996 |
Rapid tumour lysis syndrome in a metastatic colorectal cancer increased by treatment (CPT-11)
Topics: Adenocarcinoma; Adult; Antineoplastic Agents, Phytogenic; Camptothecin; Colonic Neoplasms; Fatal Outcome; Female; Humans; Irinotecan; Tumor Lysis Syndrome | 1996 |
Variation in topoisomerase I gene copy number as a mechanism for intrinsic drug sensitivity.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Cell Line; Cell Survival; Colonic Neoplasms; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Female; Gene Amplification; Gene Expression; Genetic Variation; Humans; In Situ Hybridization, Fluorescence; Irinotecan; Karyotyping; Kinetics; Nuclear Proteins; Tumor Cells, Cultured | 1996 |
[Caring for patients treated with Campto (CPT-11)].
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase II as Topic; Colonic Neoplasms; Drug Monitoring; Humans; Irinotecan; Nursing Records | 1996 |
Interferon potentiates antiproliferative activity of CPT-11 against human colon cancer xenografts.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Division; Colonic Neoplasms; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Interferon-alpha; Interferon-beta; Interferon-gamma; Irinotecan; Mice; Mice, Inbred BALB C; Mice, Nude; Recombinant Proteins; Transplantation, Heterologous; Tumor Cells, Cultured | 1996 |
CPT-11 in human colon-cancer cell lines and xenografts: characterization of cellular sensitivity determinants.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carboxylesterase; Carboxylic Ester Hydrolases; Colonic Neoplasms; DNA Topoisomerases, Type I; Drug Screening Assays, Antitumor; Female; Humans; Irinotecan; Mice; Mice, Nude; Transplantation, Heterologous; Tumor Cells, Cultured | 1997 |
The multidrug resistance-associated protein gene confers drug resistance in human gastric and colon cancers.
Topics: Antineoplastic Agents; Camptothecin; Cisplatin; Colonic Neoplasms; Doxorubicin; Etoposide; Genes, MDR; Humans; Irinotecan; Mitomycin; Polymerase Chain Reaction; RNA, Messenger; Stomach Neoplasms; Tumor Cells, Cultured; Verapamil; Vincristine | 1996 |
SN-38, a metabolite of the camptothecin derivative CPT-11, potentiates the cytotoxic effect of radiation in human colon adenocarcinoma cells grown as spheroids.
Topics: Adenocarcinoma; Camptothecin; Cell Survival; Colonic Neoplasms; Humans; Irinotecan; Radiation Dosage; Radiation Tolerance; Radiation-Sensitizing Agents; Tumor Cells, Cultured | 1997 |
[A case of recurrent advanced colon cancer treated with CPT-11 for second-line chemotherapy].
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoembryonic Antigen; Cisplatin; Colonic Neoplasms; Drug Resistance, Neoplasm; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Remission Induction | 1997 |
Irinotecan hydrochloride (CPT-11) resistance identified by K-ras mutation in patients with progressive colon cancer after treatment with 5-fluorouracil (5-FU).
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Codon; Colonic Neoplasms; Disease Progression; DNA, Neoplasm; Drug Resistance, Neoplasm; Exons; Female; Fluorouracil; Forecasting; Genes, ras; Guanine; Humans; Irinotecan; Male; Middle Aged; Mutation; Prognosis; Retreatment; Sequence Analysis, DNA; Survival Rate; Thymine; Treatment Failure | 1997 |
Antitumor activity of a novel quinoline derivative, TAS-103, with inhibitory effects on topoisomerases I and II.
Topics: Adenocarcinoma; Aminoquinolines; Animals; Antineoplastic Agents; Camptothecin; Cisplatin; Colonic Neoplasms; DNA; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Etoposide; Humans; Indenes; Indoles; Irinotecan; Lung Neoplasms; Male; Melanoma; Mice; Mice, Inbred Strains; Neoplasm Transplantation; Neoplasms, Experimental; Pyridines; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1997 |
Studies of the efficacy and pharmacology of irinotecan against human colon tumor xenograft models.
Topics: Adenocarcinoma; Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Division; Colonic Neoplasms; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Injections, Intravenous; Irinotecan; Metabolic Clearance Rate; Mice; Mice, Inbred CBA; Models, Biological; Neoplasm Transplantation; Thymectomy; Transplantation, Heterologous | 1998 |
Schedule-dependent synergism between raltitrexed and irinotecan in human colon cancer cells in vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Survival; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Humans; Irinotecan; Quinazolines; Thiophenes; Tumor Cells, Cultured | 1998 |
Irinotecan-induced immune thrombocytopenia.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Camptothecin; Colonic Neoplasms; Fluorouracil; Humans; Immunoglobulin G; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Thrombocytopenia | 1998 |
Comparison of the pharmacokinetics and efficacy of irinotecan after administration by the intravenous versus intraperitoneal route in mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Colonic Neoplasms; Female; Injections, Intraperitoneal; Injections, Intravenous; Irinotecan; Mice; Mice, Inbred BALB C | 1998 |
Colon cancer: new drug options improve on 5-FU.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colonic Neoplasms; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Fluorouracil; Folic Acid Antagonists; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Survival Analysis; Tegafur; Thiophenes; Thymidylate Synthase; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome | 1998 |
Potent and broad antitumor effects of DX-8951f, a water-soluble camptothecin derivative, against various human tumors xenografted in nude mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Colonic Neoplasms; Humans; Irinotecan; Kidney Neoplasms; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Stomach Neoplasms; Subrenal Capsule Assay; Tumor Cells, Cultured | 1998 |
Prevention of intestinal toxic effects and intensification of irinotecan's therapeutic efficacy against murine colon cancer liver metastases by oral administration of the lipopeptide JBT 3002.
Topics: Adjuvants, Immunologic; Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Administration Schedule; Drug Synergism; Intestinal Diseases; Irinotecan; Lipopeptides; Lipoproteins; Liver Neoplasms, Experimental; Macrophage Activation; Macrophages; Mice; Mice, Inbred BALB C | 1998 |
Evaluation of irinotecan in combination with 5-fluorouracil or etoposide in xenograft models of colon adenocarcinoma and rhabdomyosarcoma.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Etoposide; Female; Fluorouracil; Humans; Irinotecan; Mice; Mice, Inbred CBA; Neoplasm Transplantation; Rhabdomyosarcoma; Transplantation, Heterologous | 1996 |
Irinotecan (CPT-11) metabolites in human bile and urine.
Topics: Antineoplastic Agents, Phytogenic; Bile; Camptothecin; Colonic Neoplasms; Female; Humans; Irinotecan; Liver Neoplasms; Mass Spectrometry; Middle Aged; Neoplasm Metastasis | 1996 |
Combination of irinotecan (CPT11) and 5-fluorouracil with an analysis of cellular determinants of drug activity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Screening Assays, Antitumor; Flow Cytometry; Fluorouracil; Humans; Irinotecan; Tumor Cells, Cultured | 1998 |
Bradycardia induced by irinotecan: a case report.
Topics: Aged; Antineoplastic Agents, Phytogenic; Bradycardia; Camptothecin; Cholinergic Agents; Colonic Neoplasms; Diarrhea; Electrocardiography; Humans; Irinotecan; Male | 1998 |
Diffuse mucosal damage in the large intestine associated with Irinotecan (CPT-11).
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Camptothecin; Colon; Colonic Neoplasms; Fatal Outcome; Humans; Intestinal Mucosa; Irinotecan; Liver Neoplasms; Male; Middle Aged | 1998 |
Enhanced antitumor activity of 6-hydroxymethylacylfulvene in combination with irinotecan and 5-fluorouracil in the HT29 human colon tumor xenograft model.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Administration Schedule; Fluorouracil; HT29 Cells; Humans; Irinotecan; Mice; Mice, Nude; Neoplasm Transplantation; Sesquiterpenes; Transplantation, Heterologous | 1999 |
Detection of poly(ADP-ribose) polymerase cleavage in response to treatment with topoisomerase I inhibitors: a potential surrogate end point to assess treatment effectiveness.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biopsy; Camptothecin; Caspases; Cell Division; Colonic Neoplasms; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Irinotecan; Mice; Mice, Nude; Neoplasm Transplantation; Poly(ADP-ribose) Polymerases; Time Factors; Topoisomerase I Inhibitors; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured | 1999 |
Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Cell Cycle; Colonic Neoplasms; Cross-Linking Reagents; DNA Adducts; DNA Damage; DNA, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Mammary Neoplasms, Experimental; Nucleic Acid Synthesis Inhibitors; Organoplatinum Compounds; Oxaliplatin; RNA, Neoplasm; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 1999 |
CPT-11 converting carboxylesterase and topoisomerase activities in tumour and normal colon and liver tissues.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Carboxylic Ester Hydrolases; Colon; Colonic Neoplasms; DNA Topoisomerases, Type I; Enzyme Activation; Enzyme Inhibitors; Female; Humans; Irinotecan; Liver; Liver Neoplasms; Male; Middle Aged; Rectal Neoplasms; Topoisomerase I Inhibitors | 1999 |
[Experimental study on intraperitoneal and intravenous administration of anti-tumor agents for liver metastasis].
Topics: Animals; Antineoplastic Agents; Camptothecin; Cisplatin; Colonic Neoplasms; Fluorouracil; Infusions, Intravenous; Infusions, Parenteral; Irinotecan; Liver Neoplasms; Mice; Mice, Inbred BALB C; Tumor Cells, Cultured | 1999 |
Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): a clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer.
Topics: Adult; Aged; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Diarrhea; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neutropenia; Rectal Neoplasms | 1999 |
Schedule-dependent cytotoxicity of SN-38 in p53 wild-type and mutant colon adenocarcinoma cell lines.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Cycle; Colonic Neoplasms; DNA Topoisomerases, Type I; Flow Cytometry; Humans; Irinotecan; Mutation; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 1999 |
Tumor necrosis factor-related apoptosis-inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Camptothecin; Colonic Neoplasms; Disease Models, Animal; Drug Screening Assays, Antitumor; Drug Synergism; Female; HT29 Cells; Humans; Irinotecan; Membrane Glycoproteins; Mice; Mice, SCID; Neoplasm Transplantation; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha | 1999 |
Glutamine for irinotecan diarrhea.
Topics: Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colonic Neoplasms; Diarrhea; Female; Glutamine; Humans; Irinotecan; Male; Middle Aged; Rectal Neoplasms | 2000 |
In vitro augmentation of antitumor effect in combination with CPT-11 and CDDP for human colorectal cancer.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Colonic Neoplasms; Coloring Agents; Drug Synergism; Female; Humans; Irinotecan; Male; Middle Aged; Mitomycin; Rectal Neoplasms; Tetrazolium Salts; Thiazoles; Tumor Cells, Cultured | 2000 |
Sequence-dependent growth inhibition and DNA damage formation by the irinotecan-5-fluorouracil combination in human colon carcinoma cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Division; Colonic Neoplasms; DNA Damage; DNA, Neoplasm; Fluorouracil; Humans; Irinotecan; Tumor Cells, Cultured | 1999 |
Altered pharmacokinetics and metabolism of CPT-11 in liver dysfunction: a need for guidelines.
Topics: Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Colonic Neoplasms; Female; Fever; Humans; Infusions, Intravenous; Irinotecan; Liver Diseases; Metabolic Clearance Rate; Middle Aged; Practice Guidelines as Topic; Sleep | 2000 |
Homocamptothecin, an E-ring-modified camptothecin, exerts more potent antiproliferative activity than other topoisomerase I inhibitors in human colon cancers obtained from surgery and maintained in vitro under histotypical culture conditions.
Topics: Antineoplastic Agents; Biopsy; Camptothecin; Cell Division; Colon; Colonic Neoplasms; Culture Techniques; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Doxorubicin; Enzyme Inhibitors; Etoposide; Humans; Irinotecan; Thymidine; Topoisomerase I Inhibitors; Topotecan; Tritium; Tumor Cells, Cultured | 2000 |
[A case of metastatic colon carcinoma in which a continuous intrahepatic artery-infusion of 5-FU leucovorin and cisplatin, and systemic chemotherapy with CPT-11 was very effective].
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Colonic Neoplasms; Drug Administration Schedule; Fluorouracil; Hepatic Artery; Humans; Infusion Pumps, Implantable; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged | 2000 |
Characterization of CPT-11 converting carboxylesterase activity in colon tumor and normal tissues: comparison with p-nitro-phenylacetate converting carboxylesterase activity.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carboxylic Ester Hydrolases; Colon; Colonic Neoplasms; DNA Topoisomerases, Type I; Enzyme Activation; Enzyme Inhibitors; Humans; Irinotecan; Kinetics; Liver; Nitrophenols; Rats; Substrate Specificity; Topoisomerase I Inhibitors | 2000 |
New highly lipophilic camptothecin BNP1350 is an effective drug in experimental human cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Colonic Neoplasms; Doxorubicin; Drug Resistance, Multiple; Enzyme Inhibitors; Female; Humans; Irinotecan; Lung Neoplasms; Melanoma; Mice; Mice, Nude; Neoplasms; Ovarian Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2000 |
[Response of metastatic colorectal cancers to treatment with CPT11 (irinotecan): implications of the mismatched base repair system].
Topics: Adaptor Proteins, Signal Transducing; Adult; Antineoplastic Agents, Phytogenic; Base Pair Mismatch; Camptothecin; Carrier Proteins; Colonic Neoplasms; DNA Repair; DNA-Binding Proteins; Humans; Irinotecan; Microsatellite Repeats; Middle Aged; MutL Protein Homolog 1; MutS Homolog 2 Protein; Neoplasm Proteins; Nuclear Proteins; Proto-Oncogene Proteins; Rectal Neoplasms; Retrospective Studies | 2000 |
Double cancer (lung and colon cancer) that showed complete remission with irinotecan and cisplatin combined chemotherapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Colonic Neoplasms; Humans; Irinotecan; Lung Neoplasms; Male; Neoplasms, Multiple Primary; Radiography | 2000 |
[Experimental study on intraperitoneal versus intravenous CPT-11 for peritoneal seeding and liver metastasis].
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Colonic Neoplasms; Female; Infusions, Intravenous; Infusions, Parenteral; Irinotecan; Liver Neoplasms; Mice; Mice, Inbred BALB C; Peritoneal Neoplasms | 2000 |
[Three cases of liver metastasis of colon cancer responding to systemic combination chemotherapy utilizing CPT-11].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Colonic Neoplasms; Doxorubicin; Drug Administration Schedule; Drug Evaluation; Etoposide; Female; Humans; Irinotecan; Liver Neoplasms; Male; Tegafur; Uracil | 2000 |
Pharmacokinetics of orally administered camptothecins.
Topics: Administration, Oral; Anion Transport Proteins; Antineoplastic Agents, Phytogenic; Biological Transport, Active; Biotransformation; Caco-2 Cells; Camptothecin; Carrier Proteins; Cell Membrane Permeability; Colonic Neoplasms; Enzyme Inhibitors; Humans; Hydrolysis; Intestinal Absorption; Intestinal Mucosa; Irinotecan; Liver; Liver Neoplasms; Probenecid; Prodrugs; Rectal Neoplasms | 2000 |
Ternary combination of irinotecan, fluorouracil-folinic acid and oxaliplatin: results on human colon cancer cell lines.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colonic Neoplasms; Drug Interactions; Drug Therapy, Combination; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Tumor Cells, Cultured | 2001 |
[Weekly low dose CPT-11 for multiple lung metastases of colon cancer on an out-patient treatment: a case report].
Topics: Adult; Ambulatory Care; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colonic Neoplasms; Drug Administration Schedule; Female; Floxuridine; Humans; Irinotecan; Lung Neoplasms | 2001 |
North Central Cancer Treatment Group--Mayo Clinic trials in colon cancer.
Topics: Adjuvants, Immunologic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Humans; Irinotecan; Leucovorin; Levamisole | 2001 |
Use of a modified ornithine decarboxylase promoter to achieve efficient c-MYC- or N-MYC-regulated protein expression.
Topics: Animals; Antineoplastic Agents, Phytogenic; Biotransformation; Camptothecin; Carboxylesterase; Carboxylic Ester Hydrolases; Chloramphenicol O-Acetyltransferase; Colonic Neoplasms; Gene Expression Regulation, Neoplastic; Genes, myc; Genes, Reporter; Glioblastoma; Humans; Immunoblotting; Irinotecan; MyoD Protein; Neuroblastoma; Ornithine Decarboxylase; Promoter Regions, Genetic; Proto-Oncogene Proteins c-myc; Rabbits; Rhabdomyosarcoma; Transfection; Transgenes; Tumor Cells, Cultured | 2001 |
Two unusual sites of colon cancer metastases and a rare thyroid lymphoma. Case 2. Chemotherapy-responsive right artial metastasis from colon carcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Camptothecin; Colonic Neoplasms; Heart Atria; Heart Neoplasms; Humans; Irinotecan; Male; Middle Aged; Ultrasonography | 2001 |
High-performance liquid chromatographic technique for the simultaneous determination of lactone and hydroxy acid forms of camptothecin and SN-38 in tissue culture media and cancer cells.
Topics: Camptothecin; Cell Extracts; Chromatography, High Pressure Liquid; Colonic Neoplasms; Culture Media; Drug Stability; HT29 Cells; Humans; Irinotecan; Lactones; Reproducibility of Results; Sensitivity and Specificity; Sonication; Time Factors | 2001 |
Combination of oxaliplatin and irinotecan on human colon cancer cell lines: activity in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Colonic Neoplasms; DNA Adducts; DNA Repair; DNA-Binding Proteins; Drug Interactions; Drug Screening Assays, Antitumor; Drug Synergism; Endonucleases; Enzyme Inhibitors; Female; Humans; Irinotecan; Mice; Organoplatinum Compounds; Oxaliplatin; Poly(ADP-ribose) Polymerases; Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA-Binding Proteins; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; Xeroderma Pigmentosum Group A Protein | 2001 |
[Pharmacokinetic study of the intraperitoneal administration of CPT-11 for patients with peritoneal seedings of gastric and colonic cancers].
Topics: Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colonic Neoplasms; Female; Humans; Injections, Intraperitoneal; Irinotecan; Male; Middle Aged; Neoplasm Seeding; Peritoneal Neoplasms; Stomach Neoplasms | 2001 |
[Two cases of multiple liver metastases of colon cancer with systemic irinotecan and hepatic arterial injection of 5-FU].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Male | 2001 |
[A case of lung metastasis from colon cancer treated successfully with combined chemotherapy of CPT-11 and 5'-DFUR].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Drug Administration Schedule; Female; Floxuridine; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Middle Aged | 2001 |
Augmentation of apoptosis and tumor regression by flavopiridol in the presence of CPT-11 in Hct116 colon cancer monolayers and xenografts.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Colonic Neoplasms; Flavonoids; Humans; Irinotecan; Male; Mice; Mice, Nude; Piperidines; Transplantation, Heterologous; Tumor Cells, Cultured | 2001 |
Treatment of human colon carcinoma cell lines with anti-neoplastic agents enhances their lytic sensitivity to antigen-specific CD8+ cytotoxic T lymphocytes.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Apoptosis; Camptothecin; Caspase 3; Caspases; CD8-Positive T-Lymphocytes; Cell Survival; Chromium; Cisplatin; Colonic Neoplasms; Cytotoxicity, Immunologic; fas Receptor; Flow Cytometry; Fluorouracil; Humans; In Situ Nick-End Labeling; Intercellular Adhesion Molecule-1; Interferon-gamma; Irinotecan; Recombinant Proteins; T-Lymphocytes, Cytotoxic; Tumor Cells, Cultured | 2001 |
Sphingomyelin enhances chemotherapy efficacy and increases apoptosis in human colonic tumor xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Cisplatin; Colonic Neoplasms; Disease Models, Animal; Drug Synergism; Female; Fluorouracil; Humans; Irinotecan; Mice; Mice, Nude; Neoplasm Transplantation; Signal Transduction; Sphingomyelins; Time Factors; Transplantation, Heterologous; Tumor Cells, Cultured | 2002 |
[Irinotecan and tomudex in the treatment of patients with advanced cancer of the large intestine].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colonic Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Quinazolines; Rectal Neoplasms; Thiophenes; Time Factors | 2001 |
Promising drug is victim of bad business.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Cetuximab; Clinical Trials as Topic; Colonic Neoplasms; Drug Approval; Drug Industry; ErbB Receptors; Humans; Irinotecan; Patents as Topic; Recombinant Fusion Proteins; United States; United States Food and Drug Administration | 2002 |
Antisense anti-MDM2 mixed-backbone oligonucleotides enhance therapeutic efficacy of topoisomerase I inhibitor irinotecan in nude mice bearing human cancer xenografts: In vivo activity and mechanisms.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Colonic Neoplasms; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Dose-Response Relationship, Drug; Drug Resistance; Drug Synergism; Female; Humans; Irinotecan; Mice; Mice, Nude; Mutation; Neoplasm Transplantation; Nuclear Proteins; Oligonucleotides, Antisense; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-mdm2; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2002 |
Efficient induction of apoptosis by ONYX-015 adenovirus in human colon cancer cell lines regardless of p53 status.
Topics: Adenoviridae; Antineoplastic Agents; Apoptosis; Camptothecin; Colonic Neoplasms; Combined Modality Therapy; Fluorouracil; Humans; Irinotecan; Mutation; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2002 |
Factors influencing the cellular accumulation of SN-38 and camptothecin.
Topics: Adenocarcinoma; Biological Transport; Camptothecin; Colonic Neoplasms; Drug Resistance, Multiple; Enzyme Inhibitors; Female; Genes, MDR; Humans; Irinotecan; Kinetics; Membrane Transport Proteins; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Ovarian Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Time Factors; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 2002 |
Enhanced clearance of topoisomerase I inhibitors from human colon cancer cells by glucuronidation.
Topics: Anthraquinones; Camptothecin; Colonic Neoplasms; Enzyme Inhibitors; Glucuronates; Glucuronides; HT29 Cells; Humans; Irinotecan; Magnetic Resonance Spectroscopy; Mass Spectrometry; Metabolic Clearance Rate; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Tyrosine | 2002 |
Anaphylactic shock secondary to intravenous administration of folinic acid: a first report.
Topics: Aged; Aged, 80 and over; Anaphylaxis; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Fluorouracil; Humans; Injections, Intravenous; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Treatment Outcome | 2002 |
Enhanced tumor killing by Apo2L/TRAIL and CPT-11 co-treatment is associated with p21 cleavage and differential regulation of Apo2L/TRAIL ligand and its receptors.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Apoptosis Regulatory Proteins; Camptothecin; Carcinoma; Caspases; Cell Cycle; Cells, Cultured; Colonic Neoplasms; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Drug Synergism; Humans; Irinotecan; Kinetics; Membrane Glycoproteins; Neoplasms; Receptors, Tumor Necrosis Factor; RNA, Neoplasm; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 2002 |
GEM 231, a second-generation antisense agent complementary to protein kinase A RIalpha subunit, potentiates antitumor activity of irinotecan in human colon, pancreas, prostate and lung cancer xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Camptothecin; Colonic Neoplasms; Cyclic AMP-Dependent Protein Kinases; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Lung Neoplasms; Male; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Oligonucleotides; Oligonucleotides, Antisense; Pancreatic Neoplasms; Prostatic Neoplasms; Survival Rate; Treatment Outcome | 2002 |
Antisense oligonucleotide targeted to RIalpha subunit of cAMP-dependent protein kinase (GEM231) enhances therapeutic effectiveness of cancer chemotherapeutic agent irinotecan in nude mice bearing human cancer xenografts: in vivo synergistic activity, phar
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Breast Neoplasms; Camptothecin; Colonic Neoplasms; Cyclic AMP-Dependent Protein Kinases; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; Irinotecan; Lung Neoplasms; Male; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Oligonucleotides; Oligonucleotides, Antisense; Prostatic Neoplasms; Survival Rate; Tissue Distribution; Treatment Outcome | 2002 |
[A case of advanced colon cancer with para-aortic lymph node metastasis responding greatly to treatment by adjuvant chemotherapy of low-dose CPT-11 on an outpatient basis].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Lymph Nodes; Lymphatic Metastasis | 2002 |
Irinotecan pharmacokinetics-pharmacodynamics: the clinical relevance of prolonged exposure to SN-38.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Drug Administration Schedule; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Ovarian Neoplasms; Prodrugs; Random Allocation; Tumor Cells, Cultured; Uterine Cervical Neoplasms | 2002 |
[The effect of CPT-11 in combination with interferon-alpha against human colon carcinoma heterotransplanted in nude mice: preliminary report].
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Cycle; Colonic Neoplasms; DNA, Neoplasm; Humans; Interferon-alpha; Irinotecan; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation | 1992 |